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What is key and/or novel in these guidelines
Area Recommendation Pages
Chapter 2:
Epidemiology
c It is recommended that recognition be given that patients with PAD have a high risk
of vascular events in other vascular beds.
(Evidence Level A), and as such these patients should always be considered high
risk for further events. (Level A, class I)
12
c In patients with PAD, it is recommended that optimization of treatment of the
concomitant coronary artery disease and cardiac failure should be undertaken.
(Evidence Level B, class I)
12
c It is recommended that in patients with renal failure, that attention be paid to the
concomitant presence of arteriosclerosis (atherosclerosis plus calcification) in the
lower limb, as such disease in this patient population has a poorer prognosis.
(Evidence Level B, Recommendation class I)
13
Chapter 3:
Diagnosis of
peripheral
arterial disease
c It is recommended to perform clinical examination of the feet regularly in patients
with PAD.
(Evidence level C, recommendation level I)
17
c It is recommended that ABI values 6 0.9 are evidence of clinically significant PAD.
(Evidence level B, recommendation level I)
17
c In patients with trophic disorders, diabetes mellitus and in all those with an ABI
score of[ 1.3, toe pressure measurements and calculation of the toe-brachial
Index are recommended to detect PAD (because of proven or susprected medial
sclerosis of the lower limb arteries).
(Consensus recommendation, Evidence level C, Recommendation class I)
19
Chapter 4:
Therapy for
peripheral
arterial
disease –
Introduction
c In CLI, a multidisciplinary treatment approach is to be applied to control pain,
cardiovascular risk factors and comorbidity.
(Evidence level B, Recommendation class I)
25
Chapter 5:
Conservative
treatment for
PAD: Risk factor
management
c Smoking cessation (and abstinence from other drugs taken through smoke
inhalation, e.g. cannabis) is indicated as being urgently required in all PAD stages.
(Evidence level A, Recommendation class I)
27
c It is recommended that smokers are to be provided with a cessation program
consisting of medical supervision, group therapy and nicotine replacement.
(Evidence level A, Recommendation class I)
27
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c In the absence of evidence on the long-term effects, it is recommended that
eCigarettes should be considered. These should be an interim activity to reduce
habituation and making smoking cessation possible.
(Evidence level C, Recommendation class II)
27
c It is recommended that in patients with PAD, statins are indicated for the prevention
of cardiovascular events. Statins reduce morbidity and mortality in PAD and are
recommended for secondary prevention in all PAD patients who tolerate such
medication.
(Evidence level A, Recommendation class I)
28
c It is recommended that lipid levels are only important in terms of achieving
recommended decreases, not as a value to decide whether or not to start a statin.
(Evidence level A, Recommendation class I)
28
c It is recommended that in PAD patients, LDL should be lowered to 1.8 mmol/l
(70mg/dl) or reduced by P50% to reduce CV events.
(Evidence level A, Recommendation class I)
28
c A combination of a statin medication with ezetimibe can be considered to get better
tolerance of the statin medication (with reduced doses) or to achieve the given
target values in LDL-cholesterol
(Evidence level B, Recommendation class IIa)
28
c It is recommended that in patients on maximum tolerated statin therapy, plus
ezetimbe, who do not reach a greater than or equal to 50% fall in LDL, or a target
LDL of 70mg/dl or 1.8 mmol/l, a PCSK9 inhibitor should be introduced
(Evidence level B, recommendation class I).
28
c It is recommended that patients with diabetes should be screened for PAD
preferably with TBI (toe brachial index) measures
(Evidence level B, Recommendation class I)
30
c It is recommended that all PAD patients should be screened for diabetes and
effectively treated in the case of a proven diagnosis of diabetes.
(Evidence level B, Recommendation class I)
30
c It is recommended that high blood pressure be treated at 130/80 mmHg rather than
140/90 if tolerated
(Evidence level A, Recommendation class I)
31
c In patients with symptomatic PAD, platelet aggregation inhibitors are indicated for
the secondary prevention of cardiovascular events. Clopidogrel or Ticagrelol may be
preferred over aspirin
(Evidence level A, Recommendation class I)
32
c Based on the results of the COMPASS trial, the combined therapy of ASA 100 mg/d
and rivaroxoaban 2 x 2.5 mg/d should be considered in PAD patients without a high
risk of bleeding, or other contraindications.
(Evidence level B, Recommendation class IIa)
34
Chapter 6:
Conservative
treatment
for PAD:
Symptom control
c It is recommended that a supervised Vascular workout in patients with intermittent
claudication should take place at least 3 times a week for at least 30-minutes over
at least 3 months. (Evidence level B, Recommendation class I)
36
c Surgical or interventional revascularization is the first-line therapy in CLI
(Evidence level A, Recommendation class I)
36
c A multidisciplinary approach by vascular specialists is to be implemented in all CLI
patients, to manage pain, cardiovascular risk factors and comorbidities, in addition
to the primary revascularization
(Evidence level B, Recommendation class I)
37
Chapter 7:
Interventional
treatment for
peripheral
arterial disease
c It is recommended to refer and to treat CLI patients in specialised institutions
(ideally, accredited vascular centers) that offer rapid and reliable diagnostic
procedures, as well as timely therapy to these severely ill patients at high risk.
(Consensus recommendation: Evidence level C, Recommendation class I)
43
c Effective pain management is one of the most important prerequisites for
successful catheter interventions.
(Consensus recommendation: Evidence level C, Recommendation class I)
43
Chapter 8:
Care of the
patient
undergoing
vascular
interventions
c Rehabilitation programmes are recommended in patients with
intermittent claudication post intervention, such as:
62
 instruction in structured walking exercise
 optimisation of secondary prevention and reduction of
cardiovascular risk
 promotion of compliance
 improvement and promotion of participation in social life
(Consensus recommendation, Evidence level C, Recommendation class I)
Chapter 9:
The elderly
patient with
PAD
c It is recommended that foot pulse palpation is part of a physical examination in frail
elderly patients, even in the absence of PAD symptoms, to identify the risk of
potential pedal (pressure) lesions. Adequate vascular evaluations are imperative in
patients with non-palpable pulses, even in the absence of trophic changes to avoid
ulceration, and muscle atrophy which contributes to falls.
(Consensus recommendation: Evidence level C, Recommendation class I)
63
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1 The process of guideline
compilation
Ulrich Franka (Switzerland), Sigrid Nikola (Germany), and Jill Belcha (UK)
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PAD Guideline Writing Group
aall co-first authors
ESVM Board Authors
Vinko Boc* (Slovenia), Marianne Brodmann (Austria),
Patrick H Carpentier (France), Ali Chraim* (Ukraine),
Caitriona Canning (Ireland); Evangelos Dimakakos*
(Greece), Anders Gottsäter (Sweden), Christian Heiss
(Germany), Lucia Mazzolai (Switzerland), Juraj Madaric*
(Slovakia), DanMircea Olinic* (Romania), Zsolt
Pécsvárady* (Hungary), Pavel Poredoš* (Slovenia), Isabelle
Quéré (France), Karel Roztocil (ESVM President, Czech
Republic), Agata Stanek (Poland), Dragan Vasic* (Serbia),
Adriana Visonà (Italy), and Jean-ClaudeWautrecht*
(Belgium)
ESVM Country Society Authors
Miroslav Bulvas (Czech Republic), Mary-Paula Colgan
(Ireland), Walter Dorigo (Italy), Graeme Houston (UK),
Thomas Kahan (Sweden), Holger Lawall (Germany), Isak
Lindstedt (Sweden), Guillaume Mahe (France), Romeo
Martini (Italy), Giles Pernod (France), Stanislaw Przywara
(Poland). Marc Righini (Switzerland), Oliver Schlager
(Austria), and Piotr Terlecki (Poland)
*Indicates ESVM Board members who were also
nominated by their Country Society as reviewers.
The European Society of Vascular Medicine (ESVM) was
founded in Paris in 2012 as a confederation of already exist-
ing and emerging European societies of vascular medicine.
At the founding congress of the new society in Potsdam,
Germany in 2015 the different national societies sent
experts to a panel to draft an ESVMGuideline on Peripheral
arterial disease (PAD). After reviewing and discussing the
already existing national guideline of the different coun-
tries, the panel decided to consider the latest German S3
Guideline on PAD from November 2015 [1] as the back-
bone of the new ESVM PAD Guideline, update where
appropriate and supplement with data from rigorous litera-
ture searches. Permission from the German Society was
given.
The ESVM acknowledges the significant and valuable aid
from the German Angiology Society and their generosity in
allowing their own Guideline to form the basis of this
Guideline.
Thus, the German S3 guideline [1], which is a national
intersociety consensus guideline – with multiple different
participating specialties – was translated into English,
reviewed and shortened or adapted according to consensus
achieved among ESVM experts and some new chapters and
new recommendations/statements added.
The clear focus of the new ESVM Guideline is – in the
spirit of the Society – the medical and endovascular aspects
of the diagnosis and therapy of PAD. The aim of the ESVM
guideline process was to harmonize and optimise the con-
tent and the principal statements between the different
national member societies of the ESVM. Thus, a draft of
the new guideline was presented to all national European
societies for revision and comment prior to finalization.
The literature has been reviewed to January 2019.
Summary of consensus process
For the German guidelines, a total of 27medical societies/
organisations, two support groups and the German Pension
Fund (Deutsche Rentenversicherung Bund) received writ-
ten invitations to participate in the original guideline. A
total of 24 societies/organizations had responded by the
end of 2012, altogether signaling their interest in
collaboration.
For this current ESVM guideline, the 19-member states
of the ESVM contributed, with a small writing group taking
the lead. All 19 angiology societies were given time to
review the new common guideline and formally endorsed
its content. The key issues were formulated and agreed
upon at consensus meetings and were gradually elaborated
by the ESVM PAD guideline working group to harmonize
standards of care within the ESVM member countries.
Then, the content was further discussed and accredited
in final format by the national angiology/vascular medicine
societies.
Timeline of work
 Guideline Committee approval of subject matter, per-
mission from German Society of Angiology to use
2019 Hogrefe Vasa (2019), 48 (Supplement 102), 7-9
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German Guideline as basis for ESVM Guideline (Rome
May 2016)
 Allocation of writing group (Rome 2016), translation
from German, literature search (May to Nov 2016)
 Draft 1: Presentation of draft 1 to Guideline
Committee and ESVM Board by nominal group
process, (Hamburg November 2nd 2016)
 Draft 2: Full day Consensus Meeting (Hamburg
November 3rd 2016)
 Draft 3: Circulation of draft 3 to ESVM Board taking
into account Consensus Meeting comments,
 Draft 4: Presentation of draft 4 to ESVM Congress
(Prague, March 2018) at a Consensus Meeting,
 Draft 5: Circulated to the ESVM Board
 Draft 6: Circulated and approved by the ESVM Board,
after taking into account further ESVM Board
comments, as ready to be shared with Country
Societies, by nominal group process (May 2018)
 Draft 7: circulated to all Vascular Medicine/Angiology
Society representatives/authors for comments (May to
Oct 2018).
 Draft 8: Circulated to ESVM Board and Society
Representatives, considering Society Representatives
comments (Oct 2018)
 Draft 9: ESVM Board meeting (Frankfurt Oct 2018) by
nominal group process
 Draft 10: Literature update via ESVM Guideline
Committee (Jan 2019)
 Draft 11: Incorporation of final comments from all,
penultimate draft, circulated to ESVM Board and
Country Society Representatives for final approval and
sign off (May to June 2019)
 Draft 12: Penultimate version circulated to ESVM
Board, Guideline Committee and Country Reviewers
 Draft 13: Final version circulated as per version 12 and
approved
1:1 Objective
The objective of the present guideline is to provide evi-
dence-based, comprehensive and optimal care recommen-
dations for patients with atherosclerotic peripheral artery
disease (PAD) of the lower limbs. The guideline is meant
to aid medical personnel and patients in making decisions
regarding the optimal diagnostic and therapeutic measures
for patients with PAD, and to aid with action and decision
routes, which may be modified in justified cases. Guideli-
nes established by scientific medical societies are not leg-
ally binding for physicians and may thus neither cause
liability nor release physicians from liability. What legally
constitutes a medical standard in the treatment of a given
individual can only be determined individually. The pre-
sent guideline thus does not relieve physicians from their
obligation to individually manage their patients by apprais-
ing their patients’ overall situation.
The present guideline aims to compile the most signifi-
cant evidence and information on the treatment of periph-
eral arterial disorders from various specialties to offer the
reader reliable assistance in everyday practical clinical life.
1.2 Which patients does this guideline
refer to?
The guideline refers to adults of any age with asymptomatic
or symptomatic peripheral arterial circulation disorders
due to atherosclerosis. It is also valid for patients at a mark-
edly increased PAD risk, e.g. atherosclerosis patients with
coronary artery disease, carotid stenosis, renal impairment,
diabetes mellitus or cerebrovascular disease. The guideline
covers all areas of epidemiology, diagnostics, treatment
and follow-up care for patients with PAD bar the surgical
options.
The guideline does not apply to children. Treatment
strategies for non-atheromatous causes of peripheral artery
occlusion processes (vasculitis, dissection, giant-cell arteri-
tis, fibromuscular dysplasia, radiogenic stenoses, and
entrapment syndromes) are to be distinguished from
atherosclerotic stenoses/occlusions and they are not the
focus of the present guideline.
1.3 Guideline users
The guideline is addressed to all concerned with the care
and treatment of patients with PAD. The addressees
include physicians, and allied health professionals in outpa-
tient/in-patient care and rehabilitation medicine who care
or treat patients with PAD. The guideline is also intended to
serve as a source of up-to-date information for public-
health institutions, and government policy.
1.4 Participation of interest groups
1.4.1 Organization, financing, and editorial freedom
This Guideline was financed by the ESVM. Nomonies from
Industry were received for the preparation of this guideline.
All the current guideline group members disclosed poten-
tial conflicts of interest in writing and these are present
online in Appendix 1.
1.5 Review and selection of scientific
documents (evidence-based)
National and international guidelines were systematically
reviewed in the guideline International Network (http://
www.g-i-n.net/) database for national and international
guidelines that had been published under the search terms
“PAD”, “peripheral arterial disease”, “peripheral artery
disease” and “claudication “and “critical limb ischemia”.
Vasa (2019), 48 (Supplement 102), 7-9 2019 Hogrefe
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Importance was attached to the systematic development of,
and comprehensible evidence base for, the given recom-
mendations. Secondly, the literature was scanned for fur-
ther new evidence-based findings that would modify the
German guideline including more recent publications to
January 2019.
1.6 Recommendations and levels
of evidence
For the description of the scientific evidence and the
degree of recommendation we adopted our systematology
on the recommendations of the European Society of Cardi-
ology and the European Society for Vascular Surgery [2].
Thus, we describe the level of evidence in three categories,
from A (best level of evidence based on multiple random-
ized clinical trials) to C (consensus of opinion of the experts
or small studies or registries. Based on these different
levels of evidence we formulated our recommendations
in the generally accepted way of type I (recommended) to
III (not recommended) statements (Table 1.6).
Table 1.6. Class of recommendation used in these Guidelines.
Class of
Recommendation
Definition Proposal
Class I Evidence and/or general agreement, that a given treatment or procedure is beneficial, useful,
effective
Recommended/indicated
Class II Conflicting evidence and/or divergence of opinion about usefulness/efficacy of the treatment or
procedure
Class IIa Weight of evidence/opinion in favour of usefulness/efficacy Should be considered
Class IIb Usefulness/efficacy is less well established by evidence/opinion May be considered
Class III Evidence or general agreement that the given treatment or procedure is not useful/effective and
in some cases may be harmful
Not recommended
(Source: ESC Recommendation for Guideline Production 2010) [2].
Level of evidence
Level of
Evidence A
Data derived from multiple randomized clinical trials
or meta-analysis
Level of
Evidence B
Data derived from single randomized clinical trial or
large non-randomized studies
Level of
Evidence C
Consensus of opinion of the experts and/or small
studies, retrospective studies, registries
2019 Hogrefe Vasa (2019), 48 (Supplement 102), 7-9
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2 Definition and epidemiology
2.1 Definition
Peripheral arterial disease (PAD) affecting the lower limb
occurs where there is a blood circulation disorder of the
arteries that supply the limbs, which may be partial (due
to a stenosis) or complete (due to an occlusion). In approx.
95 % of cases, chronic PAD is caused by atherosclerosis. It
is a complex medical condition, which may be asymp-
tomatic in its early stages, although that may affect all arte-
rial vascular regions of the body. In addition to the large
peripheral vessels, smaller vessels supplying the skin and
muscles are often affected. Acute severe peripheral circula-
tory disorders are rarer than the chronic form, developing
from acute embolic or atherothrombotic vascular obstruc-
tions such as plaque rupture. The following guideline rec-
ommendations address acute and chronic arterial
circulatory disorders in the lower limbs distal to the abdom-
inal aorta.
Inflammatory, genetic, and traumatic causes (approx.
5 % of PAD cases) become less frequent with increasing
age, while embolic events (cardiac or arterio-arterial)
become more frequent [3].
Myocardial infarction, stroke, and PAD are different
manifestations of atherosclerosis [4]. Themost severe form
of PAD is tissue death / necrosis with the threat of ampu-
tation of the affected limb. This Guideline deals with
peripheral arterial disease affecting the lower limb only.
In Europe, the Fontaine staging system is applied to clin-
ically classify PAD in terms of symptoms. The Rutherford
classification is more conventional in the USA and interna-
tional science, and distinguishes between 3 grades and 6
categories, which makes the categorization of the severity
of the disease more precise. Table 2.1 shows the classifica-
tion of PAD according to Fontaine stages and Rutherford
grades and categories. The clinical stages are indicated
with the terms “intermittent claudication” (Fontaine stage
II) and/or “critical limb ischemia” (CLI) in later Fontaine
stages III and IV.
2.2 Ankle-brachial pressure index
The prevalence of asymptomatic PAD among the gen-
eral population can only be estimated by non-invasive
methods of investigation. Most frequently this is detected
by the ankle-brachial pressure index (ABI) measured by
non-invasive Doppler pressure measurement (also see
Chapter 3.2, Diagnostics). The cut-off value for the diagno-
sis of PAD is an ABI value  0.9. The sensitivity of an ABI
value of  0.9 for the presence of at least a 50 % vascular
stenosis (verified by the gold standard angiography) is
almost 95 % at rest, with a specificity of nearly 100 % [5].
Systematic ABI measurements following stress tests
increase the detection and thus the prevalence of PAD by
approx. 30 %. An ABI decrease by 15 to 20 % following
walking stress – compared with baseline values at rest – is
indicative of PAD [6, 7].
2.3 Epidemiology
2.3.2 Prevalence and incidence
Numerous epidemiological studies based on objective
research techniques (usually ABI measurements) have
shown an overall 3 to 10 % prevalence of PAD within the
population. The prevalence of symptomatic intermittent
claudication increases from 3 % among 40-year-old
patients to 6 % among those aged 60-65. From age 70
the prevalence is seen to increase to 15 to 20 % [8, 9]. In
2010, the global prevalence of PAD (ABI  0.9) was math-
ematically estimated from the data of a systematic review
to be worldwide 202 million. Within the EU between
2000 and 2010, the incidence increased by 28.7 % in
low- and medium-income countries and by 13.1 % in
high-income countries [10].
The ratio between patients diagnosed as asymptomatic
by ABI and those presenting with symptomatic claudication
(who mostly have decreased ABI values) is approx. 4:1
irrespective of age [11].
Table 2.1. Classification of PAD according to Fontaine stages and Rutherford grades and categories.
Rutherford
Fontaine Stage Clinical symptoms Grade Category Clinical symptoms
I Asymptomatic 0 0 Asymptomatic
II a Walking distance > 200 m I 1 Mild claudication
II b Walking distance < 200 m I 2 Moderate claudication
I 3 Severe claudication
III Rest pain II 4 Rest pain
IV Ischemic ulcers or gangrene III 5 Limited Ischemic ulceration not exceeding ulcer of the digits of the foot
III 6 Severe ischemic ulcers or frank gangrene
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Multisite atherosclerotic artery disease is common and
associated with a worse outcome, as reviewed elsewhere
[12]. Thus, in people with PAD (ABI < 0.90), CAD was pre-
sent in 25–70%, carotid artery stenosis (> 70%) in 14–19%,
and renal artery stenosis (> 75 %) in 10–23 %. In patients
with carotid artery stenosis, PAD was present in 18–22 %,
whilst patients with CAD were reported to have PAD in
7–16 % [12]. Compared to people with no PAD, the preva-
lence of CAD is two- to four-fold higher in PAD patients,
and the severity of PAD is associated to the prevalence of
CAD. Conversely, left main coronary artery stenosis and
multivessel CAD are independent predictors of PAD, and
patients with PAD exhibit more advanced coronary
atherosclerosis. Accordingly, coexisting PAD in patients
with CAD is associated with a worse outcome.
Also, cardiac conditions other than CAD are common in
PAD patients [12]. Compared to a general population, left
ventricular dysfunction is at least two-fold more prevalent
in patients with PAD, matched for age and sex. PAD
increases the risk for incident heart failure, at least in peo-
ple with no prevalent CAD. A multivariable-adjusted popu-
lation-attributable risk for incident heart failure with an
ABI < 1.00 was 6 %, compared with 8 % for CAD, 15 %
for hypertension, and 14 % for diabetes [13]. Furthermore,
the presence of PAD in patients with heart failure indepen-
dently predicts hospitalizations and death. Patients with
PAD have an increased risk for incident atrial fibrillation.
Also, the presence of atrial fibrillation in patients with
PAD is associated with more severe forms (assessed by
the Rutherford classification) and with an increased cardio-
vascular morbidity and mortality.
In the prospective, non-interventional nationwide epi-
demiological trial on Ankle-Brachial Index (Get-ABI
Study), every fifth (21%) of 6,880 patients aged 65 or older
had an ABI of < 0.9 or clinical manifestation of PAD [14].
Investigating 4,814 subjects aged 45 to 75 in the general
population, the Heinz Nixdorf Recall Study identified an
ABI of < 0.9 in 6.4% (men) and 5.1% (women), increasing
to 8.2% and 5.5%when asymptomatic forms of PAD were
additionally taken into consideration [15].
The PAD Awareness, Risk, and Treatment: New
Resources for Survival (PARTNERS) Program produced
prevalence data of patients at risk (aged  70 years or
50- to 69- year-old smokers or patients with diabetes) in
primary care. In this study, 29 % of the overall population
showed a decreased ABI or manifest PAD [16]. In diabetes
patients in the POPADAD study over the age of 40 years
this was 20 % [17].
According to the current literature, however, general
screening of asymptomatic patients is not recommended
at present, the prevalence among low-risk groups being 1
to 4 % and approximately 17–20 % in mixed-risk popula-
tions [17, 18]. Although, asymptomatic patients have a
higher than normal risk of cardiovascular events, this
guideline does not deal with recommendations for the
management of these subjects but focusses on the key area
of risk reduction in symptomatic patients.
2.3.2.1 Gender prevalence
Claudication is more frequent among men in younger age
groups, but there is practically no gender-specific differ-
ences in older age groups. Indeed, in the GetABI Study,
PAD prevalence was seen to be higher in women than in
men after the age of 75 [9]. At the time of diagnosis of
PAD, women are older, more frequently obese, have dia-
betes, and more frequently present with CLI and vascular
obstruction; men are more frequently smokers [19, 20].
However, preliminary indications suggest a gender-
dependent distribution pattern of PAD – with cumulative
femoropopliteal and multilevel disease in women and a
more frequent infrapopliteal distribution pattern among
men – this requires further confirmation in larger-scale
study populations [21].
2.3.2.2 Prevalence in different ethnic groups
Links with different ethnic populations such as those of
Afro-Caribbean decent (non-Hispanic origins) have been
seen to increase the risk of PAD by more than twofold,
which cannot be exclusively explained on the basis of an
increased presence of other risk factors, such as hyperten-
sion and diabetes [22]. These differences in PAD preva-
lence have recently been corroborated by the Genetic
Epidemiology Network of Arteriopathy (GENOA) study
[23].
2.4 Cross risk of atherothrombotic events
In the presence of an atherothrombotic disease in one vas-
cular bed (e.g. PAD), patients are at high risk of cardiovas-
cular morbidity and mortality in other vascular beds.
Table 2.2 summarizes the “cross risk” between different
atherothrombotic manifestations. PAD patients, having
experienced one atheromatous disease, are thus at a clearly
increased risk for further cardiovascular events, including
myocardial infarction and ischemic stroke.
2.4.1 Concomitant PAD and coronary artery disease
and/or cardiac failure
2.4.1.1 Coronary artery disease (CAD)
The occurrence of both PAD and CAD together is frequent
and easily overlooked due to a limitation of walking dis-
tances by angina pectoris or dyspnea, or vice versa. Such
a combination severely worsens prognosis of the patients
compared with those with a single manifestation [28].
The IPSILON study, a French cross-sectional study in
primary care patients, detected PAD in 26.6 % of 1,340
patients with CAD without known manifestation of PAD
by means of the ABI [29]. An investigation with simultane-
ous peripheral and coronary angiography in patients with
claudication or CLI identified prevalent CAD ( 50%coro-
nary stenosis in coronary angiography) among 67 of 107
patients (62 %). The presence of diabetes mellitus further
increased the likelihood of coincidental CAD and especially
coronary multivessel disease in patients with PAD [16, 30].
In patients from the Reduction of Atherothrombosis for
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Continued Health (REACH) registry, fatal and nonfatal
events increased from 13 % in patients with CAD alone to
23.1 % in those with coincidental CAD and PAD after one
year of observation [31].
2.4.1.2 Heart failure
In a sub-study of the Controlled Rosuvastatin Multinational
Trial in Heart Failure (CORONA) trial in patients with heart
failure with reduced left ventricular systolic function
(HFrEF), multivariate analysis showed patients with CLI
(637 of 5,011 patients, 12.7 %) to have both an increased
mortality risk (HR 1.36; 95 % CI: 1.19–1.56) and an
increased risk for fatal and nonfatal MI (time to first event
HR 1.67, 95 % CI: 1.24–2.27) compared to patients without
concomitant PAD [32]. In addition, cardiac failure impairs
peripheral blood circulation due to decreased cardiac out-
put, as well as the patency rates after endovascular
interventions.
Patients with both disorders are physically less resilient
and show less improvement through physical training. This
was shown by an investigation within the “Heart Failure: A
Controlled Trial Investigating Outcomes of exercise traiN-
ing” (HF-ACTION) in patients with ejection fraction 35%
and cardiac failure NYHA II to IV. Patients with concomi-
tant PAD (157 of 2,331, 6.8 %) showed less improvement
in a structured physical exercise program than patients
without concomitant PAD. This disorder was shown to be
an independent predictor of mortality or hospitalization
(HR 1.31, 95 % CI: 1.06–1.62) [33].
Following endovascular intervention, participants with
concomitant HFrEF (EF < 40 %) showed poorer primary
1-year patency rates (43.2 % vs. 56.6 %) compared with
patients with an EF of > 40%, and similar differences were
seen in secondary patency rates. Finally, limb preservation
was poorer in patients with coincidental cardiac failure
[34].
2.4.2 PAD and diabetes mellitus
Regardless of type, diabetes mellitus is associated with an
increased risk of peripheral atherosclerosis. A systematic
review of risk factors for PAD from 34 trials conducted
since 1997 estimated the pooled relative risk of PAD due
to diabetes mellitus with an odds ratio of 1.88 (95 % CI:
1.66–2.14) [10]. In particular, diabetes increases the proba-
bility of distal disease in PAD and CAD multi-vessel dis-
ease, which more frequently results in the need for
coronary and/or peripheral bypass surgery compared with
patients without diabetes [35].
In patients with type 2 diabetes, the rate of cardiovascu-
lar events increases with elevated HbA1c levels. A system-
atic review estimated the pooled relative risk per 1 %
increase in HbA1c for overall mortality to be 1.15 (95 %
CI: 1.10–1.20), for cardiovascular disease to be 1.15 (95 %
CI: 1.10–1.20), for the development of cardiac failure to
be 1.11(95 % CI: 1.06–1.17), and for the emergence of
PAD to be 1.29 (95% CI: 1.18–1.40) [36]. In turn, a Danish
case-control study failed to determine the benefit of inten-
sified diabetes therapy compared to conventional treat-
ment in terms of the de novo incidence of PAD after
6 years [37].
All patients with diabetes mellitus are at risk of develop-
ing diabetic foot syndrome should undergo an ABI and
preferably toe pressure measurement alongside clinical
foot examinations [38]. In patients with elevated ABI val-
ues, additional toe pressure measurement is mandatory,
as false elevated ABI values occur in diabetes due to vessel
stiffening/calcification [39].Recommendation Class of
recommendation
Level of
evidence
It is recommended that
recognition be given that Patients
with PAD have a high risk of
vascular events in other vascular
beds, and as such these patients
should always be considered very
high risk for further events.
I A
In patients with PAD, it is
recommended that optimization
of treatment of the concomitant
clinical coronary artery disease
and cardiac failure should be
undertaken.
I B
Recommendation Class of
recommendation
Level of
evidence
It is recommended that in all
patients with diabetes and
abnormal (especially at low, but
also with high) Ankle Brachial
Indices, to carry out toe pressure
measurements and calculation of
Toe Brachial Index to determine
accurately whether the patient
has PAD.
I B
Table 2.2. Cross risk between various atherothrombotic manifestations.
Risk compared to overall population
New event In the event of previous MI:
Frequency of occurrence
In the event of previous stroke:
Frequency of occurrence
Ischemic stroke 2–3  including angina and sudden death* 9
Myocardial infarction 5–7  including death 3–4  including transient ischemic attack
PAD 4  fatal coronary events 2–3  including TIA
*Sudden death = occurrence within 1 hour and usually from coronary artery disease (CAD) cause. [24–27].
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2.4.3 PAD and concomitant renal failure
Concomitant renal failure (chronic renal failure (CKD))
impairs the prognosis of cardiovascular disorders overall
and lowers the rate of amputation-free survival. In a
prospective cohort study, 104 patients with CKD were fol-
lowed up for 3 years following CLI therapy, survival and
limb preservation were recorded. Treatment had consisted
of bypass surgery (55%), endovascular intervention (45%),
conservative treatment (22 %), or primary amputation
(9 %). Subjects with cardiac comorbidity and renal failure
with serum creatinine levels > 2 mg/dl showed a poorer
outcome in terms of amputation-free survival (HR3.68,
95 % CI: 1.51–8.94) [40, 41]. Arteriosclerosis may compli-
cate this, where calcium deposits appear in the media caus-
ing vessel stiffening. Carotid artery disease is very common
in this group.
2.5 Progression of PAD and prognosis
2.5.1 Asymptomatic PAD
Both pathologically lowered, and pathologically increased
ABI values are predictors of cardiovascular morbidity and
mortality [42–45]. There is a direct correlation between
ABI and CV events and death. The lower the ABI, the
higher the cardiovascular morbidity and mortality. The
exception to this is in diabetes where vessel stiffening
may give a false high reading (Figure 2.1).
2.5.2 Symptomatic PAD
Symptoms improve spontaneously in approximately one
quarter of patients with claudication. The disorder remains
unchanged in approximately one third to one half of all sub-
jects and deteriorates in about one quarter. The fate of
patients with claudication is determined by cardiac and
cerebral events. The risk for CLI is very low among patients
with claudication and only 2 % experience an amputation
within 10 years of PAD diagnosis [7].
Thirty years ago, Wolfe reported a 20% 1-year mortality
rate in CLI [46]. In the recent French “Cohorte des Patients
Artériopathes” (COPART) registry with 940 patients, the 1-
year mortality rate among patients with stable intermittent
claudication (IC) was 5.7% compared to 21.1% in patients
with CLI. The rate was 28.7%among those presenting with
ulceration [47]. In the “Bypass versus Angioplasty in Severe
No PAD
Asympomatic PAD
Symptomatic PAD
Percentage
of mortality 
1 year 3 years 5 years
30
25
20
15
10
5
0
Figure 2.1. The GetABIstudy: Mortality
rates after 1, 3, and 5 years in symp-
tomatic and asymptomatic PAD patients
compared to patients without PAD.
Recommendation Class of
recommendation
Level of
evidence
It is recommended that in
patients with renal failure, that
attention be paid to the
concomitant presence of
arteriosclerosis (atherosclerosis
plus calcification) in the lower
limb, as such disease in this
patient population has a poorer
prognosis.
I B
It is recommended that patients
with known PAD and rapidly
progressing renal failure should
be screened (preferably by duplex
ultrasound) for possible (bilateral
or unilateral in the situation of a
functional single kidney)
atherosclerotic renal artery
stenosis
I B
Recommendation Class of
recommendation
Level of
evidence
In patients with PAD, the Ankle-
Brachial Index (ABI) is
recommended as an appropriate
parameter to assess
cardiovascular risk with regard to
morbidity and mortality.
I B
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Ischemia of the Leg” (BASIL) study, 1- and 3-year amputa-
tion-free survival amounted to 70%and 55%, respectively,
in the overall group of participants with CLI, with a 1-year
mortality rate of approximately 20 % [48].
A recent meta-analysis by Sigvant et al, described that
symptomatic PAD subjects continue to have higher 5 year
cumulative CV mortality than the reference population,
13% versus 5%. During follow up 21% of IC patients were
diagnosed as having critical limb ischemia, with 4–27 %
undergoing amputations [49].
Prognosis is even worse in patients with diabetes melli-
tus. An Italian study identified a 12-month mortality rate
of 26% in patients with diabetes and 12% in patients with-
out diabetes; the major amputation rate was 50% after one
year [50].
The “Reduction of Atherothrombosis for Continued
Health” (REACH) registry [51] is a multinational database
registering the frequency of atherothrombotic disorders
and atherothrombosis-associated risk factors in clinical
practice. With some 68,000 patients in 44 countries, it is
the largest atherothrombosis registry in geographical terms
and also by its patient sample size. After one year of follow-
up, subjects with symptomatic PAD already showed a sig-
nificantly higher mortality rate than those with coronary
artery or cerebrovascular disease: 2.4 % in PAD patients
vs. 1.8 % in CAD. The annual amputation rate was 1.3 %
and the annual intervention rate for vascular interventions
was 10 % among PAD patients [31].
The annual rates of major amputation in Europe have
shown a decrease, reducing from 4.6 % in 2005 to 3.5 %
in 2009. At the same time, the rate of minor amputations
increased minimally from 5.0 to 5.1 %. Intra-hospital mor-
tality among patients with claudication remained stable
(2.2 %) and dropped from 9.8 % to 8.4 % among CLI
patients in this period [52]. Similarly there is an improved
use of preventative measures.
In terms of Rutherford categories, the 4-year mortality
risk projected from the Kaplan-Meier model increases from
18.9% (grade 1 to 3), to 37.7% (grade 4) and 52.2% (grade
5), and to 63.5% (grade 6). The 4-year amputation risk esti-
mated with the same model for grade 1 to 3, 4, 5, and 6
increases from to 12.1% to 35.3%and finally to 67.3% [53].
2.6 Under-treatment of PAD patients
Many studies have reported an under-treatment of patients
with PAD, especially in direct comparison with patients
with CAD [54]. The US PARTNERS program demonstrated
medical under-treatment in this patient population [16].
The GetABI study also showed PAD patients to be under-
treatment in comparison with other atherothrombosis
patients (CAD; stroke). Two out of three patients with
CAD were given antiplatelet drugs, but only approximately
half of the patients with PAD. The situation was similar
with regard to lipid lowering with statins: 46 % of CAD
patients, yet merely 23 % of patients with symptomatic
PAD, were treated with statins. The difference between
CAD and PAD was even more pronounced in the prescrip-
tionof beta blockers [55, 56] (which are not contraindicated
for PAD). Finally, the international REACH registry also
evidenced the under-treatment of PAD patients [57].
In a population-based tele-interview investigation in the
US, a representative group of 2,501 adults aged 50 or older
were interviewed as to the issues of PAD, risk factors for
cardiovascular disease and other underlying cardiovascular
disorders [58]. Only 26%of the subjects in the sample were
knowledgeable about PAD, and half of this group was una-
ware that diabetes mellitus and smoking increase the risk
for PAD. Only one out of four respondents knew that
PAD is accompanied by increased mortality due to myocar-
dial infarction and stroke. Only 14 % of the interviewees
were aware that PAD may become acute and may result
in amputation. Respondents who were at the highest risk
for PAD due to their risk factor constellation and current
underlying disease showed a deficient level of knowledge
and/or awareness of PAD. The authors of this study con-
cluded that the public is insufficiently informed about
PAD [58].
Encouragingly although there is still under-treatment of
PAD, the figures are improving. For example, Sigvant et al
showed that among 18,742 revascularized PAD patients in
the national Swedvasc registry 2008–2013 antiplatelet ther-
apy, statins, angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers, and beta-blockers were used
by 73%, 60%, 57%, and 49%at admission for revascular-
ization. Best medical treatment, defined as any antiplatelet
or anticoagulant therapy along with statin treatment, was
offered to 65 % of patients with intermittent claudication
and 45% of patients with critical limb ischaemia [59].
Recommendation Class of
recommendation
Level of
evidence
It is recommended that
physicians and patients alike pay
as much attention to the
significance of PAD compared to
CAD for assessing general
vascular risk and the fate of the
patient. It is recommended that
risk factors and concomitant
disorders should be actively
treated in patients with PAD.
I B
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3 Diagnosis of peripheral
arterial disease
3.1 General clinical examination
of the limb: Inspection, palpation
and auscultation
Diagnostic techniques in patients with PAD should be PAD
stage- and patient-oriented, targeted and accurate. Fur-
thermore, account should be taken of the risk-benefit ratio
and cost effectiveness of each technique. Initially, medical
history and thorough clinical examination should be per-
formed with vascular auscultation and palpation.
Changes and status of skin, muscular abnormalities, and
orthopaedic deformities and the color, hairiness and tem-
perature of the legs and feet should be documented by
bilateral comparison. Clinical neurological examinations
of the lower limbs are useful especially if there are signs
of concomitant neuropathy with changes in foot anatomy
and/or skin physiology. This should be recorded and eval-
uated with a risk score [51]. The differential-diagnostic
symptoms of neurological and/or orthopedic disorders
should be considered to assess the clinical relevance of
possible impaired peripheral circulation. Patients with clau-
dication or critical limb ischemia frequently show concomi-
tant neurological or orthopedic disorders which may
confound the diagnosis of PAD. Likewise, other causes
should be ruled out in patients who have trophic disorders
and ulceration of the lower limbs, excluding such condi-
tions as venous ulceration, vasculitis, summarized in
Table 3.1.1.
Pain typically caused by claudication consists of repro-
ducible exercise stress-dependent myalgia which improves
rapidly within minutes at rest. Depending on the
localization of the vascular lesions, such pain may develop
in the gluteal region or the thigh, calf, or foot muscles. Pain
affects the ability to walk. Reduced walking performance
can be described as a measurement of pain-free maximum
walking distance and/or impaired walking speed. Unlike
CLI, blood circulation in the affected extremities at rest is
still sufficient. In stenosis of the proximal pelvic arteries,
pulses are often palpable and Duplex spectra may be
triphasic ie normal, at rest.
Pain at rest and/or trophic skin-and tissue- lesions are
present in CLI. Pain at rest always affects the part of the
limb most remote from the last open vessel, mostly the
forefoot. Lowering the leg frequently results in relief from
pain symptoms. CLI is generally defined by the loss of bal-
ance between arterial perfusion and the metabolic oxygen
and nutrient demands of the tissues.
In general, pain in the lower limb or foot can also be
caused by a primary or concomitant neuropathy. Table 3.1.2
gives some orientation about the clinical signs of the two
entities.
3.1.1 Significance of pulse examination
Pulse examinations at the lower limbs are helpful, yet
defective [60]. Pulse palpation alone is insufficient to
detect PAD. This disorder is too frequently diagnosed
according to poor or absent pedal pulses, as opposed to
diagnosis according to typical claudication symptoms [7].
We know the pulse palpation is wrong in over one third
of cases due to clinician error, oedema of foot or anatomi-
cal variation in vessels. With a sensitivity of 20 %, pulse
Table 3.1.1. Causes of occlusive arterial lesions in the lower
extremities, which may trigger claudication.
Possible causes of occlusive arterial lesions
Atherosclerosis
Arteriosclerosis
Vasculitis
Congenital or acquired vascular deformities
Fibromuscular dysplasia
Peripheral embolism
Adventitial cystic disease
Compression syndromes
Vascular tumors
Pseudoxanthoma elastica
Trauma or radiation injuries
Spinal claudication
Venous claudication
Table 3.1.2. Differentiation between neuropathy and PAD (clinical
examination).
Neuropathy PAD
Skin Dry, warm, rosy, no
change in color in
venous filling at an
elevation of even 30
Atrophic, thin, cool,
pale-livid, paling of
forefoot at elevation
Tissue Oedema frequently
found
Seldom oedema
Hyperkeratosis Marked at pressure-
exposed sites, heel
fissures
Slowed growth of
skin, sandpaper-like
hyperkeratosis
Nails Mycoses, subungual
hematoma
Thickened nails,
hyperonychia
Toes Claw/hammer toes No hair, livid, acral
lesions
Pedal muscles Atrophy of dorsal M.
interossei
General atrophy
Sole Hyperkeratosis,
rhagades, pressure
ulcers
Liftable skin within
folds
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palpation alone is insufficient to detect PAD and is to be
combined with auscultation as basic examination (sensitiv-
ity: 75 %; specificity: 40 %) [60]. According to the Basle
study, the combination of palpation by bilateral comparison
and auscultation, together with a history of claudication,
shows an efficiency of detection of 84% for clinically rele-
vant stenosis [61].
While discomfort due to claudication in the calves is
easily identified, exercise stress-dependent pain in the
soles or gluteal region – in the presence of occlusions in
the lower-leg or pelvic arteries – is frequently diagnosed
with more difficulty, by purely clinical examination.
This applies specifically to patients with diabetes and, as
shown in Table 3.1.2, assists in differentiating between pri-
marily neuropathic and ischemic changes/lesions [62].
Diabetic autonomic and symmetrically sensory and moto-
ric polyneuropathy is especially frequent in patients with
diabetes with PAD, and special protective footwear is
recommended in the presence of severely impaired perfu-
sion or typical signs and changes of neuropathy. Regular
professional foot examinations carried out by physicians,
podiatrists or trained patients themselves, may increase
awareness and are invaluable in terms of skin damage
prevention [63, 64].
3.2 Significance of the ankle-brachial
index
Alongside inspection, palpation and auscultation basic
examinations of vascular status include Doppler ultra-
sonography of occlusion pressure in the dorsal pedal and
posterior tibial arteries and, as appropriate, the peroneal
artery, in recumbent patients and the calculation of an
Ankle-Brachial Index (ABI) [5, 45].
The subjects should not have over-exercised before their
examination (e.g. by bicycling or running longer stretches).
After approximately 10 minutes at rest in supine position,
the patients undergo two systolic blood pressure measure-
ments, the first along the brachial artery according to Riva-
Rocci [65]. The mean value of both measurements is to be
estimated (exception: the respectively higher pressure
value is used in pressure differences  10 mmHg). 10 to
12 cm blood pressure cuffs are inflated above the ankle
and systolic values measured and noted along the posterior
and anterior tibial arteries with a Doppler probe (8 to 10
MHz) with the higher pressure selected for calculation of
the ABI.
In addition to Doppler ultrasound measurements, sev-
eral other non-invasive techniques have been described
for ABI measurements, primarily oscillometric methods.
The American Heart Association Scientific Statement on
the Measurement and Interpretation of the Ankle-Brachial
Index contains a detailed description of these methods and
an analysis of validation studies [66]. In summary, the ABI
measured by many of these alternative methods correlates
well with Doppler-measured ABI scores in healthy and
mildly affected subjects. However, correlations are poor
when the ABI measured by Doppler is in the low range.
Furthermore, reproducibility is poorer and intra-observer
variability is higher with these methods as compared to
the Doppler method. Therefore, the Doppler ultrasound
method should in general be used to measure the ABI.
The ABI threshold score was derived from comprehen-
sive epidemiological studies. The value is defined as 0.9
in the guidelines issued by the European Society of Cardi-
ology (ESC) [28], the American College of Cardiology/
AmericanHeart Association (ACC/AHA) [67], the National
Institute for Health and Care Excellence (NICE) [68], and
the Transatlantic Inter-Society Consensus (TASC) II [7].
The lower the score, the stronger the atherosclerotic
changes in the leg, and blood-flow obstruction is significant
(Table 3.2). It should be noted, however, that claudication
discomfort may develop with quite divergent ABI values
in different individuals. Also, with medial sclerosis ABI
may be falsely normal or increased.
Having critical ischemia is considered to be a crucial
prognostic factor for the healing of peripheral lesions and
has been described, alongside clinical symptoms, by an
ABI score of < 0.5 and a pulsatility index of 1.2with a sen-
sitivity and specificity of 36 % and 86 %, resp. 87 % and
67 % [7].
Recommendation Class of
recommendation
Level of
evidence
Examination of the patient is
recommended along with clinical
history, inspection, palpation by
bilateral comparison, and
auscultation over extremity
arteries.
I B
Recommendation Class of
recommendation
Level of
evidence
It is recommended that on
examination skin status, integrity,
turgor, perspiration, color,
muscle atrophy, deformity, and
temperature are assessed.
I C
Table 3.2. ABI categories to estimate degrees of PAD severity in the
absence of mediasclerosis.
ABI value Degree of PAD severity
> 1.3 Falsely high value (suspected medial calcific sclerosis)
 0.9 Normal finding
0.75–0.9 Mild PAD
0.5–0.75 Moderate PAD
< 0.5 Severe PAD
Comment: This classification is only valid in the absence of mediasclerosis:
If mediasclerosis is suspected, we strongly recommend toe pressure
measurement.
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3.2.1 Calculation of the ABI
The ABI can be determined by a physician, vascular
technologist, trained podiatrist or nursing staff. A compre-
hensive systematic comparison of examination results
obtained by angiologists, family physicians, and assistants
in healthy subjects demonstrated no differences between
the ABI values measured by three different professional
groups in individual patients and a low, approx. 8 % level
of variance between repetition measurements [69]. In spite
of the high level of accuracy, it should be noted that, due to
measurement error, confirmatory repeat measurements
should thus be carried out in patients whose ABI values
approximate to the threshold value of 0.9.
The ABI is commonly calculated either by dividing, first,
the highest of the obtained pressure values in the foot (pos-
terior tibial artery [PTA], dorsalis pedis [DP]) by the highest
or medium arm pressure values or, second, the highest of
the obtained calf pressures in the foot by the highest or
medium arm pressures. There is consensus that the mean
systolic blood pressure (SBP) values of both arms should
be taken as denominator unless the systolic blood pressure
difference exceeds 10 mmHg, in which case the highest
SBP value should be taken as denominator and a subcla-
vian artery stenosis should be ruled out at the side with
the lower pressure [66].
The first method (taking the lowest value of the foot)
may be used to determine the presence of arterial disease
and thus to predict cardiovascular morbidity and mortality
with a high degree of sensitivity and specificity. The conse-
quence of this prediction, however, remains unclear, in par-
ticular in asymptomatic patients. To date, there is no
evidence that the prophylactic treatment of such patients
with statins or platelet inhibitors would lower cardiovascu-
lar morbidity and mortality, although intellectually this
makes sense [17].
The second method (taking the highest value of the foot)
is used to determine the presence of ischemic disease and
thus to diagnose PAD on a functional level. Normal ABI
measures at rest do not rule out PAD in symptomatic
patients. In such subjects, it is strongly recommended that
a treadmill test with ABI measurements be carried out
immediately after reaching maximum walking distance.
Furthermore, medial sclerosis may obscure the presence
of peripheral arterial disease, which means that the ABI is
in normal or supernormal range in the presence of clinically
relevant PAD. Measurements of toe pressure and calcula-
tion of a Toe Brachial index (TBI) instead of an ABI are rec-
ommended especially in these patients and in patients with
diabetes. TBI result accuracy is enhanced by pre-heating of
the foot prior to measurement.
3.2.2 Exercise tests to objectify claudication
It should be noted that ABI values of > 0.9 can be found in
well collateralised, proximal high-grade stenoses or occlu-
sions, or with haemodynamically borderline stenoses.
De-masking is accomplished by measuring the ABI after
exercise. Thus, in the presence of non-conclusive ABI find-
ings, an additional ABI measurement at rest immediately
after physical exercise by repetitive tiptoe standing, tread-
mill or ergometric stress increases the sensitivity of detect-
ing PAD at rest by 10 %. Detection of a monophasic
frequency spectrum after stress also improves the sensitiv-
ity for PAD masked at rest [70] (See also Chapter 3.3.2).
The technique is as follows: The ABI is measured at rest
and subsequently walking performance (e.g. on a treadmill
at 3.2 km/h and 12% incline, i.e. 100W load) is measured.
Pain-free and maximum walking distances are docu-
mented, as well as walking time and ankle pressure after
stress. An ABI decrease of 20 % confirms the diagnosis
[70].
In the absence of a treadmill, the exercise may be carried
out by supervised rapid walking along a defined corridor
stretch. Patients incapable of treadmill examinations or
rapid level walking can be examined by active plantar flex-
ion. Findings are seen to correlate very well with those
obtained in treadmill ergometry [71].
The success of claudication therapy can be objectively
quantified with exercise testing. Initial values of pain-free
and maximum walking distances or absolute walking time
serve as comparative parameters of PAD patients’ walking
performance. Objectified stress in terms of walking time
and distance as well as patient-based validated disorder-
specific questionnaires (e.g. Medical Outcome Short Form
SF-36, Walking Impairment Questionnaire [WIQ]) can be
applied to evaluate treatment [72].
Exercise testing also plays an important role in the differ-
ential diagnosis of claudication. The differential diagnoses
of PAD are listed in Table 3.2.2.
Recommendation Class of
recommendation
Level of
evidence
Measurement of the ABI by non-
invasive measurements using
Doppler occlusion pressure is
indicated as an appropriate test
to verify PAD.
I C
It is recommended that the ABI
score with the highest ankle
artery pressure value is to be
used for the calculation of ABI.
I C
It is recommended that ABI
values  0.9 are evidence of
significant PAD.
I B
Recommendation Class of
recommendation
Level of
evidence
In the case of atypical PAD
discomfort, treadmill ergometry
with or without subsequent
ankle/toe pressure
measurements are indicated to
be carried out to back up
diagnosis and/or as quantitative
initial examination.
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Besides the PAD with different complaints, depending
on the localization of the arterial narrowing or occlusion,
there are some pathologies which cause comparable symp-
toms but have another underlying cause. For instance,
spinal claudication will not lead to a pressure decrease after
exercise.
3.2.3 The ABI in medial calcific sclerosis
In patients with diabetes, the ABI is unhelpful in PAD diag-
nosis in 10 to 30 % due to Mönckeberg’s arteriosclerosis
(> 1.3 high values in a situation of true ischemia). Apart
from an ABI value  1.3, a (pseudo) normal ABI score with
flattened Doppler pulse curves (acoustic or graphic reduc-
tion of pulsatility) indicates the presence of medial calcific
sclerosis with relevant stenoses [66].
The association between the ABI and cardiovascular
mortality/morbidity is different between patients with dia-
betes and patients without diabetes. While patients without
diabetes feature a linear correlation between increasing
risk and decreasing ABI values, the correlation in patients
with diabetes corresponds to a U-shaped curve: not only
ABI scores  0.9 but also  1.3 are associated with
increased cardiovascular risk [73].
Apart frommedial calcific sclerosis, falsely high pressure
values in peripheral ankle pressure measurements are also
found in peripheral edema or cases in which perfusion of
the ankle arteries is exclusively fed by an unobstructed
fibular artery. To rule out medial calcific sclerosis in the
arm arteries, a permanently elevated systemic blood pres-
sure  250 mmHg necessitates a duplex examination or
alternately an X-ray-radiography of the upper arm.
Another equally sensitive method in medial calcific scle-
rosis, the pole test, uses hydrostatically assessed pressure
values at the hallux or the dorsal pedal artery as measures.
Passive leg elevation is applied (and the distance in cm
from bottom line, in which the Doppler signal vanishes cor-
responds to the arterial perfusion pressure in the extremity;
1 cmH2O corresponds to 0.74mmHg) instead of the sphyg-
momanometer technique [74].
3.3 Complementary methods of
measurement in implausible ABI scores
3.3.1 Toe-brachial index
Medial sclerosis occurs in patients with diabetes mellitus,
severe renal insufficiency and long-term immunosuppres-
sive therapy. Since medial calcific sclerosis affects the digi-
tal arteries less than the lower-leg arteries, assessment of
hallux pressure with readings  30 mmHg offers an addi-
tional sign for the presence of CLI. Toe pressure is approx-
imately 30 mmHg below systolic ankle pressure, and the
pathological Toe-Brachial Index (TBI) is 0.7 and less. Mea-
suring the pressure in the big toemainly measures perfusion
via the posterior tibial artery. Additional toe measurements
are recommended, as the perfusion in the lateral half of the
forefoot is provided by the anterior tibial artery and cannot
be evaluated by a great toe measurement.
Contrary to the ABI, the TBI shows a linear association
with cardiovascular events and thus differs from the
U-shaped curve of the ABI in medial calcific sclerosis.
There is one prospective comparative study in diabetic
and non-diabetic patients [75]. Therefore, it should be used
in the presence of implausible ABI readings. Regardless of
coincidental diabetes mellitus, the ABI and the TBI are
strongly positively correlated in the presence of ABI values
 0.9 and  1.4 [75, 76].
While the ABI threshold of 0.9 as a cardiovascular risk
indicator has been validated in many cases, the TBI thresh-
old of 0.7 is scientifically less well proven and requires
further validation [77].
3.3.2 Doppler frequency spectrum
Evaluation of the acoustically or graphically documented
Doppler frequency spectrum results in valuable additional
parameters in the diagnosis of PAD. In one investigation,
one third of the patients with occlusions of the lower-leg
arteries showed normal ABI values at rest and under stress.
Relevant PAD was detected by applying the criterion of
“monophasic Doppler frequency curve” [6]. The classic
monophasic Doppler frequency curve at the common
femoral artery showed a highly positive predictive value
of 92 % in patients with significant aortoiliac lesions [78].
3.3.3 Oscillography
As additional non-invasive methods, oscillography and
light reflection rheography (LRR) may prove helpful in
specific questions (e.g. presence of medial calcific sclero-
sis). The advantage of mechanical and electronic oscillog-
raphy is its quick and simple feasibility and its possibility
to identify the approximate level of stenosis or occlusion
[65].
LRR of the digital arteries is helpful in acral perfusion
examination, also for bilateral comparison. The form of
the pulse curves facilitates rapid diagnosis of the presence
of peripheral blood-flow disorders and offers a good
impression about the severity of the perfusion disorder.
However, no sufficient evidence for these two methods
has emerged from recent studies.
Recommendation Class of
recommendation
Level of
evidence
It is recommended that in the
presence of implausible ABI
values, complementary methods
such as Toe-Brachial-Index and
calculation of pulsatility index are
to be employed.
II B
In patients with trophic disorders,
diabetes mellitus and in all those
with an ABI > 1.3, toe pressure
measurements and calculation of
the toe-brachial Index are
recommended to detect PAD
(because of proven or suspected
medial sclerosis of the lower limb
arteries).
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3.3.4 Transcutaneous oxygen pressure measurement
Assessment of transcutaneous partial pressure of oxygen
(TcPO2) can additionally be used especially to estimate
the risk and or level of amputation in CLI. CLI is defined
as a TcPO2 value < 30 mmHg in supine patients, yet it is
dependent on several influential variables (skin texture,
anemia, blood oxygenation, i.a.) and relevant data are defi-
cient. A TcPO2 value < 40 mmHg is associated with an
increased complication rate following amputations, and a
value < 30mmHg is an independent predictor of wound-
healing disorders (OR 3.21, 95 % CI 1.07–9.69) [79]. The
amputation risk in the presence of TcPO2values < 10
mmHg is 70 % [78].
The certainty of detecting CLI is improved by changing
leg positions (from a lying to a sitting position) without an
increase in TcPO2 values [80]. Reactive hyperemia can
be used to assess skin perfusion by changing probe temper-
ature (probe heating to 37C or 44C) and oxygen inhala-
tion. To increase validity, it is recommended to carry out
measurements over at least 3 different positions on the
involved extremity.
Due to the limited sensitivity and specificity of this
method, a combination of various analytical proce-
dures (clinical, Doppler methods, capillary microscopy,
TcPO2measurements) may be used to quantify circulation
and assess the chances of healing, though little evidence
exists for their use.
3.5 Non-invasive diagnostic imaging
procedures
3.5.1 Colour-coded duplex sonography (CCDS)
Vascular duplex ultrasonography has become the single
innovative diagnostic method in all areas of everyday vas-
cular medicine. For the stepwise diagnosis of PAD, it occu-
pies a key role in treatment planning prior to invasive
procedures. It is the diagnostic imaging method of choice
for both arteriosclerotic and non-arteriosclerotic vascular
disorders.
CCDS is a non-invasive method of investigation, which
facilitates successful surgical or endovascular recanaliza-
tion in claudication as well as in CLI. This was demon-
strated by a retrospective evaluation of intraoperative
and/or peri-interventional digital subtraction angiography
(DSA) images of 4,783 patients with infrainguinal Transat-
lantic Inter-Society Consensus (TASC) C and D lesions.
With a sensitivity of 97 % and a specificity of 98 %, CCDS
as sole diagnostic method was successfully used in
treatment planning and decision-making for bypass surgery
or endovascular treatment [81]. With CCDS, important
differential diagnoses can be identified, including vasculi-
tis, muscular compression syndrome, aneurysmal vascular
occlusion, and rare cystic adventitial degeneration.
Duplex sonography is widely available, non-invasive,
reproducible and biologically inert. Applied by experienced
investigators, it shows high levels of sensitivity and speci-
ficity [82, 83] and, based on reliable findings, facilitates
the safe planning of necessary treatment steps (conserva-
tive treatment, catheter intervention, bypass surgery)
[81]. It provides morphological imaging of vascular walls,
perivascular tissue or details of early atherosclerotic
change by capturing intima-media thickness (IMT), and
thus delivers a valuable parameter for clinical studies
[64, 84].
Color flow imaging facilitates full understanding of the
hemodynamics of stenoses and occlusions [85], as well as
offering valuable and valid direct and indirect flow param-
eters [78]. The disadvantages of this method include a high
level of investigator dependency, artifact interference
(medial calcific sclerosis, calcifications, electromagnetic
fields), and elaborate documentation. Further disadvan-
tages include difficulty in imaging aorto-iliac vessels in
patients with significantly elevated body mass index (BMI).
The use of contrast agents suitable for ultrasound may
serve to further enhance the validity of duplex sonography
findings. Routine contrast application, however, is not
required.
Recommendation Class of
recommendation
Level of
evidence
Oscillography and Light
Reflection Rheography (LRR) may
be considered as useful methods
to evaluate PAD, especially in
medial calcific sclerosis and acral
circulatory disorders.
IIb C
In the case of incompressible
ankle arteries, in medial calcific
sclerosis, acral circulatory
disorders or ABI > 1.30,
alternative methods such as the
toe-brachial index, Doppler
frequency analysis, oscillography
or LRR or pulse volume recording
may be considered.
IIb C
Recommendation Class of
recommendation
Level of
evidence
Color-coded duplex sonography
(CCDS) is indicated as the initial
method of choice to evaluate the
architecture of the aorta and its
branches, as well as the pelvic
and leg arteries. Its validity
depends on the investigator’s
expertise, the technical capability
of the device, and the patient’s
individual situation.
I B
Colour-coded Duplex sonography
(CCDS) is indicated as the primary
diagnostic tool in PAD to enable
visualization and localization of
vascular stenoses and
occlusions.
I B
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3.5.2 Computerized tomographic angiography (CTA)
Due to widely available modern multi-slice CT machines,
CTA has been established as a valid method of measure-
ment with high levels of sensitivity and specificity in vascu-
lar disorders [86, 87]. Drawing on 20 studies in 957 patients
with CI or CLI (at least 10 participants per study), a system-
atic review found a sensitivity of 95 % and specificity of
96% for CTA to detect at least a 50% stenosis (measured
by DSA). CTA correctly diagnosed vascular occlusions in
94%, and at least a 50% stenosis in 87%, and the absence
of significant stenosis in 96 %. However, the methodical
quality of the included studies was limited: Only 2.2 % of
a total of 909 studies with data comparing CTA and DSA
were eligible for the meta-analysis [88].
The method produces high-quality, multiplanar and
three-dimensional images of the aortoiliac, femoropopli-
teal, and crural vascular system and its surrounding
anatomical structures. Centerline reconstructions facilitate
exact computations of interventional and reconstructive
surgical procedures and are indispensable for measuring
endografts in aortoiliac vessels. The advantages of the
method consist of a very short time of investigation, the
detectability of treatment-relevant comorbidities that may
imitate PAD symptoms, a spatial resolution within the sub-
millimeter range, and an imaging potential that is surgically
important in anatomic-topographic terms.
The disadvantages of CTA include exposure to radiation,
the need for iodine-containing contrasts (with a contrast
volume of approx. 100 ml per examination), the overesti-
mation of stenosis grades in the presence of small-caliber
vessels with calcified stenosis i.e. crural vessels (although
these can be improved by use of dual-source CT), and the
effort expended in image post-processing depending on
the age of the machine.
3.5.3 Magnetic resonance angiography (MRA)
MR angiography is a non-invasive, investigator-
independent imaging methods. High-quality three-
dimensional vascular reconstructions can be produced with
high levels of sensitivity and specificity by applying com-
mon MR tomography, surface coils and three-dimensional
gradient echo sequences [82]. Data from a small meta-
analysis have shown a pooled sensitivity of 86 % and
specificity of 93 % compared to the gold standard DSA
for the infragenicular region [89]. There is an urgent need
for more comprehensive studies, as the absence of radia-
tion exposure with MRA is a significant benefit over CTA.
Such techniques as time-of-flight angiography and
phase-contrast angiography, as used in cerebral vascular
diagnosis, are unsuitable for PAD diagnosis. Therefore,
contrast-enhanced magnetic resonance angiography
(CEMRA) is considered the standard in pelvis-leg vessel
imaging. Like DSA, this method provides initial non-
contrast examinations of the aortoiliac, femoral, and crural
regions. After determining the ideal bolus time (test bolus),
the measurements are repeated after contrast admin-
istration and subtracted from one another. Resulting
subtraction images are calculated as maximum intensity
projections and require no post-processing. By making
use of first-pass effects, it is possible to obtain images that
are free from super-positions and high in contrast. As in
CTA, the examination is standardized and completed,
together with reconstructions, within less than 30minutes.
The advantages of MRA include a rapid and simple
acquisition of valid and clear angiographic images without
potentially nephrotoxic contrast media (nevertheless older
linear MR-contrast media are contraindicated in severely
impaired renal function because of the risk of nephrogenic
systemic fibrosis) and without exposure to radiation. The
disadvantages are MR contraindications (magnetic metal
implants, cardiac pacemakers, severe renal failure) and
limited image quality due to movement artifacts. Overesti-
mations of intermediate stenosis grading in severe stenoses
may occur, especially in small-caliber vessels (susceptibility
artifacts) and aortic side branches.
The contrast doses applied in CEMRA are frequently
higher than in other indications. For instance, 0.1 mmol/
kg BW are recommended for central nervous system and
liver applications, and the 2- to 3-fold quantity (0.3
mmol/kg BW) in CEMRA, an examination that thus applies
relatively high contrast doses. Gadolinium-based contrast
agents have a 6- to 8-fold lesser rate of allergic side effects
(1 %) and are not per se nephrotoxic. However, linear
gadolinium-based contrast agents had a serious side effect,
nephrogenic systemic fibrosis (NSF), which is specific in
comparison to other contrast media. Recently, also new
contrast-free MR based methodologies have become avail-
able in specialized centers.
3.5.3.1 Nephrogenic systemic fibrosis (NSF)
In 2006, NSF was suspected to be associated with the
administration of linear gadolinium-based contrasts for
the first time. NSF has so far only been observed in patients
with severe renal failure (GFR < 30ml/min/1.73m2), those
with acute renal insufficiency due to hepatorenal syn-
drome, or perioperatively in liver transplantations. This
applies especially to dialysis patients who have been exam-
ined with linear gadolinium.
The disorder led to skin sclerosis with swelling and con-
tractures and other systemic organ involvements. NSF
Recommendation Class of
recommendation
Level of
evidence
Additional diagnostic procedures –
magnetic resonance angiography
(MRA), computed tomographic
angiography (CTA) or digital
subtraction angiography (DSA) –
are recommended only if CCDS
fails to sufficiently reveal the
underlying pathology, and if
proceeding to elective surgical
revascularization.
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became progressive in 5% of patients. In terms of etiology,
it is considered to represent a multifactorial process. Pre-
disposing factors included surgical operations, vascular
injuries, high doses of erythropoietin, and high levels of
serum phosphate. No precise frequency rates are known.
The Yale NSF Registry reported 380 cases by 2013 (www.
icnfdr.org), although causalities have not proved definitive
in all cases [90]. No causal connection with the emergence
of NSF has so far been reported following the administra-
tion of macrocyclic gadolinium-based contrasts.
To prevent gadolinium-induced NSF, contrast use should
be critically assessed in patients requiring dialysis and
those with severe renal failure and a GFR of < 30 ml/
min/1.73m2, and other imaging methods should be consid-
ered. However, some macrocyclic MR-contrasts are also
approved for use in patients with manifest renal failure.
The ionic linear chelate gadodiamide should not be used
if possible. In cases in which it must be used, the quantity
is to be dosed as small as possible and following contrast
examination, a timely hemodialysis should be carried out
in patients with terminal renal failure. No further gadolin-
ium-based contrast agent is to be used in future if NSF is
clinically suspected.
3.6 Intra-arterial angiography (digital
subtraction angiography, DSA)
Intra-arterial DSA is considered to be the gold standard in
terms of the accuracy and clarity of vascular imaging. How-
ever intra-arterial angiography as a purely diagnostic pro-
cedure is increasingly superseded by highly sensitive and
specific non-invasive procedures, such as CCDU, MRA
and as appropriate, CTA.
The advantages of intra-arterial DSA consist of good doc-
umentation, high levels of experience as an established
procedure, and the opportunity to combine diagnostics
and interventions in one single session. DSA is substantially
more precise than any other imaging procedure, particu-
larly in evaluating in-stent stenoses. The combination of
ultrasound Doppler frequency spectrum analysis and DSA
ensures an optimal validity.
Disadvantages result from the invasiveness of this ana-
lytical method. Potential complications include hematoma,
false aneurysm, bleeding, arteriovenous fistula and con-
trast-related complications (contrast-induced nephropathy,
allergic contrast reaction, contrast-induced hyperthy-
roidism), which influence subsequent patient management
in 0.7% of cases and are associated with a mortality rate of
0.16% [7]. Complication rates in intra-arterial angiography
depend on comorbidities (heart failure, renal failure) and
the presence of other risk factors (advanced age, diabetes
etc.) and amounts to 0.5 to 1 %.
3.6.1 Risks of iodine-containing contrast agents and
prophylactic measures
Contrast-induced nephropathy (CIN) is defined as impair-
ment of renal function secondary to the use of contrast
medium for radiological procedures. It is measured as
either a 25 % increase in serum creatinine from baseline
or 0.5 mg/dL (44 μmol/L) increase in absolute value, on
condition that there is a temporal connection with intra-
venous or intra-arterial contrast administration and there
are no other causes. The increase may be delayed by up
to 7 days after contrast administration.
The frequency of CIN varies depending on its definition,
concomitant risk factors, the kind and dose of contrast
agent, and its route of application [91]. It occurs in 1 to
6 % in the normal population and reaches its lowest levels
where there is normal renal function and no other risk
factors, after intravenous and intra-arterial contrast admin-
istration (1%and 3%, resp.). In the presence of risk factors,
the incidence increases to 14 to 50 %. The frequency of
CIN with at risk patients requiring dialysis treatment has
been reported to be0.8% [92–94]. Patient-specific risk fac-
tors include preexisting chronic renal function disorders,
diabetes mellitus, age above 75 years, manifest heart
failure, dehydration and hypovolaemia, nephritic syn-
drome and multiple myeloma. The necessity of routine
assessments of serum creatinine is subject to debate.
Examination-related risk factors include intra-arterial
delivery, high contrast dose, highly viscous and highly
osmolar contrast agents, and multiple contrast administra-
tion within 48 hours. Surveys have shown a 13 to 20% rate
of such assessments prior to intravenous contrast adminis-
tration [95].
Recommendations have assumed that the risk for CIN
increases above a serum creatinine level of > 1.4 mg/dl.
This value may be misleading in older patients and those
showing little muscle mass, as it corresponds to an approx.
50% reduction in renal function in normal-weight subjects.
Therefore, it is more robust to estimate the glomerular fil-
tration rate (GFR), rather than to exclusively use screening
parameters.
Nephrology Scientific Societies thus recommend grading
chronic renal failure according to the GFR. Moderate
chronic renal failure with an increased risk of CIN is
thought to occur at a GFR of < 60ml/min [96]. In the pres-
ence of moderate renal failure with a GFR of < 60 ml/min
prior to contrast administration, a second reading of serum
creatinine and the GFR should be done 24 to 72 hours after
contrast administration in order to establish or rule out
CIN.
Metformin may cause lactic acidosis in connection with
CIN. If safe, metformin-containing oral antidiabetic drugs
should be discontinued 2 days before and withheld for
2 days after planned contrast administration. In known
chronic renal failure, CIN (GFR < 40ml/min) is to be ruled
out prior to restarting the drug because of already estab-
lished concerns about metformin use in cases where the
GFR is < 50 ml/min.
3.6.2 Prophylaxis against CIN
Sufficient intravenous hydration (10 ml/kg body weight)
depending on comorbidities (e.g. heart failure) is recom-
mended. Fluid substitution in patients at risk should be
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carried out 12 hours before and up to 12 hours after contrast
administration. Volume administration is to be modified in
the presence of heart failure. Additional protective
measures include the discontinuation of non-steroidal
anti-inflammatory drugs (especially diclofenac), discontin-
uation of diuretics (as far as possible), reduction of contrast
administration to the absolute necessary minimum, and
warming of contrast agents to reduce viscosity.
In the past acetylcysteine was recommended as prophy-
laxis. However, no scientific evidence of effectiveness has
so far been produced for this recommendation [97] and
the latest Preserve Trial [98] showed no advantage of
bicarbonate and/or acetylcysteine over sodium chloride
infusion alone.
The value of theophylline, aminophylline and ascorbic
acid administration has not been verified.
Sufficient data do not exist to support post-treatment
prophylactic hemodialysis in an attempt to rapidly elimi-
nate contrast media.
3.6.3 Iodine-induced hyperthyroidism
Assessment of basal thyroid-stimulating hormone (TSH)
values serves to exclude a diagnosis of hyperthyroidism.
Patients with severe concomitant disorders and a poor gen-
eral condition may present with suppressed TSH due to
non-thyroidal causes. Subjects with latent hyperthyreosis
and/or adenomatous goiter, as well as scintigraphically evi-
denced over activity are at risk.
The recommendation for prevention of iodine-induced
hyperthyreosis is 900 mg sodium perchlorate daily. In
cases of manifest hyperthyroidism, optionally 10 to
20 mg daily methimazole can be given no later than 2 to
4 hours before contrast administration and then after
contrast exposure for 14 days. Should suppression prove
not to be feasible, iodine-containing contrast agents should
not be used in manifest hyperthyreosis or latent hyper-
thyreosis and/or over-activity.
Sodium perchlorate given at 900mg daily is indicated in
manifest hyperthyroidism. In such cases 40 to 80 mg/d
methimazole are also to be administered for 14 days.
Adjusted doses of methimazole are to be given thereafter.
In manifest iodine-induced hyperthyroidism, methimazole
is to be dosed at 40 to 120 mg/d over weeks to counteract
iodine. A combination with sodium perchlorate serves to
accelerate normal thyroid function [99].
3.6.4 Carbon dioxide angiography
In patients with renal failure, carbon dioxide (CO2) angiog-
raphy is an alternative to intra-arterial angiography using
nephrotoxic contrast agents. Sufficient imaging of the pel-
vic and thigh vasculature is feasible up to the popliteal
artery and the proximal calf arteries and can help to pre-
vent CIN during peripheral interventions [100]. Endovas-
cular treatment supported by reliable documentation is
also possible with images of the calf vessels and (if neces-
sary and possible) a few milliliters of conventional iodine-
containing contrast.
3.7 Choice of imaging diagnostic
procedures
The on-site availability of modalities and investigator
expertise is to be considered in choosing whether to select
CCDS, CTA, MRA, or intra-arterial angiography. However,
in most units this means that CCDS should be the first
choice, however if this technique does not reveal the under-
lying problem or the images are limited, then other modal-
ities should be chosen. Likewise, patients’ individual
conditions are to be considered taking into account con-
comitant disorders (e.g. renal failure, thyroid disorders,
heart failure, and cardiac pacemakers). Table 3.7 summa-
rizes the significance of various imaging procedures.
The most important reason for imaging is a clinical situ-
ation in need of treatment. The objective of imaging is to
evidence and further characterise the vascular lesions with
PAD, which then are preferably revascularised by interven-
tional or surgical treatment as required. Furthermore, other
differential diagnostic causes of vascular lesions (e.g.
aneurysm) or discomfort (e.g. compression syndromes)
can be excluded by imaging.
In summary, imaging diagnostics are necessary for
patients with PAD who are suitable for invasive treatment.
Prior to this, the disorders should be detected with non-
invasive hemodynamic diagnostic methods and assessed
in connection with history and clinical symptoms [101].
Recommendation Class of
recommendation
Level of
evidence
It is recommended that when
findings are inconclusive, a
second imaging method must be
applied prior to invasive
procedures. Individual risk profile
and the diagnostic precision of
the additional method must be
considered in selecting the
further diagnostical procedure.
I B
It is recommended that prior to
making treatment decisions, the
results of vascular imaging
should be correlated with the
results of the history and clinical
examination.
I C
Table 3.7. Sensitivity and specificity of various imaging procedures in
diagnosing symptomatic PAD for stenoses > 50 % and lower-limb
occlusions.
CEMRA TOF CTA CCDS
Number of studies 7 5 6 7
Median sensitivity; % 95 92 91 88
(range) (92–99.5) (79–94) (89–99) (80–98)
Median specificity; % 97 88 91 96
(range) (64–99) (74–92) (83–97) (89–99)
CCDS, color-coded duplex sonography; CEMRA, contrast-enhanced mag-
netic resonance angiography; CTA, computed tomographic angiography;
TOF, time-of-flight angiography. Source [82].
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4 Therapy for peripheral arterial
disease – introduction
This chapter introduces the concepts for conservative med-
ical treatment for chronic PAD in all stages: the asymp-
tomatic stage (PAD I according to Fontaine, Rutherford
0), intermittent claudication (Stage II according to Fon-
taine, Rutherford 1–3), and critical limb ischemia (Stages
III and IV according to Fontaine, Rutherford 4–6). Medical
treatment recommendations in terms of peri- and post-
interventional platelet inhibition and anticoagulation are
outlined in the section on peri-interventional management.
It must be remembered that alongside structured exer-
cise and medical treatments, endovascular and surgical
therapies are integral to patients with PAD.
Patients’ treatment compliance is often reduced because
of lack of knowledge, thus impeding conservative treat-
ment, in particular. Despite structured exercise being a rec-
ognized constituent of optimal vascular treatment, it is
efficiently and regularly practiced by very few patients. Fur-
ther, warning signals of worsening symptomatic PAD are
often misinterpreted or ignored by both the patient and
the uninformed clinician.
4.1 Principles of PAD therapy
The number of patients with PAD is continuously increas-
ing due to the aging population and growing number of
patients with diabetes. By 2020, the workload for vascular
medicine will have increased by more than 40%compared
to the beginning of the millennium [102].
The cornerstone of PAD therapy is twofold: reduction of
cardiovascular risk factors and concomitant disorders, espe-
cially CAD and cerebrovascular diseases, and secondly, the
improvement of peripheral blood flow in symptomatic
patients. Depending on the clinical stage of disease, the
emphasis on specific treatment modalities change. Thus,
for asymptomatic and long-distance claudication patient’s
emphasis is put on the reduction of cardiovascular risk
(stage I according to Fontaine, Rutherford 0), for short
distance claudication patients, the symptomatic improve-
ment of pain-free and maximum walking distances, the
preservation of mobility and thus quality-of-life improve-
ment is important along with CV risk management (stage
II according to Fontaine, Rutherford 1-3). Limb preservation
is critical in more severe stages, but vascular risk factor
modification must not be forgotten (stages III and IV
according to Fontaine, Rutherford 4-6, CLI) [7, 28, 67].
4.1.1 Stage-adapted approach
Arterial reconstruction in PAD is a symptomatic treatment
and does not resolve the underlying problem of progressive
atherosclerosis. Endovascular or surgical interventions are
carried out depending on clinical symptoms, localization,
and pathology of disease, risk-benefit ratios, and the
patients’ individual treatment requests.
There is sufficient available data regarding endovascular
and surgical arterial reconstructions to quantify their bene-
fits in appropriate indications, as well as the short- and
long-term risks associated with such invasive interventions
[48, 103, 104]. These results emphasize the need for
interdisciplinary treatment planning prior to vascular
reconstructions (also see the section on interventional
treatment of PAD and surgical treatment).
Recommendation Class of recommendation Level of evidence
The objectives of treatment (in symptomatic PAD) are:
 to inhibit the progression of PAD
 to reduce cardiac and cerebrovascular events
 to reduce the risk of peripheral arterial events in an aneurysm
 to reduce pain
 to improve mobility/walking performance and quality of life
I C
Recommendation Class of
recommendation
Level of
evidence
Both endovascular and
surgical arterial
reconstruction decisions in
PAD should be based on a
balance between risks and
projected results.
Interdisciplinary decision-
making, especially in
complicated cases, is
recommended.
I C
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4.1.2 Vascular surgery versus interventional
procedures
Open vascular surgery and endovascular interventional
treatment for PAD are mutually complementary treatment
options and should be allocated appropriately to the right
specialist invascularcenters.Appropriate therapeuticproce-
dures can be selectedwithin an interdisciplinary framework
while also considering patients’ requests. Many interven-
tionists and vascular surgeons offer joint hybrid interven-
tions that combine surgical and interventional measures.
Patients qualifying for vascular interventions often have
multiple comorbidities. Surgery as well as catheter inter-
vention thus becomes more difficult and risky with more
limited prognosis [105]. As patients increasingly present
with more severe concomitant disorders, the rates of peri-
operative mortality and morbidity is at risk of rising [106].
Minimally invasive, secure, and rapid interventional
approaches are, therefore, preferred especially in the CLI
patient with multiple comorbidities. These should be inter-
disciplinary in terms of deciding management pathway.
4.1.3 Procedures in diabetes mellitus
Practically none of the therapeutic studies carried out so far
(surgical and interventional revascularization, medical
treatment) have separated patients with and without dia-
betes. Patients with diabetes account for the majority of
subjects with progressive vascular disease and CLI, who
frequently experience a multiple-stage process and very
often severe and diffuse disease in the lower-leg arteries.
Frequently, pedal flow is still preserved [107]. However,
in these mixed studies treatment options for patients with
diabetes are identical to those obtained in patients without
diabetes.
Lack of pain perception in diabetic polyneuropathy
frequently masks progressive PAD, and in such cases, there
is a high risk of neuro-ischemic foot syndrome. For this
reason, arterial revascularization is often the first choice
therapy in this high-risk group in the presence of hemody-
namically relevant vascular lesions.
Another group, the patients with rheumatoid arthritis and
connective tissue disorders often present with vascular
changes that are comparable to, or even more severe, than
those seen in patients with diabetes. This patient groupwith
diffusely affected vessels and often very high-grade focal
calcifications represents a special therapeutic challenge.
Where inflammation is present e.g. vasculitis, endovascu-
lar intervention should not be attempted, and these
patients should be initially treated with anti-inflammatory/
immunosuppressant drugs, and intervention should only be
considered if a relevant stenosis remains present after
inflammation resolution.
4.1.4 Procedures in claudication
In intermittent claudication, the criteria for vascular sur-
gery and angioplasty should be more strictly applied than
in CLI, as in a long-term prospective study, the primary
treatment results are no better than with purely conserva-
tive treatment. Invasive procedures do not positively affect
mortality and leg-preservation rates and/or the patency of
leg arteries in long-term observation [103]. The important
criteria for treatment in intermittent claudication are the
patients’ quality of life and reduction of vascular risk.
In suitable localizations (proximal lesion) and morphol-
ogy, endovascular treatment for claudication can be con-
sidered [7]. Structured exercise should additionally be
offered. The same applies to the surgical removal of
severely stenosed lesions of the common femoral artery,
which may be indicated in the presence of significant
patient suffering.
4.1.5 Procedures in CLI
The primary treatment objectives in CLI are pain relief,
healing of trophic disorders and ulceration, avoidance of
amputation, improvement of limb function and walking
performance, quality-of-life improvement in the short
term, and improved survival in the medium term.
The preferred treatment option in CLI is revasculariza-
tion [48].
Therapeutic approaches also include analgesic adminis-
tration and other medical strategies for pain relief, infec-
tion treatment and the optimization of cardiac and
pulmonary function, if required. Monitoring of and treat-
ment for cardiovascular risk factors is as necessary in
patients with CLI as in all other patients with PAD [7].
Interventional and/or surgical revascularization is possi-
ble in up to 70 to 90% of patients with CLI [108–110]. This
produces high healing rates and a significant decrease in
rates of major amputation [48, 111]. At least in the medium
term, interventional results prove comparable to the out-
comes of vascular surgery when the TASC II criteria are
observed [48, 112]. Table 4.1 summarizes the treatment
recommendations in PAD.
Recommendation Class of
recommendation
Level of
evidence
Interdisciplinary decisions
about the choice of
revascularization procedure
are to be made as rapidly as
possible in CLI.
I C
It is recommended that rapid
and less invasive
endovascular treatment is
given preference for
revascularization if
improvements are
comparable to those
achievable by open vascular
surgery.
I C
Recommendation Class of
recommendation
Level of
evidence
In CLI, a multidisciplinary
treatment approach is
recommended to control pain,
cardiovascular risk factors
and comorbidity.
I B
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Table 4.1. Stage-adapted treatment of PAD depending on Fontaine Stages I to IV.
Fontaine Stages
I II III IV
Procedures
Risk factor management: nicotine abstention, diabetes management,
lipid lowering (eg statin therapy), blood pressure management
+ + + +
Antiplatelet drugs + + +
Physical therapy: structured walking training + +
Medical treatment: naftidrofuryl, cilostazol +
Medical Treatment: prostanoids +
Structured wound treatment +
Interventional therapy +* + +
Surgical therapy +* + +
*In the presence of appropriate vascular morphology and poor quality of life.
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5 Conservative treatment for
PAD – Risk factor management
5.1 Objectives of conservative PAD
treatment
The objectives of PAD treatment are to reduce the risk of
future cardiovascular events (all Fontaine Stages) to
improve walking performance, mobility and quality of life
in Fontaine Stage II, and limb preservation, pain reduction
and improved/
maintain quality-of-life in Fontaine Stages III and IV.
This chapter deals with cardiovascular risk and its man-
agement in patients with PAD.
5.2 Cardiovascular risk management
in PAD
Basic conservative treatment consists in monitoring
of and treatment for cardiovascular risk factors for
atherothrombosis. This covers regular physical activity,
weight reduction in overweight patients, nicotine abstention
in smokers, antiplatelet medication, as well as treatment for
arterial hypertension, dyslipidemia and diabetes mellitus
[113–117].
5.2.1 Smoking
Smoking is at present the most important risk factors for
PAD. The corresponding amount of exposure (number of
pack years) is associated with the severity of PAD, a higher
amputation rate, peripheral prosthetic bypass occlusion
and mortality [118, 119]. The rate of amputations is mark-
edly increased among smokers. Smoking cessation has
been evidenced to impact on progression of PAD [120,
121], yet its significance for walking performance in inter-
mittent claudication is less definite.
The rate of abstinence can demonstrably be improved
with nicotine replacement preparations, formal cessation
programs and bupropion [122–124]. Regularly and medi-
cally addressing the problem, along with intensive supervi-
sion, is the key to withdrawal. Other options, including
group therapy or nicotine replacement preparations, should
also be considered and can be combined with one another.
5.2.2 Depression
The presence of concomitant reactive depression in
patients with PAD has become increasingly important
[125]. The development of depression appears to limit qual-
ity of life and walking performance to a significant extent.
In turn, reduced walking performance may possibly have
a causative effect on the development of reactive depres-
sive conditions. Data from interventional studies of antide-
pressants or psychiatric treatment for patients with PAD
have not yet become available.
5.2.3 Dyslipidemia
Elevated total cholesterol concentrations, increased levels
of low-density lipoprotein (LDL) cholesterol, triglyceride
and lipoprotein (a), and decreased high-density lipoprotein
(HDL) levels [126] are independent risk factors for the
development of PAD. An inverse correlation has been
shown between the level of LDL cholesterol and the ABI
in patients with newly diagnosed PAD [127].
In the Heart Protection Study (HPS), simvastatin signifi-
cantly lowered the rates of vascular and cardiac events in
patients with PAD, irrespective of the presence of CAD at
Recommendation Class of
recommendation
Level of
evidence
Lifestyle changes are
recommended in the presence of
obesity and/or physical inactivity.
I C
Recommendation Class of
recommendation
Level of
evidence
Smoking cessation (and
abstinence from other drugs
taken through smoke
inhalation, e.g. cannabis) is
recommended as being
urgently required in all PAD
stages.
I A
It is recommended that
smokers are to be provided
with a cessation program
consisting of medical
supervision, group therapy and
nicotine replacement
considered.
I A
In the absence of evidence on
the long-term effects, it is
recommended that eCigarettes
should be considered to aid
smoking cessation. In the light
of adverse effects on the
endothelium these should be a
short interim activity to reduce
habituation and making
smoking cessation possible.
IIa C
I
I
A
A
IIa C
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the beginning of the study [128–130]. This also applied to
patients with so called ‘normal’ cholesterol values – indeed
benefit was seen down to total cholesterol levels of
3.5 mmol/l. A cholesterol threshold value under which no
benefit was detectable was not evidenced.
In prevention of vascular events and overall mortality,
the most recent Cochrane analyses endorsed the benefits,
cost efficiency and improved quality of life associated with
statins, without accepting relevant undesirable effects even
in low-risk patients [131].
The extent to which LDL values should be lowered in
PAD patients remains unclear, no prospective interven-
tional studies have so far been carried out in PAD alone
patients. However, the results of the Improved Reduction
of Outcomes: Vytorin Efficacy International Trial
(IMPROVE-IT) supported the “LDL hypothesis” and sug-
gested monitoring and the reduction of LDL values in
patients at a high risk of cardiovascular disorders. Further
the Fourier study [132] which enrolled 27,564 patients of
which 13.2 % (3,642) had symptomatic PAD, all of whom
were on statin therapy evaluated benefit in the preplanned
PAD subgroup. The full study which was placebo con-
trolled, of evolocumab, showed a significant decrease in
the combined CV endpoints of MI, Stroke, and death (HR
0.80, 95%CI 0.73–0.88) combined with a very good safety
profile for very low levels of LDL. In the PAD subgroup,
evolocumab significantly reduced the primary end point
consistently in patients with PAD (hazard ratio [HR] 0.79;
95%confidence interval [CI], 0.66–0.94, and also reduced
the risk of major adverse limb events in all patients (HR,
0.58; 95% CI, 0.38–0.88) [133]. This suggests that current
targets are set to fall as these new drugs reach endpoint
study conclusion.
The benefits of lipid lowering with statins and other
lipid reducing agents in PAD is without doubt. Intriguingly,
there is also some evidence in support of lipid lowering
improving claudication. In the Scandinavian Simvastatin
Survival Study (4S), simvastatin served to reduce the
development of intermittent claudication in patients with
coronary and stroke disease [128–134]. Further studies
applying various doses of atorvastatin or simvastatin to
treat patients with claudication yielded significantly
improved pain-free or absolute walking distances
compared to placebo after 3, 6, and 12 months. However,
these studies examined small numbers of patient only
[135–137].
Intensive statin therapy has been shown in retrospective
studies to not only reduce CVmortality but also amputation
[138, 139] and to enhance graft patency [140]. New data,
recently available, shows that intensive statin therapy ver-
sus low intensity statin therapy better reduces adverse limb
outcomes such as amputation [141].
Further consideration on additional therapy such as
ezetimibe [142] and evolocumab [132], may need to be
considered in this group which has such a high risk of fur-
ther CV events.
The current European Society of Cardiology (ESC)
guidelines recommend a lowering of LDL cholesterol
depending on the overall cardiovascular risk to
< 100 mg/dl (< 2.58 mmol/l) in high-risk patients and to
< 70 mg/dl (< 1.81 mmol/l) in those at a very high risk
including PAD patients (see the ESC Systematic Coronary
Risk Evaluation [SCORE] system) [113]. To achieve these
lower levels, monitoring of patient results, to ensure targets
are reached, is crucial. Thus, it is not sufficient to merely
start lipid lowering therapy, but the clinician must also
ensure arrangements are in place for follow-up (e.g., in
Primary Care) to ensure “treating to target”.
Identical target values can be recommended for women
and men. However the current US guidelines have disasso-
ciated themselves from LDL titration as a target value
[143]. PAD patients are considered very high-risk patients
and are to be given “intensive” statin treatment with
the aim to effectively and tolerably lower vascular risk.
Medical Care has to focus on concordance, as non-adher-
ence has shown to be a considerable problem in everyday
practice.
Recommendation Class of
recommendation
Level of
evidence
It is recommended that in
patients with PAD, statins are
indicated for the prevention of
cardiovascular events. Statins
reduce morbidity and
mortality in PAD and are
recommended for secondary
prevention in all PAD patients
who tolerate such medication.
I A
It is recommended that Lipid
levels are only important in
terms of achieving
recommended decreases, not
as a value to decide whether
or not to start a statin.
I A
Based on the pleiotropic
(multifactorial) and plaque-
stabilizing effects of statins,
statins should be considered
for all PAD patients when
tolerated, independent of LDL
levels in all stages of disease.
IIa C
It is recommended that in PAD
patients, LDL should be
lowered to 1.8 mmol/l (70 mg/
dl) or reduced by  50 % if
pretreatment values are 1.8–
3.5 mmol/l (70–135 mg/dl)
I A
A high dose of a potent statin is
usually indicated, if tolerated,
(eg 20–40 mg of rosuvastatin,
40–80 mgs and above
atorvastatin or comparable
doses of potent other statins).
I A
A combination of a statin
medication with ezetimibe can
be considered to get better
tolerance of the statin
medication (with reduced
doses) or to achieve the given
target values in LDL-
cholesterol.
IIa B
I
I
A
A
IIa
C
I
I
A
A
IIa
B
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The recent publication of the Fourier Study using the
PCSK9 Inhibitor evolocumab, and its predefined sub-study
of PAD [133], shows a significant decrease in both MACE
and major adverse limb events (MALE). MACE in patients
with PAD (hazard ratio [HR]0.79; 95%confidence interval
[CI],0.66–0.94 andwithout PAD (HR0.86; 95%CI,0.80–
0.93) and MALE (HR, 0.58; 95 % CI, 0.38–0.88;
P = 0.0093).
61% of PAD patients recruited had had an intervention,
40% had diabetes, and the evidence showed the lower the
LDL the better in terms of CV outcome with no lower limit
being recommended and no overt side effects from this
lower LDL. However, at present cost precludes us treating
all patients, although a cost benefit analyses shows accept-
able cost-effective thresholds [144] and so we recommend
the following therapeutic strategy:
No data are available to evidence reduced morbidity and
mortality by treating elevated triglyceride levels and low
HDL cholesterol values.
Nicotinic acid reduces femoral atherothrombosis and
delays coronary atherothrombosis in patients with PAD
[145], yet has no additional verified benefits compared to
statins in terms of reduced clinical endpoints and so cannot
be recommended [146]. Although, omega-3 fatty acids has
shown no effect on platelet activation or inflammatory
parameters in patients with PAD, positive data are available
for other risk populations [147–149]. However, there are no
positive endpoint studies for patients with PAD [150, 151].
5.2.4 Diabetes mellitus
Apart from smoking, diabetic metabolic disorders are the
most important risk factors for PAD progression. Every
HbA1c increase in the magnitude of 1 % is associated with
a 28 % increase in the relative risk for manifest PAD
[152]. Diabetes elevates the risk of PAD by a factor of 3
to 4 and the risk of claudication by a factor of 2. A subgroup
analysis of United Kingdom Prospective Diabetes Study
(UKPDS) [40] in 3,884 patients showed a lower amputation
rate with lower levels of HbA1c and/or lower levels of
chronic hyperglycemia [152]. Another study showed signif-
icantly reduced walking performance and lower-limb
mobility in patients with diabetes with PAD compared with
patients without diabetes with PAD [153].
Among type 2 patients with diabetes under intensified
treatment (diabetes stabilization, CSE inhibitor i.e. statin
and antiaggregant administration), the Steno-2 study
observed a 25% relative risk reduction in amputation rates
and a 10% decrease in vascular interventions over 7 years
[154]. Both type 1 and type 2 patients with diabetes bene-
fit from improved glucose stabilisation in terms of reduced
PAD progression. Current guidelines issued by the
American Diabetes Association (ADA), the European
Association for the Study of Diabetes (EASD), and the
European Society of Cardiology recommend the formula-
tion of individualised treatment objectives for HbA1c
together with the affected patients, considering the factors
of age, comorbidity, hypoglycemic risk and patient’s
preference. The aim is an HbA1c range of 6.5 % to 7.5 %
to prevent subsequent complications [115, 155, 156]. In
elderly vascular patients, a range of 7 % to 8 %, is seen as
tolerable, while avoiding hypoglycemic events.
While 10-year follow-up data of the UKPDS has suggested
a significant reduction in overall mortality, other studies
have revealed no significant reduction in cardiovascular
mortality by approximating the HbA1c value to normal by
way of intensified diabetes treatment. These include Action
to Control Cardiovascular Risk in Diabetes (ACCORD
[157]), Action in Diabetes and Vascular Disease: Preterax
and Diamicron Modified Release Controlled Evalua-
tion (ADVANCE [158]), Veterans Affairs Diabetes Trial
(VADT [159]), Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modified Release Controlled
Evaluation Post-trial Observational Study (ADVANCE-ON
[160]).
The inconsistent database regarding the advantages of
close-to-the-norm HbA1c stabilization is the reason for
querying the lowest possible HbA1c target values and turn-
ing toward more individualised treatment strategies. Care
for patients with vascular disorders and diabetic metabolic
disorders requires interdisciplinary cooperation between
vascular physicians and diabetologists.
Intentionally including pre-diabetes, the recent
ESC/EASD guidelines classified patients with diabetes in
groups at high and at very high risk for cardiovascular
events. Individual specification of treatment objectives,
measured according to HbA1c values and the avoidance
of hypoglycemia, is the most important aspect of anti-
hyperglycemic treatment. In individual cases, lifestyle
interventions and treatment for comorbidities are to be
applied.
Recommendation Class of
recommendation
Level of
evidence
A PCSK9 inhibitor may be
considered in PAD patients on
maximum tolerated statin
therapy, plus ezetimibe, who
do not reach a target LDL.
I B
In view of the primary
prevention studies with
statins and the known risk
profile in asymptomatic PAD
disease, consideration should
be given to also treating
asymptomatic PAD patients.
IIb C
IIb C
I B
Recommendation Class of
recommendation
Level of
evidence
Nicotinic acid preparations
are not recommended in the
prevention of cardiovascular
events in patients with PAD
III A
Omega-3 fatty acids are not
recommended in the
prevention of cardiovascular
events in patients with PAD.
III A
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5.2.4.1 Antidiabetic therapy in PAD
When it comes to diabetic therapy, the glucocentric view is
increasingly taking a back seat. Rather, the treatment of
cardiovascular comorbidities is of increasing importance.
However, this is where there are considerable differences
between the individual antidiabetic substances.
Biguanides
Metformin is the first-line oral antidiabetic drug in diabet-
ics with PAOD, although the data is thin in this respect. A
recently published study again demonstrates the positive
effect on CV survival, but not on extremity retention and
patency after peripheral revasculaization [161].
Sulfonylureas and Glinides
For both groups of substances no robust data on PAOD is
available. Because of the relatively high risk of hypoglycemia
and potential unfavorable effects in patients with coronary
heart disease, these substances are hardly relevant [162].
DPP4 inhibitors
The cardiovascular endpoint studies SAVO-TIMI 53,
EXAMINE, TECOS and CAROLINE show a non-inferiority
of tested DPP4 inhibitors to the tested outcomes CV death,
non-fatal myocardial infarction or stroke compared to pla-
cebo or glimepiride. In the SAVOR-Timi 53 study, however,
significantly more hospitalization for saxagliptin was
observed because of heart failure, so this substance should
be used with caution in patients with known heart failure.
Cardiovascular superiority or benefits in the presence of
concomitant PAD are not proven [163–167].
GLP1 agonists
Both liraglutide, dulaglutide and semaglutide have been
shown to have a positive effect on cardiovascular events
such as fatal and non-fatal myocardial infarction and
non-fatal stroke versus placebo in endpoint studies [168–
170]. In the LEADER study Liraglutide reduces the ampu-
tation rate.
For semaglutide, however, there is an increased rate of
microvascular ocular complications in combination with
insulin, which is why this GLP-1 agonist should not be used
in patients with diabetic retinopathy [169].
Thiazolidinediones (PPAR y agonists)
For Pioglitazone the PROACTIVE and the IRIS study show
positive endpoint in cardiovascular survival in type 2 dia-
betes and prediabetic patients [171–175] In the PROACTIVE
trial, amputation was also considered the primary endpoint.
Here, however, no significant advantage over the control
group could be observed.
SGLT-2 inhibitors
For the substances empaglifozin, dapaglifozin and canagli-
fozin, the EMPAREG outcome study, the DECLARE-TIMI
study and the CANVAS study provide data for positively
influencing cardiovascular outcomes such as CV death,
fatal and non-fatal myocardial infarction and stroke [176–
179]. The EMPAREG outcome study furthermore revealed
a significantly reduction in amputations in PAOD whereas
for canaglifozin a significantly increased amputation rate
(mainly toe amputations) was observed. Although these
are retrospective subgroup analyses, the use of canaglifozin
in patients with diabetes and PAOD is currently not
recommended.
Insulin
For basal insulin therapy, no endpoint studies are available
for patients with PAOD. Insulin should be used in type 2
diabetics just in case of present cardiovascular complica-
tions, if possible, only after an optimized oral or GLP-1
based therapy.
In summery only empaglifozin and liraglutid have been
shown to reduce amputations. Therefore, these substances
should be considered in addition to metformin in patients
with diabetes with previously known PAD [180, 181].
Screening for diabetes in patients with PAD should be
carried out due to the close association between diabetes
and PAD.
5.2.5 Hypertension
Hypertension is associated with an increased prevalence of
PAD [182]. The increase in risk is modest but the high
prevalence of hypertension with increasing age makes the
contribution of elevated blood pressure to incident PAD
in the general population important. In men 40–79 years
old the hazard ratio for incident PAD in the presence of
hypertension was reported to be 2.42 [183], whilst a
20 mm Hg increase in systolic blood pressure was associ-
ated with a 62 % increased risk for PAD in a large popula-
tion study [184].
Antihypertensive therapy unequivocally reduces cardio-
vascular events and mortality. Current evidence suggests
a further benefit of reducing systolic blood pressure to
lower values than previously recommended [185–187].
Thus, current guidelines recommend a target blood pres-
sure, if tolerated, of 120–129/70–80 mm Hg in patients
below 65 years, and 130–139/70–80 mm Hg for older
patients (with no upper age limit), also in people with con-
comitant cardiovascular disease (including PAD) and
Recommendation Class of
recommendation
Level of
evidence
It is recommended that
patients with diabetes should
be screened for PAD
I B
It is recommended that all PAD
patients should be screened for
diabetes and effectively treated
in the case of a proven
diagnosis of diabetes. In type 2
diabetics in addition to
metformin empaglifozin and/or
liraglutid should be considered.
I B
Appropriate diabetic control is
recommended in patients with
PAD.
I B
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diabetes [188, 189]. A systolic blood pressure below
120 mm Hg should not be targeted as it may increase the
risk for acute coronary events and the risk of harm out-
weighs the benefits, in particular in patients with advanced
CAD and in the old.
Angiotensin converting enzyme (ACE) inhibitors, angio-
tensin receptor blockers (ARB), calcium antagonists, and
diuretics are all suited for blood pressure lowering treat-
ment in patients with PAD[188, 189]. ACE inhibitors and
ARB have been shown to reduce cardiovascular events in
patients with arterial peripheral vascular diseases [190–
192]. ACE inhibitors were proposed to improve symptoms
in patients with intermittent claudication [193] but this
view has been revised [194] while the calcium antagonist
verapamil was shown to prolong walking distance in
patients with PAD [195]. Studies in hypertension show
somewhat less reduction in cardiovascular events with beta
blockers than with other antihypertensive drug classes. Of
note, beta blockers are well tolerated in PAD patients and
are not contraindicated [196–198]. Thus, beta blockers
are useful in PAD patients with concomitant cardiovascular
disorders, where they are indicated.
Most patients require two or more drug classes to
achieve target blood pressure. Thus, a blocker of the
renin-angiotensin aldosterone system in combination with
a calcium antagonist or a diuretic is recommended, adding
the third drug, if needed, to achieve target blood pressure.
If blood pressure remains uncontrolled adding spironolac-
tone may be considered, which provides a greater reduc-
tion in blood pressure than adding an alpha blocker or a
beta blocker [Williams 2015]. However, beta blockers are
recommended when there are specific clinical indications.
5.2.6 Platelet aggregation inhibitors
in symptomatic PAD
The clinical significance of decreased platelet aggregation
in the secondary prevention of atherothrombotic vascular
disorders is undisputed. However, large convincing studies
showing a benefit of aspirin (ASA) in the reduction of vas-
cular lesions in PAD have not yet been carried out. This
applies to both PAD and the inhibition of progression in
peripheral atherothrombosis. A primary meta-analysis car-
ried out by the Antithrombotic Trialists’ Collaboration
failed to detect a significant decrease in cardiovascular
events in PAD patients who were taking ASA and who pre-
sented no further vascular lesions in other organs. So, while
there are conclusive study results regarding the secondary
prevention of cardiac and cerebrovascular events in
patients with PAD with antiplatelet agents other than
aspirin, the data base regarding the primary prevention of
peripheral arterial events is insufficient and in part contra-
dictory [199–201].
In a subsequent meta-analysis including many platelet
aggregation inhibitors (ASA, clopidogrel, ticlopidine, dipyri-
damole, picotamide), a 23 % reduction in the relative risk
for ischemic events was seen in all patients with PAD
[202] butmost patients received ticlopidine in these studies.
The benefit of life-long antiplatelet treatment in patients
with PAD to prevent CAD or cerebrovascular lesions does
seem convincing [9, 16, 203]. Historically ticlopidine has
been investigated in several studies in PAD patients and
has shown to reduce the risk of MI, stroke and vascular
death [204]. However, its benefits are limited by very
frequent gastrointestinal side effects and potential side
effects as neutropenia and thrombocytopenia. Therefore,
clopidogrel, another thienopyridine derivative, has
replaced ticlopidine. Clopidogrel was investigated in the
CAPRIE study in which it proved efficacy in lowering the
rates of MI, stroke and cardiovascular mortality. The over-
all benefit in the PAD subgroup compared with ASA was a
24 % relative risk reduction [203]. In terms of numbers
needed to treat (NNT) and compared to ASA, this corre-
sponds to a total of 87 patients treated with clopidogrel over
three years to avoid one additional cardiovascular event. In
the current ESC PAD guidelines, clopidogrel was therefore
recommended over aspirin in PAD patients [12]
(Table 5.2.6).
In the EUCLID study [205], ticagrelor and clopigogrel
were equivalent in effect, though there were more drug dis-
continuations for side effects with Ticagrelol. Disappoint-
ingly, there was no ASA arm. However, the significance
of the novel P2Y12 adenosine receptor antagonists (prasug-
rel and ticagrelor) for PAD is still a matter of ongoing
research. The daily dose of clopidogrel in secondary pro-
phylaxis is 75 mg.
Based on the TRA 2P – TIMI 50 study, vorapaxar, a
thrombin receptor (protease-activated receptor, PAR-1)
antagonist, was granted approval in the US for the secondary
preventive treatment of CAD and PAD (in combination with
ASA or clopidogrel, to the exclusion of patients with cerebral
Recommendation Class of
recommendation
Level of
evidence
It is recommended that in
patients with PAD and arterial
hypertension, blood pressure
should be treated to reduce
cardiovascular events.
I A
It is recommended that
systolic blood pressure should
be targeted to 120–129 mm
Hg, if tolerated, in most
hypertensive patients aged
below 65 years, with or without
cardiovascular disease.
I A
It is recommended that systolic
blood pressure should be
targeted to 130–139 mm Hg, if
tolerated, in older (65 years
and above) hypertensive
patients, with or without
cardiovascular disease.
I A
A diastolic blood pressure
below 80 mm Hg should be
considered for all hypertensive
patients
IIa B
Antihypertensive drug
treatment should consider
including an ACE inhibitors or
an angiotensin receptor blocker
IIa B
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arterial occlusive disease or a history of intracerebral bleeding
due to the increased risk of cerebral bleeding in this patient
group). Approval in Europe is limited to CAD. TRA 2P – TIMI
50 study yielded significant benefits in terms of vascular
complications and mortality for patients with PAD and CAD
treated with vorapaxar, a protease-activated receptor 1
(PAR 1) antagonist, yet no gain for those presenting with cere-
bral arterial occlusive disease [206].
The combination of ASA and clopidogrel in high-risk
patients with multiple risk factors and atherothrombotic
manifestations (including PAD) – as well as in patients pre-
senting with risk factors for cardiovascular disorders
resulted in an increased bleeding risk and no benefit [207].
Combination treatment across the board has no statisti-
cally significant risk reductions in terms of MI, stroke or
cardiovascular death. Therefore, combination treatment can-
not be generally recommended for all patients with PAD.
However, data from PEGASUS-TIMI 54 study [208, 209]
prove that, in PAD patients with previous myocardial infarc-
tion, a selected high ischemic-risk subgroup, dual-antiplatelet
therapy with aspirin and low-dose ticagrelor (60 mg b.i.d) is
associated with a 5.2% AR reduction in MACE and a reduc-
tion of MALE, while major TIMI bleedings were in excess of
only0.12%.Therefore, DAPTwith ticagrelor60mgb.i.d and
aspirinmay be considered in PADpatients with priorMI up to
3 years following the cardiac event. Evidence for prolonged
treatment is currently lacking [12].
Evidence for dipyridamole in PAD is absent and is thus
not indicated.
In summary, every symptomatic PAD patient should be
given long-term treatment with platelet aggregation inhibitors,
if there are no contraindications, as evidenced by the meta-
analysis of the Antithrombotic Trialists’ Collaboration and
data from the Swedish Ticlopidine Multicentre Study (STIMS)
and the Clopidogrel versus Aspirin in Patients at Risk of
Ischemic Events (CAPRIE) study [42, 199, 207].
5.2.7 Platelet aggregation inhibitors
in asymptomatic PAD
In asymptomatic disease, there is no evidence for the use of
aspirin. Patients with diabetes with asymptomatic PAD
given 100 mg daily of ASA, have shown neither reduced
rates of cardiovascular events (lethal and nonlethal MI,
Table 5.2.6. Recommendations on antithrombotic therapy in patients with symptomatic Peripheral arterial disease.
Recommendation Class of
recommendation
Level of
evidence
Lower extremity artery disease
Long term SAPT is recommended I A
Long term SAPT is recommended in patients after revascularisation I C
Long term SAPT is recommended after infra-inguinal bypass surgery I A
In diabetic patients requiring SAPT clopidogrel may be preferred over aspirin [16, 179] IIb B
VKA may be considered after autologous infrainguinal bypass IIb B
DAPT at least 1 month after infrainguinal stent implantation IIa C
DAPT may be considered in below the knee prosthetic bypass graft IIb B
SAPT in asymptomatic patients III A
DAPT at least 1 month after drug coated balloon angioplasty I C
DAPT at least 3 months after drug eluting stent implantation I C
DAPT at least 3 months after covered stent implantation I C
Combination of aspirin (100 mg/d) and rivaroxaban (2  2.5 mg/d) IIa B
Antithrombotic therapy for PAD Patients requiring oral anticoagulation (OAC)
In patients with an indication for OAC, oral anticoagulation alone should be considered IIa B
After endovascular revascularisation aspirin or clopidogrel should be considered in addition to
OAC for at least 1 month
IIa B
After endovascular revascularisation OAC alone should be considered if bleeding risks are high IIa C
OAC and SAPT may be considered if ischemic risk is high or there is another firm indication for
long term SAPT
IIb C
AF = atrial fibrillation; CAS = cartoid artery stenosis; CHA2DS2-VASc = Congestive heart failure, Hypertension, AGE  75 (2 points), Diabetes Mellitus, Stroke
or TIA (2 points), Vascular disease, Age 65–74 years, Sex category; DAPT = dual antiplatelet therapy; LEAD = lower extremity artery disease; OAC = oral
anticoagulation; PADs = peripheral arterial diseases; SAPT = single antiplatelet therapy.
Recommendation Class of
recommendation
Level of
evidence
In patients with symptomatic
PAD, platelet aggregation
inhibitors are indicated for the
secondary prevention of
cardiovascular events.
I A
Clopidogrel may be preferred
over aspirin.
IIB B
IIb B
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stroke, cardiovascular mortality) nor reduced rates of
major amputations compared to placebo-treated patients
[17, 200, 201]. Amongst other reasons, the authors attribu-
ted this result to the wide application of statins in this
high-risk group [167]. A large-scale, double-blind random-
ized population study covering a total of 28,980 Scottish
residents found no clinically conspicuous cardiovascular
disorders among 3,500 individuals with a decreased ABI
score of  0.95. After a median treatment and follow-up
period of 8.2 years, administration of ASA 100 mg/day
orally had yielded no difference in the rate of cardiovascu-
lar events compared to placebo [210]. The benefit of
antiplatelet agents in reducing peripheral arterial events
has only been evidenced for patients given invasive
endovascular treatment [42, 204].
5.2.8 Anticoagulants
From a peripheral arterial perspective, there is no indica-
tion for full dose INR lowering oral anticoagulation with
vitamin K antagonists in patients with PAD, provided that
there is no acute embolic event. However, the effect of a
low dose antithrombotic therapy with the new oral antico-
agulants in combination with ASA has been investigated.
In the COMPASS Trial [211], evaluating patients with
CAD, and CAD and PAD, rivaroxaban and aspirin alone
and in combination were studied in patients with stable
atherosclerotic vascular disease. Those assigned to rivarox-
aban (2.5 mg twice daily) plus ASA 100 mg daily, had a
24 % better total survival and cardiovascular outcome
(HR 0.76 (0.66–0.86)) but more major bleeding events
than those assigned to aspirin alone (HR 1.70 (1.40–
2.05)). Rivaroxaban (5 mg twice daily) alone did not result
in better cardiovascular outcomes than aspirin alone and
resulted in more major bleeding events. Clearly a decision
weighing up risks of CV event vs bleeding is required. The
net benefit was 22 % overall risk reduction of the stable
CAD/PAD population.
Additional analysis of the PAD subgroup (stable PAD,
CAD with asymptomatic PAD and stable carotid stenosis
patients) in the Compass trial population [212, 213]
revealed, besides the 28 % general survival benefit, an
Table 5.2.8. Preventive treatment for PAD and clinical benefits.
Treatment Agent Effect on morbidity
and mortality*
Effect on PAD* Effect on walking
performance*
Effect on ABI
Smoking abstinence Reduction of
cardiovascular
mortality
Cholesterol lowering Statin 12 % reduction in
overall mortality
38 % reduction in
the incidence of
intermittent
claudication
63 % increase in
pain-free walking
distances following
1 year of treatment
Ezetimibe 5 % risk reduction in
combination with
40 mg simvastatin
Evolocumab 12 % risk reduction
(95 % CI, 3 to 20) in
the first year and
19 % risk reduction
(95 % CI, 11 to 27)
beyond the first year.
Blood-pressure
lowering
Beta blockers 53 % reduction in
cardiovascular
events
ACE inhibitors/ARBs 22 % reduction in
risk of
cardiovascular
events
24 % improvement of
pain-free walking
distances; 17.5 %
improvement of
maximum walking
distances
ABI increase from
0.59 to 0.64
Diabetes treatment 17 % reduction in
risk of
cardiovascular
events
25 % reduction in
major amputations
Platelet inhibition Clopidogrel 23.8 % reduction in
risk of
cardiovascular
events
ASA + DOAC ASA 100 mg/d and
rivaroxaban
2  2.5 mg/d
28 % net clinical
benefit HR 0.80)
46 % reduction of
major adverse limb
events including
major amputation
(HR 0.54)
Source: [216] (modified); *Relative risk reduction.
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additional significant 46% reduction in major adverse limb
events including major amputation (HR 0.54 95%CI 0.35–
0.82) for ASA 100 mg/d combined with Rivaroxaban
2  2.5 mg /d compared to ASA 100 mg/d and placebo.
The net benefit was 28 % risk reduction for the PAD sub-
group of COMPASS compared to the 24 % MACE reduc-
tion in the CAPRIE subgroup [203].
Rivaroxaban was also shown to be effective in these
patients when suffering frommild tomoderate heart failure
[214]. An additional clinical trial (Voyager PAD) [215] com-
paring ASA 100mg/d with and without 2 2.5mg rivarox-
aban/d including symptomatic PAD patients undergoing
a surgical- or catheter-based intervention- is underway.
Also, other new oral anticoagulants are being tested in a
clinical phase 3 trial in combination with ASA in this patient
population. Table 5.2.8 gives an overview of the benefits of
consistent treatment for cardiovascular risk factors in
patients with PAD.
Recommendation Class of
recommendation
Level of
evidence
Based on the results of the
COMPASS trial, the combined
therapy of ASA 100 mg/d and
rivaroxaban 2  2.5 mg/d
should be considered in PAD
patients without a high risk of
bleeding, or other
contraindications.
IIa B
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6 Conservative treatment for PAD:
Symptom control
6.1 Conservative treatment for
intermittent claudication
6.1.1 Walking training/rehabilitative
sports in PAD
Walking training and physical activity are particularly
important in the treatment of PAD. Structured walking is
the most significant non-medical treatment for PAD along
with treatment for cardiovascular risk factors. Cochrane
reviews of the effectiveness of walking training, and addi-
tional benefits arising from supervised structured vascular
training, have unambiguously shown the value of vascular
sports [217–219]. Structured and supervised walking train-
ing has been shown to be superior to non-supervised walk-
ing. Walking training programs carried out for at least 3
months under supervision and/or according to instructions
have shown both an increase in walking ability and a
decrease in the severity of claudication [220, 221].
Structured walking training (e.g. in vascular sports
groups) is effective when carried out at least three times a
week for 30 to 60 minutes [222, 223]. Controlled studies
in patients with claudication have demonstrated increases
in walking distances amounting to approx. 200 % after 12
weeks [222–225]. Individual daily interval training for 60
minutes with 5- to 15-minute intervals was shown to be
effective in prolonging walking distances. Intensities were
chosen to allow claudication pain to develop [226–228]. In
studies, functional long-term results of walking training also
proved equivalent to vascular interventions alone [227, 228].
However, the effects of endovascular revascularization and
walking training are additive [224, 229] and both treatment
modalities may be part of an integrative approach. It has
also been shown that upper limb training can benefit
endothelial function in PAD patients. The favorable prog-
nostic factors in walking training include the following crite-
ria: less than 1 year following diagnosis of PAD, femoral
artery occlusion, and good cardiopulmonary condition.
The same beneficial increase in pain free walking dis-
tance can be achieved in active smokers and nonsmokers.
Thus, walking training is to be an inherent part of treatment
for claudication.
A study [230] has demonstrated that endurance training
with arm ergometers may produce improvements in pain-
free and absolute walking distances that are comparable
to the results of treadmill training, with similar calorie con-
sumption and that such training thus could be an alterna-
tive or supplement to walking training.
Regular walking training and vascular sports lead both to
improvements in walking distances and show additional
beneficial modifications of glucose and lipid metabolism
[231, 232].
Patients with pelvic artery stenoses and occlusions may
also benefit from vascular training.
Taking into account all available study results, however,
it should be noted that the number of patients evaluated in
these studies is low [226].
As long as vascular lesions are not successfully recanal-
ized by endovascular interventions or vascular surgery,
walking training is not effective in stenoses of the deep
femoral artery and occlusion of the ipsilateral superficial
femoral artery. Thus, vascular recanalization should be per-
formed in pelvic vascular lesions, femoral bifurcation
lesions, and deep femoral artery stenoses or occlusions
before basic treatment with walking training is subse-
quently introduced [224, 233].
In patients with high-grade stenosis or occlusion of the
popliteal artery, exercise may have a limited effect on clau-
dication because of the reduced options for collateraliza-
tion. Therefore, revascularization may be recommended
in this group prior to physical training, though remember-
ing that surgical outcome may be associated with lower
patency rates.
Alternative forms of training, e.g. of the upper limbs,
should be attempted if walking training is not possible
[220, 221].
Vascular sports groups or structured training programs
have not yet been implemented everywhere. In this respect,
there is considerable need for action when compared with
the much greater numbers of coronary sports groups/exer-
cise classes.
Approximately 50 % of PAD patients present with con-
comitant orthopedic and/or neurological disorders and/
or cardiopulmonary functional deficits, which may impede
walking training or render participation in structured vas-
cular sports groups impossible. Such comorbidities are to
be recorded prior to walking training and modifications
introduced in order to facilitate participation in walking
training for as many patients as possible.
6.1.2 Medical treatment
Controlled studies have shown an effective increase in
walking distances after treatment with cilostazol and
naftidrofuryl. Maintenance of walking distance improve-
ments have been shown in 6- and up to 12-month treat-
ments with cilostazol and naftidrofuryl, respectively.
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Treatment with these agents is to be discontinued if symp-
toms fail to improve after 3months. A re-evaluation should
then be carried out and, where appropriate, vascular train-
ing be continued throughout, as regardless of possible med-
ical treatment with cilostazol or naftidrofuryl, patients with
claudication should be encouraged to engage in physical
exercises and regular walking training.
6.1.2.1 Cilostazol
Cilostazol, a type-3 phosphodiesterase inhibitor, is an oral
substance. Apart from antiaggregant properties, effects of
cilostazol on endothelial and smooth muscle tissue cells
have been reported [234, 235].
Several large-scale, placebo-controlled studies have
observed a significant increase in pain-free and maximum
walking distances with this substance, in addition to superi-
ority over pentoxifylline [236–238]. The most recent
Cochrane analysis of data from 15 double-blind, placebo-
or actively controlled studies, showed pain-free walking
distances to improve by an average of 31 m in participants
taking cilostazol 100 mg twice daily [239]. The fact that
no reduction of cardiovascular events was shown for cilosta-
zol was ascribed to low patient numbers, short observation
periods and various forms of bias which together impaired
the methodical quality of most of those investigations. Six
RCTs have investigated cilostazol in patients with intermit-
tent claudication. Administration of 100mg twice daily was
shown to yield an average increase in maximum walking
distance of 76% compared to 20%with placebo. Along with
statistically significant improvements in walking ability,
quality-of-life improvements were also documented [240].
The main side effects, headache and diarrhea, are attrib-
uted to the vasodilating properties of cilostazol [241]. In a
long-term observation in 1,885 patients, the Cilostazol: A
Study in Long-term Effects, a large-scale safety investiga-
tion, showed no increase in cardiovascular mortality or
bleeding tendency [242]. Cilostazol is contraindicated in
patients with clinically manifest heart failure, unstable ang-
ina pectoris and MI, or coronary intervention within 6
months, as well as severe tachyarrhythmia [243].
Recent studies have demonstrated amarked reduction in
restenosis rates following coronary and peripheral inter-
ventions with administration of cilostazol, in addition to
standard therapy (dual antiplatelet therapy with ASA and
clopidogrel) compared to placebo [244–250]. However,
data available to the European Medicines Agency (EMA)
indicate that the risk of bleeding may increase with con-
comitant administration of cilostazol and dual antiaggrega-
tion. Combinations with only one of the substances or sole
application do not result in an increased bleeding risk [251].
Further as above, it is contraindicated in MI.
6.1.2.2 Naftidrofuryl
Six older studies with naftidrofuryl and a Cochrane analysis
have summarized the benefits of long-term oral treatment
[252]. The Cochrane Review concluded ‘Oral naftidrofuryl
has a statistically significant and clinically meaningful,
although moderate, effect of improving walking distance
in the six months after initiation of therapy’. The Artéri-
opathie Praxilene Indépendence Evénements Critiques
(APIEC) study recruited 168 patients with claudication to
be treated with naftidrofuryl or placebo for 1 year. The
active group showed significant 107 % and 74 % improve-
ments in pain-free and maximum walking distances,
respectively [253]. Older studies had evidenced quality-
of-life improvements for participants with claudication,
which, however, more recent analyses failed to reproduce
this [254]. A Cochrane analysis has suggested Cilostazol
may be better than naftidrofuryl [239].
The effective recommended daily dose of naftidrofuryl is
200 mg tid.
Recommendation Class of
recommendation
Level of
evidence
It is recommended that
structured walking training is to
be offered to all PAD patients
with intermittent claudication as
an inherent part of basic
treatment.
I B
It is recommended that
supervised training programs
under regular instruction be
offered as they are more effective
than unstructured vascular
training.
I B
It is recommended that a
supervised Vascular workout in
patients with intermittent
claudication should take place at
least 3 times a week for at least
30-minutes over at least 3
months.
I B
Daily individual vascular training
should be considered in the
conservative treatment of
patients with intermittent
claudication, if no supervised
training programs are available. It
is less effective than supervised
programmes.
IIa B
Recommendation Class of
recommendation
Level of
evidence
It is recommended that
consideration be given to cilostazol
and naftidrofuryl as they may be
beneficial in improving walking
distance in patients with
claudication. They should be
prescribed only if the patients’
quality of life is substantially limited,
and walking training is restricted,
unfeasible or ineffective.
I B
It is recommended that treatment
with these agents is to be
discontinued if symptoms fail to
improve after 3 months.
I B
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Prescription of these substances can also be useful if,
assessing the risk-benefit profile, arterial revascularization
is too elaborate or risky or not accepted by the patient.
6.1.2.3 Others
There is no evidence that treatment with other vasoactive
substances is effective in improving walking performance
in claudication and are thus not indicated.
A systematic review comparing cilostazol, naftidrofuryl,
and pentoxifylline in intermittent claudication analysed a
total of 26 RCTs and identified naftidrofuryl as the most
effective agent. Pentoxifylline was shown to be least effec-
tive in terms of improved maximum and pain-free walking
distances. Maximum walking distances were increased by
60 % (95 % CI 20–114), 25 % (95 % CI 11–40), and 11 %
(95 % CI 1–24) under naftidrofuryl, cilostazol and pentoxi-
fylline, respectively, and pain-free walking distances by
49 %, 13 %, and 9 % respectively [255].
Statins may be useful in improving walking distance, but
studies are small and need to be substantiated, as men-
tioned above [138–140].
Prostanoids, pentoxifylline, L-arginine, buflomedil and
ginkgo biloba, have produced insufficient evidence for clin-
ical application in claudication [238, 256–259]. The same
applies to isovolemic hemodilution and other alternative
treatments.
6.2 Conservative treatment for CLI
The primary objectives of treatment for CLI are alleviation
of pain, healing of trophic lesions, avoidance of high-level
amputations, improvement of limb functioning and quality
of life, and medium-term survival improvement. These
aims necessitate an interdisciplinary approach. The pri-
mary andmost useful treatment option is revascularization.
Other approaches include analgesics administration,
infection treatment, and the optimization of cardiac and
pulmonary function. Monitoring of and treatment for car-
diovascular risk factors is required in patients with CLI at
least as much as any other patient with PAD [28, 67].
6.2.1 Treatment for ulceration
Multidisciplinary approaches are required to adhere to the
major principles of treatment [260]:
1. Improvement of perfusion/revascularization as far as
possible;
2. Local wound management: elimination of necrosis,
moist wound milieu, treatment of infection;
3. Consistent and sufficient pressure relief, initially by
immobilization, then with adequate expedients/
relief shoes.
6.2.1.1 Infection
Local disinfection is preferred over local or systemic antibi-
otics [261]. Systemic antibiotic treatment is to be restricted
unless there is the presence of systemic and or clinical signs
of infection according to the PEDIS criteria, to avoid antibi-
otic resistance [262, 263]. In contrast, some patients with
diabetes may show little inflammatory response and care
should be taken not to deprive these patients of appropriate
antibiotic therapy if there is a sudden clinical deterioration
in their limb. Local antibiotics are not recommended.
Patients with diabetic foot disease and osteomyelitis may
be well treated with minor surgical procedures.
Recommendation Class of
recommendation
Level of
evidence
Prostanoids, pentoxifylline, L-
arginine, buflomedil and ginkgo
biloba are not recommended to
relieve claudication discomfort,
as sufficient benefits in terms of
improved walking distances,
morbidity, mortality and quality of
life have not been substantiated.
III B
Recommendation Class of
recommendation
Level of
evidence
Surgical or interventional
revascularization is the first-line
therapy in CLI.
I A
Recommendation Class of
recommendation
Level of
evidence
A multidisciplinary approach by
vascular specialists is indicated
in all CLI patients, to manage
pain, cardiovascular risk factors
and comorbidities, in addition to
the primary revascularization.
I B
Recommendation Class of
recommendation
Level of
evidence
It is recommended that
I B/C
 Any chronic lesion (not healed
after 6 weeks) should be
swabbed at first presentation
of the patient.
 Optimally swabs should also
be taken from nose and groin
to exclude the presence of
multi-resistant bacteria.
 After transfer from another
hospital or care homes,
patients should be isolated
until the results of the swabs
are available.
 Patients with similar types of
multi-resistant germs can be
isolated in the same room.
 The hospital’s infection
control plan should be
implemented in all CLI
patients.
 The WIFI or PEDIS
classification systems should
be used to classify infection.
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Non-revascularisable vascular lesions and unmanage-
able infection are the most significant predictors of major
amputation. A prospective cohort study has shown
increased rates of major amputations in spite of successful
revascularization due to uncontrolled infections.
Normoglycemic metabolic status is to be achieved in
patients with diabetes with CLI [7].
6.2.2 Prostanoids
Prostanoids are used when revascularizing procedures can-
not be applied or have proven ineffective. Two randomized
double-blind studies with prostaglandin E1 (PGE1) have
demonstrated benefits in the reduction of ulcer size [264,
265]. A study with the stable prostacyclin analogue,
iloprost, showed increased lower limb preservation and
survival rates with prostanoid therapy [266]. As demon-
strated in a meta-analysis, pain at rest and ulcer size may
be reduced with 2 to 4 weeks of iloprost treatment. More-
over, after 6months of observation, a 65% rate of survival
and leg preservation was seen with active medication com-
pared to 45%with placebo [267]. Another meta-analysis of
placebo-controlled PGE1 studies showed that the com-
pound significantly improved rates of ulcer healing and
reduced pain compared to placebo [265]. Within 6months,
a significant difference in favor of PGE1 was also seen in
terms of major amputations and mortality (PGE1: 22.6 %;
placebo: 36.2 %) [265].
The most recent Cochrane analysis of prostanoid effi-
cacy in patients with CLI participating in 20 older RCTs
has identified positive effects with regards to ulcer healing
(RR 1.54; 95%CI 1.22–1.96), pain reduction (RR 1.32; 95%
CI 1.1–1.57) and improved amputation rates (RR 0.69; 95%
CI 0.52–0.93) compared to placebo or active control treat-
ments. However, these studies failed to substantiate long-
term benefits or decreases in cardiovascular mortality
[268].
A recent RCT has failed to show any significant benefit
from alprostadil in CLI [269].
Prostanoids are no longer listed as medical treatment
options for patients with CLI in the guideline recommenda-
tions issued by the American College of Cardiology/
American Heart Association (ACC/AHA) [67] and the
National Institute for Health and Care Excellence (NICE) [68].
6.2.3 Stem Cell/Growth factor/
Regenerative therapy
Cell and gene therapies are emerging as treatments for
patients with CLI who are not eligible for endovascular or
surgical revascularization. Several pre-clinical and early
clinical studies suggested that different types of genes,
angiogenic factors, and stem cells with regenerative poten-
tial and paracrine ability could improve blood circulation
and tissue perfusion, and thus prevent amputation via the
induction of capillary or collateral growth in a process
called “therapeutic angiogenesis” [270, 271]. However in
many cases larger studies have so far failed to confirm
benefit.
6.2.3.1 Gene therapy
Different types of gene therapies (i.e. hepatocyte growth
factor, fibroblast growth factor 1, and vascular endothelial
growth factor) using different vector systems (i.e. non-viral,
liposomal, viral) have been studied. They showed favorable
safety profiles with low rates of adverse events.
The only large-scale phase III randomized trial with
fibroblast growth factors (FGFs) applied in gene therapy
for PAD proved to be negative [272]. The preliminary
encouraging results of small case histories, case-control
studies and a small, randomized controlled pilot study with
genetically engineered non-viral FGF 1 (NV1FGF) in CLI
have not been corroborated [271, 273, 274].
Similarly, investigation of gene therapy for other growth
factors was discontinued over time due to missing proof of
concept in various phase II trials.
6.2.3.2 Cell therapy
Although, many cell types have been tested, most clinical
trials to date have relied on the use of adult autologous
bone marrow-derived mononuclear cells or peripheral
Recommendation Class of
recommendation
Level of
evidence
Only patients with CLI and
systemic infections are
recommended to receive
systemic antibiotic treatment,
although exceptions may occur in
patients with diabetes.
I B
Recommendation Class of
recommendation
Level of
evidence
Concomitant bone infection
should be ruled out in the
presence of soft-tissue
infections, as therapeutic regime
(duration of antibiotics, partial
resection of bone) may change
once such infections have been
detected.
I C
Recommendation Class of
recommendation
Level of
evidence
Prostanoids may be considered
to provide a modest benefit in CLI
patients.
IIb B
Prostanoids may be considered as
a medical treatment for patients
with CLI who are not eligible for
revascularization or where
revascularization has failed.
IIb B
This treatment is not
recommended as an alternative
to revascularization.
III B
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blood-derived mononuclear cells derived from the PAD
patients treated [275, 276].
Despite several small early studies documenting the pos-
itive clinical outcomes of stem cell therapy, others have
failed to confirm earlier results [277]. A recent meta-
analysis of placebo-controlled trials using autologous bone
marrow cells showed no advantage of stem cell therapy on
the primary outcome measures of amputation, survival and
amputation-free survival in patients with CLI [278]. Fur-
ther, larger randomized placebo-controlled trials have so
far failed to confirm earlier encouraging results [272].
The reasons may lie in the reduced availability and
impaired quality of those cells deriving from patients with
cardiovascular or vascular disease [279, 280].
Alternatively, mesenchymal stem cells have gained ther-
apeutic interest in interventions aimed at tissue restoration
because of their multipotent differentiation capacity and
their cytoprotective and immunomodulatory effects [281,
282]. Also, they derive from young healthy individuals
and patients do not have to undergo bone marrow aspira-
tion. Large phase III trials with placenta-derived stem cells
are currently ongoing in claudication and CLI patients.
6.2.4 Spinal cord stimulation
Available data on the efficacy of spinal cord stimulation
(SCS) are inconsistent in terms of pain reduction, ulcer
management and limb preservation in patients who are
not eligible for revascularization and in non-responders to
revasularisation [283, 284]. Among six controlled, yet
non-blinded studies, the most recent Cochrane review
identified an increased rate of limb preservation after 12
months (RR 0.71; 95 % CI 0.56–0.90) and pain reduction
with SCS compared with conservative treatment. However,
no significant effect was seen for ulcer healing. The compli-
cation risk under SCS amounted to 17%, including implant
difficulties in 9%, stimulation difficulties necessitating re-
implantation in 15 %, and local infections in 3 % [285].
Another meta-analysis covering five randomized studies
failed to identify an advantage of SCS over conservative
treatment alone [286].
6.2.5 Hyperbaric oxygen therapy
Hyperbaric oxygen therapy (HBOT) has been in use for
several decades, especially for the treatment of diabetic
wounds, including diabetic gangrene and diabetic foot
ulcers as well as chronic or recurring wounds in which
hypoxia has been demonstrated (as in critical lower limb
ischemia). However, there is currently no clear evidence
regarding its effectiveness.
In 2008 [287], a report issued by the Federaal Kennis-
centrum voor de Gezondheidszorg (KCE, Belgian Health
Care Knowledge Centre) attempted to describe the history
of HBOT, the evidence for its use in different conditions,
the economic value of its application, the costs for patients,
hospitals and society. According to this report, even if
HBOT was accepted by the European Committee for
Hyperbaric Medicine (ECHM) and the Undersea & Hyper-
baric Medical Society (UHMS) as a possible treatment for
delayed wound healing, there was only low-quality evi-
dence from small RCTs on the clinical efficacy of adjuvant
HBOT in patients with diabetic ulcers in terms of major
amputations in the medium term. Furthermore, there was
very low-quality or no evidence for the efficacy of adjuvant
HBOT for delayed wound healing other than that associ-
ated with diabetes.
According to a recent review and meta-analysis [288],
there is low- to moderate-quality evidence suggesting a
beneficial effect of HBOT when used as an adjunct to stan-
dard treatment for diabetic foot ulcers. HBOT is unlikely to
be helpful in patients with severe uncorrectable ischemia
because oxygen will not reach the ischemic area in a suffi-
cient tension to stimulate angiogenesis.
In a recent, well designed randomized study [289], 107
patients with diabetes and foot lesions (Wagner grade 2–
4) of at least 4 weeks’ duration who had comprehensive
wound care were randomly assigned to receive 30 daily ses-
sions of 90min of HBOT (breathing oxygen at 244 kPa) or
sham (breathing air at 125 kPa). At 12 weeks post-randomi-
sation, 103 patients were available for endpoint adjudica-
tion. Criteria for major amputation were met in 13 of 54
patients in the sham group and 11 of 49 in the HBOT group
(OR 0.91 [CI 0.37, 2.28]). Twelve patients (22 %) in the
sham group and 10 (20%) in the HBOT group were healed
(OR 0.90 [0.35, 2.31]). HBOT in that study failed to offer an
additional advantage to comprehensive wound care in
reducing the indication for amputation or facilitating wound
healing in patients with chronic diabetic foot ulcers.
Recommendation Class of
recommendation
Level of
evidence
Regenerative treatments outside
clinical trials is not recommended
in CLI on the basis of current
evidence.
III B
Recommendation Class of
recommendation
Level of
evidence
Due to its costs and spectrum of
side effects, use of this treatment
requires interdisciplinary
agreement and may only be
recommended once all methods
of revascularization have been
exhausted.
IIb B
Recommendation Class of
recommendation
Level of
evidence
Currently, there is no clear
evidence regarding the
effectiveness of hyperbaric
oxygen therapy as an adjunctive
therapy for the treatment of
wounds linked with severe
lowering of distal perfusion of the
lower limbs. Thus, it cannot be
recommended as a treatment.
III A
2019 Hogrefe Vasa (2019), 48 (Supplement 102), 35–40
6 Conservative treatment for PAD: Symptom control 39
6.2.6 Other medical treatments
Other medical treatments with vasoactive substances (bu-
flomedil, pentoxifylline), heparin, or fibrinolytic drugs have
shown no benefit in reducing amputation rates or promot-
ing wound healing [290]. Evidence is still lacking for anti-
platelet drugs in CLI have which failed to influence
amputation-free survival, although they reduce the fre-
quencies of cardiovascular events and mortality. However,
the combination of an antiplatelet inhibitor with DOAC has
proven to reduce limb amputations in a PAD population
studied (low ABI, Claudication, previous intervention) by
70 % in the COMPASS trial [212].
In the presence of critical ischemia, interdisciplinary
decisions regarding revascularization are to be made as
quickly as possible [48].
Figure 6.1 summarizes the current guideline-adapted
treatment recommendations for patients with CLI.
Recommendation Class of
recommendation
Level of
evidence
In patients with CLI, adequate
interventional, surgical or
conservative treatment
procedures are to be selected as
quickly as possible and on an
interdisciplinary basis.
I A/B
Clinically proven 
CLI
Imaging
Patient fit for 
revascularization
Patient unfit for 
revascularization
Revascularization, 
if possible
No pain control, 
progressive infection
Amputation
Pain and lesion 
stable
Conservative 
treatment *
* Medication, woundcare, off loading, paincontrol, antibiotics (ifindicated)
Source: Modified from TASCII(8)
Figure 6.1. Algorithm for the treat-
ment of patients with CLI. Source:
Modified from TASCII [8].
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7 Interventional treatment for
peripheral arterial disease
7.1 Introduction
Arterial reconstruction based on open surgical procedures
or endovascular methods are symptomatic treatments that
do not solve the underlying problem of progressive chronic
atherosclerosis. However, they provide a reasonable and
stage-adapted symptomatic treatment. The underlying
atherosclerotic process still needs to be addressed.
The following are to be considered in the indications for
interventional PAD treatment:
 PAD stage according to Fontaine or Rutherford
 Site, morphology and complexity of the vascular
lesions
 Concomitant disorders and procedural risk
 Patient’s individual treatment wishes
The final aspect is particularly important, as several dif-
ferent treatments have all been shown to be feasible in the
different stages of PAD. This is exemplified by the difficult
choices to be made between conservative treatment and
invasive endovascular or surgical treatment in the earlier
stages of claudication. Also, in the treatment of critical limb
ischemia (CLI), both endovascular and surgical measures
can be used effectively, and it is crucial to discuss the
advantages and disadvantages of each with the patient.
Treatment recommendations must also consider the on-
site availability of the various therapeutic methods, as well
as the specific expertise of local interventionalists and
surgeons.
Interventional treatment in PAD is characterised by
rapid technological developments and high-level accep-
tance of non-invasive procedures among patients and oper-
ators. Therefore, clinical studies of interventions are
urgently needed, e.g. in registries, and regularly assessed
in terms of efficacy and safety. Defined questions can be
addressed in the framework of multicenter studies.
7.2 Treatment according to clinical stages
7.2.1 Asymptomatic PAD
There is insufficient data as yet to confirm whether a pro-
phylactic interventional procedure may positively impact
the course of disease, limb salvage or survival in asymp-
tomatic patients.
However, rarely interventional treatments can be consid-
ered in individual asymptomatic cases – this is most
common in patients with diabetes with painless polyneu-
ropathy and severe 3 vessel disease below the knee associ-
ated with hemodynamic critical limb ischemia at high risk
for major tissue loss or amputation. Early re-intervention at
an asymptomatic stagemay also be considered in severe in-
stent restenosis or bypass stenosis where total re-occlusion
may be prevented by intervention (including graft failure)
or distal thromboembolism. However, no data is available
from evidence-based studies [38].
Table 7.1 stratifies potential patients at risk of foot
lesions, thus guiding choice of management, even though
subjective symptoms (claudication, pain at rest, necrosis)
may not yet be present.
7.2.2 Intermittent claudication
In patients with intermittent claudication, regular and
supervised exercise programs increase walking distances
(so-called structured walking training) and may be equally
efficient as revascularizations using angioplasty or vascular
surgery [228]. However, structured exercise is less effective
in pelvic and popliteal occlusions [224]. In many patients,
pharmacotherapies are less effective compared to interven-
tional therapies in the short term. Moreover, improving
walking distances by exercise training contributes also to
secondary cardiovascular prevention due to the cardiovas-
cular benefits of increased exercise and endurance train-
ing. Thus, conservative treatment options should always
be considered, especially following revascularization.
The Mild to Moderate Intermittent Claudication
(MIMIC) trial showed improved long-term treatment suc-
cess following initially successful interventional treatment
in both iliac and femoropopliteal lesions when accompa-
nied by subsequent structured vascular training [224].
Insufficient data is available regarding long-term results
of crural interventions for claudication, as intermittent
claudication is not generally an indication for crural inter-
ventions and walking exercise should be encouraged.
Recommendation Class of
recommendation
Level of
evidence
Endovascular procedures are not
generally indicated as
prophylactic treatment in PAD
Fontaine stage I.
III B
Table 7.1. Type 2 diabetes: Patients at risk for foot lesions (modified
from [38]).
Indications Risk classification
No sensory neuropathy Low
Sensory neuropathy and signs of
PAD and/or foot deformities
Increased
Early ulcer High
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Following failure of conservative and/or medical treat-
ment in patients with intermittent claudication, interven-
tional treatment can produce short- and medium-term
quality-of-life improvements along with improvement in
walking ability [291]. Interventional or surgical measures
may be considered in patients suffering from significant
discomfort or pain, and when there is a need for longer
walking distances because of the patient’s profession, or
when explicitly desired by the given patient. A warning that
a failed intervention may have serious limb consequences
must, however, be given. Revascularizing measures can
be considered, when improvement of mobility is still desir-
able but structured walking training is no longer feasible
due to various circumstances, or no longer effective.
Impaired quality of life and individual disability due to
decreased walking capacity are key to guiding recommen-
dations for interventional treatments in patients with
claudication.
However, interventional treatments below the knee
should be considered in each individual carefully – this is
most common in patients with diabetes with painless
polyneuropathy and severe 3 vessel disease below the knee
associated with hemodynamic critical limb ischemia at
high risk formajor tissue loss or amputation. These patients
may also have foot claudication, but they are at risk of
ulceration because of the neuropathy also. Structured
exercise and symptomatic medical treatments are often
insufficient in those with aortic or pelvic arterial lesions,
and probably also those with popliteal occlusions, and are
not recommended.
In this setting, and after excluding patient-related con-
traindications, endovascular treatment is the method of
choice in the presence of appropriate vascular location
and morphology (TASC A to C). Vascular surgery is primar-
ily to be considered in femoral bifurcation lesions.
Revascularization is likely to improve walking capacity
and therefore may reduce cardiovascular risk.
7.2.3 Critical limb ischemia
7.2.3.1 Basic aspects of treatment
The term CLI is used for patients with chronic ischemic
pain at rest, and/or ulcerations and/or gangrene attributa-
ble to objectively proven arterial occlusive disease (see
haemodynamic definition of PAD).
The short-term clinical results of surgical and interven-
tional treatments are equivalent in clinical Fontaine stages
III and IV [48]. Surgical treatments are associated with a
higher morbidity and mortality, as well as higher costs, par-
ticularly in the presence of co-morbidities and increased
perioperative risks for patients. Endovascular treatments
are characterised by lower levels of invasiveness and com-
plication rates, yet they more frequently require further
treatment, mostly re-interventions due to restenosis or re-
occlusion. On the basis of these advantages and disadvan-
tages, individual risks and benefits should be assessed, and
endovascular treatment given preference as the initial step.
The primary treatment objective in patients with critical
ischemia is amputation-free survival, thus a decrease in
both amputation and subsequent mortality rates among
these patients at high cardiovascular risk is the aim. The
long-term treatment results in patients with critical ische-
mia and those with intermittent claudication are thus dif-
ferent (see Table 7.2).
Reconstruction of unimpeded infrainguinal perfusion
into at least one of the crural arteries is crucial to eliminate
critical ischemia. This is a key precondition for the preser-
vation or reconstruction of functional and pain-free limbs.
Apart from revascularization, other factors have a substan-
tial influence on healing and avoidance of amputations,
Recommendation Class of
recommendation
Level of
evidence
In patients with short distance
claudication, in whom walking
training has proven impossible, or
unsuccessful, and in the
presence of suitable vascular
lesions, interventional treatment
is recommended to improve
quality of life.
I C
Interventional treatments
following failed conservative
treatment in patients with
intermittent claudication is
recommended only if
symptomatic and quality-of-life
impairment is severe.
I B
Recommendation Class of
recommendation
Level of
evidence
Interventional treatment for
claudication is recommended in
patients with proximal (including
proximal popliteal) vascular lesions
because of the good risk/benefit
ratio of catheter-based
interventions in these localizations.
I B
Table 7.2. Treatment aims in intermittent claudication and CLI.
CIaudication
 Sustained symptomatic improvement,
i.e. improvement of pain-free and maximum
walking distances
 Quality-of-life improvement
 Reduction of cardiovascular risk and limb
vascular event risk
CLI
 Increase in leg-salvage rates
 Quality-of-life improvements
 Decrease in mortality/Reduction of
cardiovascular risk and limb vascular event risk
 Increase in amputation-free survival
 Ulcer healing
 Pain reduction/resolution
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including diabetes mellitus, end-stage renal failure, and a
stage VI progressive tissue defect according to Rutherford.
Most patients with CLI present with a hugely impaired
physical condition andmultiple additional health problems,
which makes the treatment of such patients a multidisci-
plinary challenge. Rapid management is a prerequisite to
save legs and lives. The broad range of possible patholo-
gies, the frequent frailty of the patient population with
CLI, the frequent rapid progression, the urgent need for
therapy, as well as the complexity of the different therapeu-
tic options together result in the recommendation to refer
those critically ill patients to specialised institutions.
In these specialized institutions, CLI patients should be
evaluated using ankle pressure, always combined with toe
pressure, measurements due to the high prevalence of
medial sclerosis in CLI, followed by vascular ultrasound,
as the majority of pathologies can be diagnosed with these
methods without necessarily applying radiation or contrast
media. Additional angiographic CT examination is recom-
mended only in doubtful cases. Diagnostic angiography
as the initial therapeutic tool is not advised because of
the invasive nature of the procedure and the limited
amount of information obtained with this technique (only
luminal information, no vessel diameter, no additional wall
information).
In addition to ultrasound examination, which reveals the
cause of CLI, the degree of tissue impairment should also
be evaluated (and documented) with noninvasive methods,
such as pulse-volume recordings, toe oscillometry and toe
pressure measurement, in addition to functional tests,
including TcPO2measurement or laser Doppler flowmetry
(or intra-cutaneous capillaroscopy).
Prior to any interventional approach, interventionists are
required to evaluate the patients’ general clinical state and
review all diagnostic data. Particular attention is to be paid
to the medication given on admission and during the hospi-
tal stay, basic laboratory findings (blood count, renal func-
tion, potassium, creatinine kinase, coagulation, thyroid-
stimulating hormone level, blood glucose HbA1c), ultra-
sound or angiographic CT results (including access site
and access path evaluation), possible additional medication
before intervention (additional thrombocyte inhibition by
dual antiplatelet therapy – possible pre-interventional load-
ing dose), and the degree of required pain control.
Patients in uncontrolled pain (or presenting with
impaired co-operation for other reasons) are to be evalu-
ated for appropriate sedation prior to the intervention. A
horizontal position of the patient during endovascular pro-
cedures worsens the perfusion situation at least initially
and therefore, increases the pain level which can result
uncontrolled agitation of the patient which may impede
the planned interventional treatment or even make it
impossible.
Provided with all possible information, interventionists
then develop the interventional strategies that have the
best chance of yielding good functional results with the
lowest risks of acute or subsequent vascular or other (e.g.,
renal, pulmonary, cardiac) complications. The different
techniques (ballooning and stenting including drug-eluting,
catheter aspiration, thrombolysis, catheter directed
mechanical and hydrodynamic thrombectomy, atherec-
tomy, and others) may be used in each individual case
depending on the given CLI situation. Many new interven-
tional tools still require evidence of additional benefit in
comparison with drug-eluting ballooning, catheter aspira-
tion or thrombolysis. Even if benefits are not proven yet,
many of these new tools have shown at least low risk
Recommendation Class of
recommendation
Level of
evidence
It is recommended to refer and to
treat CLI patients in specialised
institutions (ideally, accredited
vascular centers) that offer rapid
and reliable diagnostic
procedures, as well as timely
therapy to these severely ill
patients at high risk.
I C
Recommendation Class of
recommendation
Level of
evidence
Ankle combined with toe
pressure measurements
combined with color-coded
duplex sonography (in special
situations also angiographic CT)
is the recommended initial
diagnostic procedure in CLI
patients.
I C
Recommendation Class of
recommendation
Level of
evidence
Evaluation and standardized
documentation of the initial
degree of tissue perfusion
impairment is strongly
recommended in CLI patients.
I C
Recommendation Class of
recommendation
Level of
evidence
Prior to any interventional
approach, interventionists are
strongly recommended to assess
the clinical situation and all
laboratory data.
I C
Effective pain management is
indicated as it is one of the most
important prerequisites for
successful catheter
interventions.
I C
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profiles (no additional bleeding risk in comparison to
thrombolysis, reduced peripheral embolization risk).
Because of the heterogeneity of CLI patients and the
urgent requirement for treatment of the disease, it will be
a considerable challenge to gain strong levels of evidence
in this topic. Nevertheless, it should be the clear aim of fur-
ther research. International prospective ESVM-initiated
registries will be a first step.
7.2.3.2 Peripheral arterial disease – diabetic foot
Due to diabetic neuropathy, often the clinical stage usually
does not correspond as well with hemodynamic and angio-
graphic findings, being mostly much more severe than
expected. In patients with diabetes, there are no limitations
(with the exception of general contrast risks) to endovascu-
lar treatment for critical ischemia. Reconstruction of unim-
peded tibial inflow is particularly important in cases of
diabetic foot with a relevant ischemic component [292,
293]. Due to the characteristics of diabetic angiopathy with
a focus on below-the-knee arterial changes, intervention-
ists should be particularly experienced in treating long-seg-
ment diffuse lower-limb changes.
More than 40 % of CLI patients with diabetes suffer
from renal insufficiency [272]. This is prognostically impor-
tant and requires additional measures. Following extensive
non-invasive diagnosis, selective angiography with PTA
with the least possible amount of contrast medium and/
or CO2 angiography should be performed, alongside suffi-
cient prior hydration with consideration given to cardiac
function, which may also be impaired due to concomitant
coronary artery disease.
Co-morbidities and re-interventions are to be expected,
due to the complex vascular disease with obstructions
encountered at various levels with distal and multilevel
lesions present particularly in patients with diabetes with
end stage renal failure. Apart from several retrospective
case series, only one randomized controlled study has indi-
cated that if a tibial artery can be recanalized supplying the
foot healing process of foot ulcers is significantly shortened
following successful recanalization [294].
Recanalization with unimpeded tibial inflow into one or,
if possible, both of the tibial vessels remains the primary
objective [295]. Inflow alone does not seem to be sufficient
– the target is a consistently patent vessel combined with
wound therapy. The state of the vessels and clinical criteria
should be considered in everyday triage processes.
7.3 Revascularization of chronic limb
ischemia according to vascular beds
7.3.1 Aorto-iliac level
The Introduction of several large self-expanding stents and
balloon-expanding covered stents and self-expanding aor-
toiliac stent grafts allow nowadays for the endovascular
treatment of isolated aortic lesions or aortoiliac lesions.
Recently, a new covered stent with very large diameters
became available to treat isolated infra- or suprarenal
aortic stenoses, which are typically highly calcified and thus
requiring stents with high radial force. Combined with
smaller covered stents or using such smaller covered stents
as parallel grafts a complete reconstruction of the aortic
bifurcation became possible. Using covered stents in the
aortoiliac region allows for the revascularization with
improved safety in the presence of thrombus and more
complex situations like the combination of stenotic com-
bined with aneurysmal disease. Revascularization strate-
gies with multiple covered stents have been designed
specifically for the reconstruction of the aortic bifurcation
(CERAB) [296]. Yet, high thrombus burden in Leriche syn-
drome with increased risk of renal artery thrombosis or
embolism still remains a surgical domain.
Case-control studies of interventional treatments for
intermittent claudication have reported primary 5-year iliac
patency rates of 60 % to 86 % on average (generally with
stent implantation). Secondary patency rates were seen to
be 80 % to 98 % [108, 110].
Technical progress in the methods of endovascular treat-
ment has resulted in improved primary and secondary
patency rates even in complex TASC C and D lesions.
The primary long-term patency rates (5 to 7 years) follow-
ing endovascular treatment for complex aortoiliac lesions
(TASC II – C and D) are lower than those following bypass
surgeries, yet the secondary patency rates after 4 and
5 years are comparable. This was shown by a systematic
review of 19 cohort studies involving 1,711 patients [110].
The heterogeneity of the investigated population and the
endovascular techniques used in these trials should be con-
sidered. The pooled technical success rate of 86 % to
100 %, clinical improvement was reported in 83 % to
100%, and a mortality rate of 1.2% to 6.7% was reported
in seven studies. The primary 4- to 5-year patency rates var-
ied between 60%and 80%and thus fell below those given
for bypass surgery. The secondary patency rates ranged
between 80 % and 98 % and were thus comparable to
the results of open surgery.
Furthermore, available data show higher primary
patency rates following primary stent angioplasty than after
primary balloon angioplasty with secondary stent implanta-
tion in such lesions. This is one of the results of a meta-ana-
lysis of 16 retrospective studies in a total of 948 patients
with TASC C and D lesions. The pooled technical success
rate was 92.8 % (93.7 % for C lesions and 90.1 % for D
lesions) and the pooled primary 1-year patency rate was
88.7 % (89.6 % for C lesions and 87.3 % for D lesions). In
terms of primary (vs. secondary) stenting for TASC C and
D lesions, the technical success rate was 94.2 % (88 %)
and the 1-year patency rate was 92.1% (82.9%). Long-term
patency rates were thus significantly improved in the pri-
mary stent group as compared with selective stenting [108].
Recent data continue to support the high rates of techni-
cal success as well as the independence of patency rates
from degrees of complexity (TASC II A to D). Published
in 2013, a prospective non-randomized study conducted
in Belgium and Italy reported 12-month patency rates fol-
lowing endovascular treatment for TASC A to D lesions
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of 94.0 %, 96.5 %. 91.3 % and 90.2 %, respectively. The
rates were not statistically significantly different from one
another and were in favor of primary as against selective
stent implantation [297].
Endovascular treatment for aortoiliac lesions does not
seem to lead to impaired outcomes for subsequent open
surgery. In a retrospective cohort study (with a low number
of participants (22 patients), open surgery following unsuc-
cessful endovascular treatment for aortoiliac lesions
yielded no poorer results for up to 3 years compared to pri-
mary open surgery in 21 patients. Seven amputations
proved necessary in the course of follow-up, all of which
were in the primary surgical group [298].
7.3.2 Femoro-popliteal level
7.3.2.1 Endovascular vs. surgical care
The Bypass versus Angioplasty in Severe Ischemia of the
Leg (BASIL) study is the largest randomized study to com-
pare primary endovascular (n = 224) and primary surgical
procedures (n = 228) with a long-term follow-up of up to
5 years in patients with CLI. Overall, neither method was
seen to be superior in terms of mortality or amputation-free
survival in the intention-to-treat population. Among
patients surviving 2 years after randomization, those in
the bypass group showed a survival rate improved by 7.3
months [299].
The only large-scale comparative investigation, the
BASIL study, has however, several shortcomings. Instead
of CLI, the investigators used the term “severe limb ische-
mia (SLI)”, an entity combining Rutherford IV to VI. No dis-
tinction was made between interventions or surgery above
or below the knee. Therefore, this study is not helpful in
making any definite statements regarding the treatment
of a particular vascular region. Finally, only 10 % of all
patients presenting with “SLI” at the participating centers
were enrolled, indicating enrollment bias. Initial study
results were published in 2005 and the percutaneous
approach merely involved simple balloon angioplasty. In
contrast, large clinical trials have now demonstrated the
benefit of novel approaches, in particular for the femoropo-
pliteal region. This was well recognized by the BASIL inves-
tigators who recently embarked on the BASIL II study
investigating the clinical significance and cost-effective-
ness of a ‘vein bypass first’ and a ‘best endovascular treat-
ment first’ revascularization strategy for severe limb
ischemia due to infrapopliteal disease [300].
With the progress recently made in the percutaneous
treatment of femoropopliteal lesions, in particular with
the advent of drug-eluting stents and balloons, the advan-
tage of the percutaneous approach compared to the surgi-
cal approach may be expected to increase further.
A smaller retrospective cohort study in 139 extremities
comparing primary PTA/stent with femoropopliteal polyte-
trafluoroethylene (PTFE) bypasses in long-segment femor-
opopliteal occlusions (TASC II C and D) yielded similar
results with a slightly improved patency rate following
endovascular treatment for TASC C lesions. Thus,
endovascular intervention should be given preference over
treatment with synthetic bypass surgery in the presence of
increased surgical risk [301, 302]. This applies especially to
patients beyond the age of 80 for whom interventional pro-
cedures are preferred over surgical methods due to
increased comorbidity [303].
In the course of up to 4 years, virtually equivalent pri-
mary and secondary patency (SP) rates have been achieved
using PTFE/nitinol stent grafts in percutaneous revascular-
ization as compared to synthetic implants for open bypass
surgery. A prospective randomized study yielded patency
rates of 59% (SP 74%) following percutaneous revascular-
ization and 58 % (SP 71 %) following application of syn-
thetic bypasses [304].
7.3.2.2 Endovascular treatment with stents
For endovascular treatment in the femoropopliteal seg-
ment, in the absence of sufficient morphological and func-
tional angiographic outcomes, the primary implantation of
nitinol stents compared with primary balloon angioplasty
and secondary stent implantation has resulted in the
following:
Recommendation Class of
recommendation
Level of
evidence
For the treatment for aortoiliac
lesions, classified according to
TASC II guidelines as A to D lesions,
endovascular therapy should be
considered or may be considered
according to anatomical picture
and comorbidities.
IIa/b B
Recommendation Class of
recommendation
Level of
evidence
In femoropopliteal lesions,
endovascular intervention is
recommended over treatment
with synthetic and vein graft
bypass surgery in the presence of
increased surgical risk.
I A
Recommendation Class of
recommendation
Level of
evidence
When treating femoropopliteal
lesions, endovascular procedures
are recommended as the
treatment of choice.
IIa B
Bypass procedures should be
considered in the presence of
long occlusions (TASC D > 25 cm),
recurrent femoropopliteal
disease, non-increased surgical
risk, non-substantially limited life
expectancy (> 2 years) and donor-
vein availability.
IIa B
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 No morphological or clinical advantage (in terms of
primary patency or reintervention rates, respectively)
in short lesions (< 5 cm) over the course of up to 1 year
[305].
 A morphological and clinical advantage (in terms of
restenosis and reintervention rates, respectively) in
medium-length lesions (6.4–7.5 cm) in the medium
and long term of 1 to 3 years [306–308].
 A morphological and clinical advantage (in terms of
restenosis and reintervention rates, respectively) in
long lesions (12–13 cm) after 1 and 2 years [309, 310].
The initial recommendation, that for endovascular treat-
ment for medium-length and long femoropopliteal lesions
should be given preference to primary stent angioplasty
with nitinol stents over balloon angioplasty with secondary
stent implantations (bail out) is now not valid in the pres-
ence of newer revascularization methods outlined in the
next chapter, in the presence of drug-eluting balloons.
Obstruction of the popliteal artery is frequently com-
bined with occlusion of the superficial femoral artery and
additional lesions of the trifurcation area. The popliteal seg-
ment constitutes an important potential connection seg-
ment for bypass anastomoses. This is the reason why
there are few comparative studies with isolated lesions of
the popliteal artery.
A prospective randomized investigation in 246 patients
with de novo lesions of the popliteal artery has compared
primary nitinol stent implantation and PTA with optional
stent implantation in suboptimal results following PTA,
which proved necessary in 25 % of treatments. One year
after treatment, the primary patency rates following pri-
mary stenting and following PTA with bail-out stenting
were identical, i.e. 67.4 % vs. 65.7 %, respectively [311].
7.3.2.3 Newer endovascular procedures
Restenosis remains the most serious problem associated
with endovascular procedures in the femoropopliteal
region. Many different approaches have been developed
to reduce re-intervention. Stent implantation has reduced
restenosis rates in comparison to balloon angioplasty alone.
Still, primary patency rates, particularly after treating
longer segments, have been seen to be only 60 % to
70% after one year and only 30% to 60% after two years
[312, 313]. This has led to the development of drug-eluting
self-expanding stents which improve primary patency rates
to 74.8 % after two years [314]. Five-year patency rates in
the femoropopliteal vascular bed have been reported in
the Zilver PTX Randomized Trial for the use of drug-elut-
ing stents (DES). Approximately 91% of patients had clau-
dication; 9 % had critical limb ischemia. The 5-year
primary end points of event-free survival and patency
showed superiority of primary DES in comparison with
PTA sustained through 5 years. Clinical benefit (freedom
from persistent or worsening symptoms of ischemia;
79.8 % versus 59.3 %, P < 0.01), patency (66.4 % versus
43.4%, P < 0.01), and freedom from reintervention (target
lesion revascularization, 83.1%versus 67.6%, P < 0.01) for
the overall DES group were superior to standard care in
non-randomized comparisons. Similarly, clinical benefit
(81.8 % versus 63.8 %, P = 0.02), patency (72.4 % versus
53.0%, P = 0.03), and freedom from target lesion revascu-
larization (84.9% versus 71.6%, P = 0.06) with provisional
DES were improved over provisional BMS. These results
represent > 40 % relative risk reduction for restenosis
and target lesion revascularization through 5 years for the
overall DES in comparison with standard care and for pro-
visional DES in comparison with provisional BMS [315].
However, stents, in particular long self-expanding stents,
impose constant mechanical strain on the vasculature. This
applies even more to oversized stents.
A significant improvement in the results of endovascular
procedures has been achieved with the introduction of
drug-eluting balloons. Currently, 2-year results are avail-
able from two large randomized controlled trials and from
a single-arm pivotal trial using various drug-eluting
balloons.
At 24months, patients treated with drug-eluting balloons
(DEB) (frequently also named drug coated balloons),
showed in the Randomized Trial of IN.PACT Admiral Drug
Coated Balloon vs Standard PTA for the Treatment of SFA
and Proximal Popliteal Arterial Disease (INPACT SFA) sig-
nificantly higher primary patency when compared with
non-coated PTA (78.9 % vs. 50.1 %; p < 0.001). The rates
of CD-TLR were 9.1% and 28.3% (p < 0.001) for the DEB
and PTA groups, respectively. Both groups showed similar
functional improvement at 2 years, although DEB patients
achieved this level of function with 58% fewer re-interven-
tions [316].
In the single-blind, randomized LEVANT-2 trial, 476
patients with symptomatic intermittent claudication or
ischemic pain while at rest and angiographically significant
atherosclerotic lesions were randomized to angioplasty
with a paclitaxel-coated balloon or to standard angioplasty.
At 12 months, the rate of primary patency among patients
who had undergone angioplasty with the drug-eluting bal-
loon was superior to that among patients who had under-
gone conventional angioplasty (65.2 % vs. 52.6 %,
P = 0.02). The proportion of patients free from primary
safety events was 83.9 % with the drug-eluting balloon
and 79.0% with standard angioplasty (P=0.005 for nonin-
feriority). There were no significant between-group differ-
ences in functional outcomes or in the rates of death,
amputation, thrombosis, or reintervention [317].
Taken together, current evidence and expert opinions
primarily support the use of drug-eluting balloons after
Recommendation Class of
recommendation
Level of
evidence
Balloon angioplasty with optional
stent implantation is
preferentially recommended for
treatment of lesions of the
popliteal artery as standard care
for limb symptom improvement.
I C
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vigorous pre-dilatation, as the results are at least as good if
not better than with stenting. An advantage is that nothing
is left behind in arteries that may cause constant strain on
the vasculature. Focal stenting should be limited to areas of
relevant dissection. The concept of focal stenting, however,
is currently derived from indirect evidence only and is the
subject of ongoing clinical studies. Therefore, it can only be
considered on the basis of expert opinion. Self-expanding
stenting to primarily treat highly calcified arterial obstruc-
tions does not appear to be appropriate. In the Surgical
vs. Percutaneous Bypass (Super-B) trial, with a wire-inter-
woven stent that possesses the strongest radial force of
all available stents, inadequate vessel preparation led to
increasing rates of restenosis. In this trial 325 patients
(264 intention-to-treat and 64 roll-in subjects) were
enrolled. Treated lesion lengths were 7.8 cm ± 4.3 cm in
the trial with chronic total occlusions comprising 24.6 %
(65/264) of subjects. Freedom from clinically driven target
lesion revascularization (CD-TLR) at 12 months was 89%,
at 24 and 36months it was 84%and 82% respectively. At 2
and 3 years, freedom from CD-TLR in minimal compres-
sion was 86.7 % and was 90.0 % for moderate compres-
sion. At 2 and 3 years, freedom from CD-TLR for
moderate elongation was 81.8% and 78.2%, and for severe
elongation was 63.4 % and 42.3 %, respectively. Fractures
were distinctly uncommonwith this stent with a single frac-
ture event in the 36-month follow-up period. Thus, the
interwoven nitinol design stent is a stent that achieves an
excellent primary patency but further maintains the dura-
bility of the stent through 36months. Optimal stent deploy-
ment remains critical to the performance of this stent
device and requires optimal vessel preparation [318].
Drug-eluting balloon angioplasty is superior over plain
balloon angioplasty and stenting is superior over plain bal-
loon angioplasty. According to current evidence, plain bal-
loon angioplasty without using drug-eluting balloons and/
or without using stents cannot be justified for endovascular
treatment of the femoropopliteal segment any longer.
A number of tools are available to achieve this goal even
in heavily calcified vessels, including different atherectomy
systems and scoring balloons. However, large controlled
clinical trials using these systems in this indication are still
missing. The recommendations of particular endovascular
techniques to achieve an optimal result are thus to be con-
sidered as a focus for research in a currently very active
field.
Also, new stent devices are being currently tested mini-
mizing stent material left behind while preserving arterial
flexibility by using multiple 6 mm Tack stent rings focally.
Tacks were used in 130 patients with post-PTA dissections
(74.0% grade C) following standard balloon angioplasty.
The 12-month patency was 76.4 %, and freedom from tar-
get lesion revascularization was 89.5 % [319].
A current trial evaluates Tack mini stents in combination
with DEB.
The meta-analysis of Konstantinos et al. (2018) [320].
raised concerns about the safety of paclitaxel coating
because of an excess mortality in the paclitaxel treated
patient population. The investigation of the authorities,
especially the FDA are on-going and for now the recom-
mendations of the FDA (https://www.fda.gov/medical-
devices/letters-health-care-providers/august-7-2019-
update-treatment-peripheral-arterial-disease-paclitaxel-
coated-balloons-and-paclitaxel), medical associations and
national authorities is to restrict the use of these devices
as far as possible and to use alternate techniques. Also,
patients should be informed about ongoing investigations
ahead of use and have the choice to object the use of such
paclitaxel-eluting devices.
In the meantime, independent adjudication found zero
deaths attributable to one of the frequently used 0.03500
paclitaxel-coated balloons [321]. An analysis with German
health claims data of 9.2 million insurants was evaluated
for long-term mortality after use of paclitaxel-based drug-
eluting devices in lower limb arteries from their introduc-
tion to the market in Germany in 2007 until present. In this
cohort, 64,771 patients were included who underwent
107,112 endovascular procedures in which 200,681
devices, thereof 23,137 paclitaxel-based DES and DCBs,
were applied. A time-dependent multivariable Cox regres-
sion analysis was conducted accounting for each single
device that was applied during the entire study period. This
allowed to assess mortality hazards which might change
over time and to assess also for various combinations of
all devices and multiple interventions [322]. In summary,
taking any performed intervention and all applied devices
into account, there was no signal of increased mortality
over 11 years of follow-up after use of paclitaxel-based
DCBs or DES in lower limb artery disease [323].
Recommendation Class of
recommendation
Level of
evidence
Treatment of (longer and more
complex) femoropopliteal lesions
with drug-eluting balloons after
pre-dilatation is recommended
as standard of care.
II B
Recommendation Class of
recommendation
Level of
evidence
It is recommended that stenting
be restricted to focal stenting in
regions of recoil after balloon
angioplasty with or without drug
eluting balloons, relevant
dissection or eccentric
calcification with severe recoil.
I B
Adequate vessel preparation is
recommended for successful
drug-eluting balloon or self-
expanding stent application.
I B
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7.3.3 Infra-popliteal level
Randomized comparative data regarding interventional
and surgical revascularization techniques are limited to
the results of the BASIL study which, however, included
few infrapopliteal recanalizations [112]. This prospective
randomized trial showed no difference in amputation-free
survival up to 5 years after primary endovascular vs. pri-
mary open surgery. Endovascular procedures were associ-
ated with increased rates of re-intervention and open
surgery with increased rates of morbidity and mortality,
in addition to higher costs.
Comparable patency and leg-salvage rates following
endovascular vs. surgical revascularization have been
computed from retrospective cohort analyses [323]. The
study cohort consisted of 1,023 patients with critical ische-
mia, of whom 262 and 761 received endovascular treat-
ment and open surgery, respectively. Following risk
adjustment, the 5-year rates of limb salvage were 75.3 %
after endovascular treatment and 76.0 % after bypass
procedures. Amputation-free survival amounted to 37.7 %
and 37.3 %, respectively. Systematic analyses of the litera-
ture reveal that both endovascular treatment and open sur-
gery yield an approximately 80 % leg-salvage rate 3 years
post-therapy [324]. Improvements in catheter techniques
have contributed to a high success rate in recanalizations,
even in long infrapopliteal occlusions (> 10 cm) in the stage
of critical ischemia [104, 325, 326].
Case series have rarely investigated angioplasty alone in
infrapopliteal arteries (below the knee arteries – BTK) in the
presence of intermittent claudication. For example, in the
DEBELLUM trial 122 lesions were treated: 92 (75.4 %)
SFA, 30 (24.6 %) BTK. Twenty (40 %) patients presented
multilevel concomitant femoropopliteal and infra-popliteal
lesions. Late lumen loss (LLL) was 0.64 ± 0.9 mm in the
Drug Eluting Balloon (DEB) group vs. 1.81 ± 0.1 mm in
the control group (P = 0.01). In non-stented segment LLL
was 0.63±0.9 mm (DEB) vs. 1.70 ± 0.6 mm (PTA),
P < 0.01. In the stent subgroup was LLL 0.65 ± 0.2 mm
(DEB) vs. 1.91 ± 0.3 mm (PTA), P < 0.01. BTK the overall
LLL was 0.66 ± 0.9 mm (DEB) vs. 1.69 ± 0.5 mm (PTA)
(P = 0.03). The overall TLR was 12.2 % for DEB and
35.3 % for PTA (P < 0.05). Amputation rate was 4 %
(DEB) vs. 12 % (PTA), P = 0.36. Fontaine stage increased
(from II b to I) 80 % DEB vs. 56 % PTA (P < 0.05). The
Debellum trial used In.Pact DEB balloons, which can be
considered efficient to reduce restenosis rate [327].
Another investigation has reported a relatively high rate
of major complications (5.8%) and a poor long-term result
with a re-occlusion rate of 33.7 % after one year [328].
Thus, exclusive use of angioplasty cannot be consistently
recommended, although still considered in individual
cases, after carefully assessing risks and benefits and pro-
viding comprehensive information.
Several controlled randomized studies have addressed
the issue as to whether balloon angioplasty or stent angio-
plasty are primarily indicated in the presence of infrapopli-
teal vessels and have failed to evidence superiority for
primary stenting [329, 330]. A meta-analysis of 16 non-ran-
domized clinical trials has demonstrated no advantage of
primary Bare metal stent (BMS) implantation over PTA
alone, yet showed a tendency toward improved results with
Drug eluting stent (DES) implantation versus BMS and PTA
alone [331] but this is only true for focal lesions in segments
suitable for stent implantation.
7.3.3.1 Drug-eluting stents (DES)
With endovascular recanalizations of less extensive
(< 3 cm) infrapopliteal lesions, the short-term application
of DES ( 1 year) has resulted in reduced rates of both rest-
enoses and re-interventions compared to those achieved
with non-DES. Individual studies have indicated a med-
ium-term decrease in amputation rates after one year
[331–337]. A comparative investigation analysing the revas-
cularization of infrapoplietal de novo stenoses in 161
patients using sirolimus-eluting stents (SES) showed a ten-
dency towards a 2.6% lower amputation rate after approx-
imately 3 years as against 12.2%with the use of BMS [336].
Two meta-analyses of randomized studies in 2013 compar-
ing DES and BMS have yielded similar results in 1-year out-
comes [334, 335].
The use of sirolimus-eluting stents (SES) in secondary
stent implantation following insufficient balloon angio-
plasty has resulted in decreased restenosis and re-interven-
tion rates compared to the use of non-DES. However, no
effect has so far been evidenced as to the rate of amputa-
tions [338]. A systematic review of 18 non-randomized tri-
als has established both higher primary patency rates and
lower restenosis rates following SES implantation after
failed balloon angioplasty compared to non-DES or pacli-
taxel-eluting stent (PES) implantation [339]. Again the
influence of DES on the clinical endpoints of limb salvage
and amputation-free survival has not yet been sufficiently
explored. In addition, their application is always limited
because of their relatively short length and the crushing
risk in regions of increased motion and bending.
In a newer meta-analysis of randomized trials, the 1 to
48-month follow-up outcomes of different endovascular
treatment strategies in below-the-knee (BTK) arterial seg-
ments in critical limb Ischemia (CLI) patients were evalu-
ated. Twelve trials including 1,145 patients were
identified, with 90 % of patients having CLI. Six BMS ver-
sus PTA and two DES versus PTA trials showed low-quality
Recommendation Class of
recommendation
Level of
evidence
In patients with critical limb
ischemia and infrapopliteal
vascular lesions endovascular
treatment is recommended as
the first line of therapy.
I B
Open surgery should be
considered in the presence of low
surgical risk and a suitable
autologous vein.
IIa B
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evidence of equal efficacy. One trial, comparing DEB with
PTA, showed moderate-quality evidence of improved
wound healing (RR 1.28; 95 % CI: 1.05 to 1.56), improve-
ment in Rutherford classification (RR 1.32; 95 % CI: 1.08
to 1.60), and lower TLR-rates (RR 0.41; 95 % CI 0.23 to
0.74) and binary restenosis (RR 0.36; 95 % CI 0.24 to
0.54) in diabetic patients after 12 months. Amputation
and death rate did not differ significantly. For DES versus
BMS, most trials showed equal efficacy between strategies
[340].
More recent comparative studies of bare-metal stents
(BMS) and drug-eluting stents (DES) have shown primary
1-year patency rates in mixed patient groups with intermit-
tent claudication and CLI to range between 48% and 66%
with PTA and no stent implantation. In a meta-analysis of
randomized trials, investigating the outcomes of percuta-
neous revascularization with primary drug-eluting stenting
in patients with atherosclerotic disease of infrapopliteal
arteries compared with plain balloon angioplasty or bare-
metal stents (BMSs), a total of 611 patients from 5 trials
were randomly assigned to DES (n = 294) versus control
therapy (plain balloon angioplasty/BMS implantation,
n = 307). At a median follow-up of 12 months (IQR: 12
to 36 months), DESs reduced the risk of target lesion
revascularization (odds ratio [OR]: 0.31; 95 % confidence
interval [CI]: 0.18 to 0.54; p < 0.001), restenosis (OR:
0.25; 95 % CI: 0.15 to 0.43; p < 0.001), and amputation
(OR: 0.50; 95% CI: 0.26 to 0.97); p = 0.04) without a sig-
nificant difference in terms of death (OR: 0.81; 95 % CI:
0.45 to 1.49; p = 0.50) and Rutherford class improvement
(OR: 1.36; 95 % CI: 0.91 to 2.04; p = 0.13) versus control
therapy. Thus, in focal disease of infrapopliteal arteries,
DES therapy reduces the risk of reintervention and ampu-
tation compared with plain balloon angioplasty or BMS
implantation without any impact on mortality and Ruther-
ford class at 1-year follow-up [335].
In a systematic review of the literature of all studies com-
paring stent treatments of infragenicular vessels in patients
with chronic lower limb ischemia, the search identified 4
randomized clinical trials and 2 observational studies
reporting on 544 patients (287 treated with DES and 257
treated with BMS). Primary patency, freedom from target
lesion revascularization, and clinical improvement at 1 year
were significantly higher in the DES recipients compared to
patients treated with BMS (OR 4.511, 95 % CI 2.897 to
7.024, p < 0.001, NNT 3.5; OR 3.238, 95 % CI 2.019 to
5.192, p < 0.001, NNT 6.0; and OR 1.792, 95 % CI 1.039
to 3.090, p = 0.036, NNT 7.3, respectively). No significant
differences in limb salvage and overall survival at 1 year
were identified between the groups (OR 2.008, 95 % CI
0.722 to 5.585, p = 0.181; OR 1.262, 95 % CI 0.605 to
2.634, p = 0.535, respectively). Thus, this analysis demon-
strated superior short-term results with DES compared
with BMS, expressed by increased patency and freedom
from target lesion revascularization [334].
Most recent data on DES implantation achieve over
80 % one-year patency. Percutaneous stent angioplasty
was performed in 128 limbs in 114 patients presenting with
320 vascular lesions. Lesions with up to 6 cm in length and
at least one patent vessel below the obstruction were trea-
ted; 341 sirolimus-eluting Cypher(R) stents (diameter of
2.5–3.5 mm; length of 18–33 mm) were implanted. Follow-
up examinations were performed up to 18 months post-
interventionally using clinical examination, ankle-brachial
index calculation, and color-coded Duplex sonography.
The 6, 12, and 18months primary patency rate as controlled
by Duplex sonography was 89.8, 84.2 and 83.3 %, respec-
tively; 77.6 % of the lesions healed post-interventionally.
The cumulative limb salvage rate was 95.6 % [341].
7.3.3.2 Bio-absorbable (metal) stents
For revascularization of infrapopliteal arteries, no morpho-
logical or clinical benefits have as yet been achieved with
bioabsorbable metal stents compared to balloon angio-
plasty applied alone [342].
Also everolimus coated bioabsorbable scaffolds could
not show an advantage compared to non-absorbable DES
in the coronaries [343].
7.3.3.3 Paclitaxel-coated balloons
Two initial randomized pilot studies have indicated positive
6- and/or 12-month data regarding patency rates following
treatment for infrapopliteal lesions with DEBs compared to
uncoated balloons. One of the trials investigated patients
with diabetes exclusively (see section 6.4.2.4) [327, 344].
A subsequent, larger-scale prospective controlled study
comparing angioplasties in lower-limb arteries using pacli-
taxel-coated balloons vs. non-DEBs failed to confirm such
advantages for DEBs [345]. With a median length of 10
to 13 cm, lesions were treated in 358 patients with critical
ischemia. After one year, the rates of clinically induced
re-interventions showed no difference between treatments
with DEBs and non-DEBs (9.2 % vs. 13.1 %). There was a
trend, however, showing the rate of major amputations fol-
lowing DEB was higher (8.8 % vs. 3.6 %).
Such DEBs were removed from the market instantly as a
consequence of available study results. The technical prob-
lem apparently was not with the drug but rather with the
balloon design and the production process. Data from
one randomized trial and 2 several single arm studies con-
ducted with other DEBs have in the meantime became
available.
In the randomized BIOLUX P-II trial a novel paclitaxel-
coated drug-eluting balloon (DEB) versus an uncoated bal-
loon (percutaneous transluminal angioplasty [PTA]) in de
novo or native restenotic lesions of the infrapopliteal arter-
ies in patients with claudication and critical limb ischemia
was compared. 72 patients were randomized 1:1 to either
a Passeo-18 Lux DEB (n = 36) or Passeo-18 PTA balloon
(n = 36). Follow-up assessments were scheduled at 1, 6,
and 12months, with angiographic assessment at 6months.
The primary safety endpoint (a composite of all-cause mor-
tality, target extremity major amputation, target lesion
thrombosis, and target vessel revascularization at 30 days)
was 0 % in the DEB group versus 8.3 % in the PTA group
(p = 0.239). The primary performance endpoint (patency
loss at 6 months) was 17.1 % in the DEB group versus
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26.1 % in the PTA group (p = 0.298), and major amputa-
tions of the target extremity occurred in 3.3 % versus
5.6 % of the patients at 12 months, respectively. Thus, the
Passeo-18 Lux DEB has been proven to be safe and effec-
tive in infrapopliteal lesions with comparable outcomes to
PTA [346].
In a retrospective review 208 patients suffering from
either severe claudication (38.6%) or critical limb ischemia
(CLI; 61.4 %) in 220 limbs were analysed. Almost two-
thirds (140, 63.6 %) of the 220 target lesions were total
occlusions, and 37 (17.8 %) of all patients had occlusion
of all 3 BTK vessels before intervention. Over a median
9-month follow-up, target lesion revascularization
occurred in 15.9% of patients with an average time to first
reintervention of 8 months. In total, 39 amputations were
performed in 31 limbs. However, 17 of these amputations
were preplanned minor amputations below the ankle; only
9 (4.1 %) major amputations occurred corresponding to
6.6 % of the CLI cohort. Freedom from the composite of
death or major amputation was estimated as 92 % and
85 % at 6 and 12 months, respectively, by Kaplan-Meier
analysis. In the full cohort, improvement of at least 1
Rutherford category was seen in 130 (59.1 %) limbs after
1 year or at the last follow-up, with 104 (80.0 %) of those
limbs showing an improvement of 2 categories. From this
single-center experience, the Lutonix DEB shows thera-
peutic promise in a disease state where new treatment
options were needed [347].
In another retrospective analysis, 21 patients (15 men;
mean age 66.6 ± 11.2 years) were followed-up for
356.5 ± 159.2 days and 90.47 % had 12-months follow up
data available for analysis. TcPO2 increased
(14.3 ± 11.6 mmHg to 53.8 ± 11.7 mmHg; p < 0.05). Limb
salvage rate was 100 %, and 90.4 % of patients achieved
the combined endpoint of reduction in ulcer size/depth
or complete healing.
DEB had superior efficacy (MALE+post-operative death,
amputation free survival, freedom from re-intervention,
limb salvage and survival rates), while attaining superior
or equivalent safety (Major Adverse Limb Events, major
adverse cardiovascular events and Amputation) endpoints
for the overall, modified clinical and anatomical high-risk
groups. Thus, use of Lutonix DEB was safe and effective
for recurring infrapopliteal disease. It outperformed the
objective performance goals (OPG) for CLI patients with
clinical and anatomical high-risk features [348]. The signif-
icance of drug-eluting balloons in angioplasty for infrapo-
pliteal arteries have not yet been sufficiently assessed.
The results of the ongoing randomized trials in lower limb
arteries are awaited.
7.3.3.4 Angiosome concept
Direct revascularization of the artery covering an ischemic
region (angiosome) is the primary aim, as it tends to yield
better results in terms of ulcer healing and leg salvage than
indirect revascularization [294, 349–352]. Revasculariza-
tion of the crural arteries that provide the ischemic lesions
via collaterals, however, has also been seen to be effective
in ulcer healing and leg preservation [353]. Direct revascu-
larization also serves to promote the healing of ischemic
ulcers which, however, is substantially and negatively influ-
enced by the presence of terminal renal failure, diabetes or
advanced tissue defects as in Rutherford stage VI [354].
In patients with diabetes, the recanalization of tibial
arteries seems to be more efficient in allowing for healing
of ischemic tissue lesions than the recanalization of the
fibular (peroneal) artery [355]. Implementation of several
crural artery revascularizations does not improve clinical
long-term results [356].
7.3.4 General considerations
Interventional treatment in patients with critical ischemia
has high rates of technical and primary clinical success
up to 65% to 95%depending on the complexity of vascular
lesions, length and degree of calcification in the affected
vascular stenosis/occlusions [108, 110, 297, 299, 307,
331]. Following interventional therapy for infrapopliteal
vascular occlusions in critical ischemia, the primary
patency rate is 40% to 60%after 3 to 5 years, respectively.
In turn, secondary patency rates following re-interventions
are up to 80 %, with over 90 % leg-salvage rates in small
case series [109, 292, 299, 325, 357].
Re-occlusions in treated vessel are not necessarily asso-
ciated with ulcer recurrences, as the healing process in crit-
ical ischemia generally only requires a temporary
improvement of cruropedal perfusion. The quicker and
more completely cruropedal revascularization is success-
fully carried out, the lower the risk of major amputation.
Multilevel disease is frequent in CLI. Lesions of the aor-
toiliac vascular bed should be treated first in order to
improve inflow into the limb. At the same time, or as a
Recommendation Class of
recommendation
Level of
evidence
In treating critical ischemia
accompanied by ischemic tissue
defects, it is recommended that
the crural artery supplying the
relevant region (angiosome) be
preferentially revascularised. If
direct revascularization proves
unfeasible, indirect
revascularization, (possibly with
retrograde PTA via the plantar
arch), is recommended. The
short-term clinical outcome may
be improved by revascularising
even more than one crural artery.
IIa B
Recommendation Class of
recommendation
Level of
evidence
In patients with CLI, rapid and
efficient revascularization regardless
of treatment techniques applied, is
recommended.
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second step, treatment for critical ischemia also requires
the elimination of obstruction frequently present in the
femoropopliteal and/or cruropedal outflow tracts. In the
presence of combined lesions in the inflow and outflow seg-
ments, these should be treated next in an attempt to recon-
struct an unimpeded pedal inflow over at least one crural
artery. Due to improved guidewires and catheters available
and depending on the length of occlusion and degree of cal-
cification, primary technical success rates are up to 80% to
90 %, even in long lesions. In this situation, application of
retrograde transpopliteal, transpedal and transcrural
recanalization may prove useful in individual cases.
However, when treatment of proximal lesionmay techni-
cally obstruct future endovascular treatment of distal
lesions as in the event of stenting of common iliac stenosis
in the presence of proximal femoral stenosis or occlusions,
the strategy may be inverted.
In critical ischemia there will be also an ‘endovascular
first’ therapy in regions, where the best treatment (surgical
vs. endovascular) is still under debate. So, it can be reason-
able to treat long iliac or common femoral stenoses or occlu-
sions by endovascular techniques, to have the option to treat
lesions below the pelvic or common femoral artery level.
There are now many new devices for the interventional
therapy of vascular lesions causing CLI. The evidence is
still not robust but in specialized institutions some of the
devices are already an indispensable part of the interven-
tional armamentarium, making therapies faster and safer
than before [290, 358–361].
7.3.5 Emergency catheter therapies in acute limb
ischemia
Four entities of atherosclerotic acute limb ischemia need to
be distinguished:
1. acute worsening of pre-existing chronic limb ischemia
2. acute re-occlusions after earlier (stent) angioplasty
or bypass surgery
3. acute occlusion in thromboembolic disease
4. acute occlusion in compression syndromes
The underlying cause of acute worsening of chronic PAD
is very different from the other causes. In most cases, CLI
presents as a multifocal disease with critically reduced
tissue perfusion of limb or foot. Acutely or subacutely,
aortoiliac or femoropopliteal atherosclerotic disease may
lead to plaque rupture (with or without hemodynamically
relevant pre-existing stenosis), resulting in an acute arterial
occlusion or, more rarely, distal cholesterol embolisation as
a cause of CLI worsening. Depending on underlying or
concomitant diseases, the cause of threatened tissue perfu-
sion may be located at different levels of the vasculature.
Thus, initial therapy may vary within a broad spectrum of
options.
In contrast, distal embolization due to atrial fibrillation
can occur in the absence of PAD and is also very common
in the aging patient, – confounding with worsening of pre-
existing PAD may be therefore possible. Other underlying
causes are arterial aneurysms also leading to distal embo-
lism and/or acute vascular occlusions at the site of, mostly,
popliteal aneurysms. Furthermore, compression syn-
dromes with mostly bilateral manifestations may lead to
acute vascular occlusions.
Finally, secondary to previous endovascular procedures
(mostly with stent) or bypass surgeries re-occlusions may
occur quite suddenly from embolization or even dissection.
In general, the more distally the perfusion problem is
located, the more difficult is its treatment. Because of the
broad range of possible pathologies and the emergency
character of acute limb ischemia, RCT evidence for the dif-
ferent treatment options is still required but difficult to
generate.
Depending on the underlying cause, therapy will be
endovascular or surgical. Thrombosed and occluded popli-
teal aneurysms need surgical therapy to avoid further distal
embolism by exclusion or resection of the aneurysm and
circumvention using an extra-anatomic bypass or venous
interposition. However, in cases where the embolising
popliteal aneurysm is still patent, an endovascular exclu-
sion with a flexible covered stent is possible and has the
advantage of possible combination with selective throm-
bolysis of the distal emboli.
A total of 72 popliteal aneurysms (PAA) were treated in
70 patients. The majority of PAA were asymptomatic
(78 %). Sixteen cases (22 %) had a symptomatic PAA, of
which seven (44%) presented with acute ischemia. Median
follow-up was 13 months (range 0–63 months). Primary
patency rate at 1 year was 83% and after 3 years 69%; pri-
mary assisted patency rate was 87 % at 1 year and 74 %
after 3 years. Secondary patency rate was 88 % and
76% at 1 and 3 years, respectively. There were no amputa-
tions during follow-up. Thus, endovascular treatment of
PAA with heparin-bonded stent grafts is a safe treatment
option with good early and mid-term patency rates compa-
rable with open repair using the great saphenous vein
[362]. However 90% of patients in this study did not have
acute symptoms and serious cardiopulmonary disease was
an exclusion criterion. Aspiration thrombectomy is indi-
cated if the limb is acutely ischemic.
Recommendation Class of
recommendation
Level of
evidence
In vascular multilevel disease, it
is recommended that eliminating
inflow obstructions take priority
over treating downstream
lesions.
I B/C
Recommendation Class of
recommendation
Level of
evidence
In patients with critical ischemia,
endovascular treatment is
recommended to be employed
initially for inflow lesions and
subsequently for outflow lesions,
if possible.
I C
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Recently, multilayer flow diverting bare cobalt alloy self-
expanding stents were used to exclude peripheral and vis-
ceral artery aneurysms. In a multicentre, prospective, vol-
untary registry, 54 patients underwent multilayer stent
deployment for peripheral (n = 35) or visceral aneurysms
(n = 19). Among the 54 lesions, 44 had a total of 53 side
branches. There was no aneurysm rupture. Six (11.1 %)
stents occluded over the 1-year period. Cumulative primary
and secondary patency estimates were 86.9 % and
90.7 % at 1 year. The cumulative side branch patency
was 96.1 % and the freedom from all complications was
83.0 % at 1 year. Complete aneurysm thrombosis was
recorded in 42 (93.3 %) of 45 patients at 1 year. Percent
diameter reduction was 15.5 %, 3.8 %, and 11.0 % at 1, 6,
and 12months (p <0.05), respectively [363]. In acute ische-
mia aspiration thrombectomy may be preferred over
thrombolysis because of safety concerns.
Arteries occluded by external compression will need sur-
gical external decompression and venous interpositions.
Following distal thromboembolism in the absence of
aneurysmal disease or compression, catheter directed
mechanical or hydrodynamic thrombectomy [364, 365]
and/or selective fibrinolysis are therapies of choice in the
absence of contraindications. If there are severe motor or
sensory impairments immediate surgical thrombectomy/
embolectomy is still the first line therapy. Rotational
atherectomy may be preferable in those patients at high
risk of bleeding.
Catheter directed mechanical or hydrodynamic
thrombectomy has the advantage of avoiding a bleeding
risk associated with thrombolysis and therefore, in most
cases does not need the use of an intensive care bed.
In the first publication, 98 patients (65men; mean age 66
±9 years, range 47–90) with 100 thrombotic occlusions
(mean age of occlusion 31±33 days, range 0–140) measur-
ing an average of 21±11 cm long (range 2–40) were treated
with rotational thrombectomy (Rotarex). There were 33
acute ( 14 days) thrombotic/embolic native artery occlu-
sions (group I), 58 subacute/chronic (> 14 days) native
artery occlusions (group II), and 9 acute bypass graft occlu-
sions (group III).
Slightly less than half the arteries (48 %) were stented.
Primary success (residual stenosis < 30 %) was achieved
in 92 % (94 % for group I, 93 % for group II, and 78 %
for group III; 100 % for the ipsilateral approach, 56 % for
the crossover approach). 8 vessel perforations and 7 cases
of peripheral embolization allowed further therapies to be
considered and readiness for selective thrombolysis and
covered stents became a prerequisite to perform this proce-
dure safely [365]. Catheter directed mechanical or hydro-
dynamic thrombectomy is thus the treatment of choice
for acute and subacute/chronic thrombotic infra-aortic
occlusions of native vessels and bypass grafts but has been
used also in visceral arteries and subclavian and vertebral
arteries.
In acute limb ischemia, compartment syndrome must be
screened for, and fasciotomy carried out where necessary.
Recommendation Class of
recommendation
Level of
evidence
In selected cases of distal
embolism and where perfusion of
popliteal aneurysm persists,
implantation of covered stents,
multilayer stents or stent
prosthesis is recommended, if
necessary, in combination with
fibrinolytic therapy to improve
distal outflow.
IIa B
Recommendation Class of
recommendation
Level of
evidence
In acute and subacute arterial
occlusions, catheter directed
mechanical or hydrodynamic
thrombectomy is recommended
as first-line therapy in larger
vessels, if necessary, in
combination with fibrinolysis
therapy to improve distal outflow.
IIa B
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8 Care of the patient undergoing
vascular interventions
8.1 Peripheral interventions: Peri- and
post-interventional medical follow-up
Endovascular treatment for PAD has undergone dynamic
developments over the past years. It is nowmostly first-line
treatment in multi-morbid high-risk patients with Stage III
and IV disease, and increasingly in complicated Stage II dis-
orders. The main objective of peri- and post-interventional
care – improved patency rates – can be achieved both by
preventing early or later-stage post-interventional arterial
thrombosis, and by avoiding restenosis. The following
chapter thus focuses exclusively on anticoagulation and
antithrombocytic/antiplatelet treatment used to avoid arte-
rial thrombosis.
Local vascular inflammation following PTA or stent
implantation is mainly responsible for medium- and long-
term restenosis processes [366]. Early thrombosis and
occlusion mostly develop as a result of dissection or local
arterial platelet activation. Rates of restenosis or re-occlu-
sions depend not only on vascular morphology and the kind
of endovascular technique or implanted stent chosen, but
also on the vascular region. For example, stent implanta-
tions into the femoropopliteal regions are associated with
a markedly higher restenosis risk than into the iliac vessels.
This is possibly caused by higher levels of local inflamma-
tion in the muscular arteries of the femoral vascular bed as
opposed to less severe inflammatory reactions in the elastic
arteries of the pelvic vascular bed [367].
Restenosis or re-occlusion resulting from balloon dilata-
tion may develop in three successive phases of different
etiology:
 Elastic recoiling which mostly occurs within 24 hours
after intervention and can be avoided with stent
implantation.
 Thrombus formation which occurs usually within the
first weeks or months depending on the length of
the lesion and the implanted material used.
 Neointimal hyperplasia which is detectable around
three to six months, by activation of smooth muscle
cells and synthesis of extracellular matrix [368].
Disorder-related chronic inflammation of the vascular
walls may also affect restenosis and the risk of occlusion
following primarily successful interventions. Examples of
this include advanced chronic renal failure and diabetic
metabolic disorders, which are particularly important.
The restenosis risk is significantly higher in patients with
renal failure and/or diabetes compared to those without
these comorbidities [369]. Evidence-based recommenda-
tions on the most beneficial antithrombotic treatments to
be used in peripheral interventions are limited by the lack
of corresponding randomized controlled clinical trials and
are adapted from the coronary interventional trials.
8.1.1 Antiplatelet drugs
Platelet activation is elevated in patients with PAD, indicat-
ing an increased intra-arterial thrombotic tendency [370].
Antiplatelet treatment is thus recommended for all patients
with symptomatic PAD, regardless of secondary prophylac-
tic interventions, in order to reduce associated cardio- and
cerebrovascular morbidity and mortality (see Chapter 5).
However, this chapter focuses on the peri- and post-inter-
ventional period.
Two randomized trials investigated whether antiaggre-
gant treatments may improve patency rates following
peripheral PTA. The first trial randomized 199 patients fol-
lowing angioplasty of the femoropopliteal vasculature to
one of three treatment arms: Dipyridamole (225 mg) com-
bined with high-dose ASA (990 mg) vs. dipyridamole with
low-dose ASA (300 mg) vs. placebo. Both arms on active
treatment showed better patency rates compared with the
placebo group, of which the high-dose ASA group showed
statistically significant improvements [371]. Following bal-
loon dilatation of the pelvic or femoral vasculature, the sec-
ond clinical trial randomized 223 patients to combination
therapy with ASA (50 mg) and dipyridamole (400 mg) vs.
placebo. The primary patency rates were identical in both
groups and no benefit of antiaggregant treatment was iden-
tified. However, the study was limited in the fact that the
placebo arm included a larger share of PTAs of the iliac
arteries which per se show a better outcome [199, 372].
One single study examined whether combination treat-
ment with ASA and dipyridamole was superior to ASA alone
[373]. After 14 days of treatment, no significant difference
was seen between the groups in terms of primary patency
rates following femoral or popliteal PTA.
Several older studies explored whether high-dose ASA is
better than low-dose ASA in preventing re-occlusion [371,
374–377]. Six months after PTA, higher-dose ASA (900 to
1,000 mg) yielded no advantage, yet the number of gas-
trointestinal side effects increased with the dosages of
ASA. ASA dosages between 50 mg and 300 mg are effec-
tive in follow-up care.
In clinical practice, as well as in most interventional tri-
als, a temporary Dual Anti-Platelet Therapy (DAPT) with
ASA and clopidogrel is recommended after using drug-elut-
ing balloon angioplasty, implantation of bare metal stents
or implantation of drug-eluting stents following femoropo-
pliteal and/or infrainguinal treatment.
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Combination treatments of ASA and thienopyridines
(ticlopidine, clopidogrel) are frequently used in everyday
clinical practice, following balloon angioplasty with stents
or drug eluting techniques, especially when the femoropo-
pliteal or tibial arterial vasculatures are affected. Only one
single double-blind randomized trial (the MIRROR trial)
with 80 patients compared monotherapy with ASA (100
mg/d) and dual antiplatelet treatment (ASA 100 mg/d +
clopidogrel 75 mg/d) for 6 months, and subsequently for
1 year, following endovascular treatment with stent PTA
in the femoropopliteal segment, concluding that the drug
should be given longer. However, the primary endpoint
was the local concentration of platelet-activating β-throm-
boglobulin and cluster of differentiation of 40 ligand
(CD40L), as well as the rate of clopidogrel resistance.
The clinical endpoints of re-intervention (target lesion
revascularization) and bleeding were predefined merely
as secondary endpoints. Re-interventions at the target
lesions were significantly less frequent under dual antipla-
telet treatment (p = 0.04). In terms of absolute frequency,
however, re-interventions with only two vs. eight patients
strongly limited the validity of the study. Bleeding compli-
cations under dual treatment were not increased [378].
ASA in combination with thienopyridines was shown to
be superior to ASA alone or combined with oral anticoagu-
lants (OAC) in terms of patency rates following the setting
of coronary arterial stents [379–381]. The issue remains
questionable as to whether these results can be extrapo-
lated to peripheral interventions.
Likewise, the question whether a loading dose of
clopidogrel (300 mg vs. 600 mg) should be given prior to
planned peripheral interventions with stent implantations
is unclear, as no trial has addressed this question. Finally,
apart from the small study mentioned above, no random-
ized investigation has addressed the necessary duration
of time to give dual antiplatelet treatment following
endovascular treatment with stent implantations. No
evidence-based conclusions can be drawn in this
connection.
The Clopidogrel and Aspirin in the Management of
Peripheral Endovascular Revascularization (CAMPER) trial
was initiated in the USA to investigate the combination of
ASA and clopidogrel vs. ASA alone following femoropopli-
teal angioplasty. However, the study was discontinued after
one year due to insufficient randomization, possibly
because an excessive number of patients in the USA had
received that off-label combination treatment after femor-
opopliteal angioplasties. Thus, it is doubtful whether such a
study could ever be carried out in the future [374]. Further-
more, in applying dual antiaggregation, it is crucial to con-
sider that combination treatment in patients at a high
vascular risk and with severe comorbidity is likely to be
associated with an increased bleeding risk as compared
to monotherapy [199]. However, data from PEGASUS-
TIMI 54 study [208, 209] prove that, in PAD patients with
previous myocardial infarction, a selected high ischemic-
risk subgroup, dual-antiplatelet therapy with aspirin and
low-dose ticagrelor (60 mg b.i.d) is associated with a 5.2
% AR reduction in MACE and a reduction of MALE, while
major TIMI bleedings were in excess of only 0.12%. There-
fore, DAPT with ticagrelor 60 mg b.i.d and aspirin may be
considered in PAD patients with prior MI [12]. In initiating
dual antiplatelet treatment and deciding on the duration of
combined therapy, due attention should be paid to the
localization and kind of stent used, as well as the individual
patients’ bleeding risks.
The trials addressing cilostazol treatment in patients
with intermittent claudication and femoropopliteal disease
following endovascular interventions are also small though
prospective. These studies have compared re-intervention
rates following administration of ASA alone or combined
with cilostazol. One of these trials showed substantial
methodical deficiencies, i.e. no blinding, unclear randomi-
sation, and small patient numbers. Revascularization was
carried out in 36 subjects, 16 under cilostazol and 20 in
the control group. Re-interventions provedmore frequently
necessary in patients not given additional cilostazol (14 vs.
6; p = 0.041) [249]. Other studies on additional cilostazol
following femoropopliteal interventions with and without
stents went in the same direction. Five retrospective case
series and two small prospective studies showed a reduced
restenosis rate after treatment with cilostazol [382].
A recent, large-scale retrospective population-based
analysis in the USA covering data from more than
23,000 subjects with PAD investigated cilostazol following
endovascular and open surgical revascularizations [383].
ASA was given to 20,335 patients as a secondary prophy-
laxis and 1,999 received additional cilostazol. Compared
with the patient group not given cilostazol, subjects receiv-
ing pre- and/or post treatment cilostazol showed signifi-
cantly reduced rates of restenosis and major amputation.
On condition that there are no contraindications and in
the presence of adequate tolerability, combination treat-
ment with ASA and cilostazol can be considered to
improve patency and reduce amputation rates following
infrainguinal endovascular treatment. In individual cases,
this especially applies to patients at a high risk for major
Recommendation Class of
recommendation
Level of
evidence
It is recommended that all
patients are to receive pre-, peri-
and post-interventional
antiplatelet therapy. In the
absence of contraindications,
treatment is to be continued on a
long-term basis.
I A
Based on indirect evidence,
75 mg and/or 300 mg ASA are
recommended for peri- and post-
interventional thrombocyte
inhibition (for sole balloon
angioplasty) but low-dose ASA
(75 to 100 mg) is as effective as
high-dose ASA but with much
less (especially gastro-intestinal)
side-effects.
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amputation after vascular reconstructions. However,
cilostazol is not approved for this indication in some EU
countries.
From a pathophysiological perspective, and based on
data pertaining to the coronary arteries, temporary dual
antiaggregation with a combination of ASA 100 mg/d
and clopidogrel 75 mg/d may be considered useful in the
absence of evidence concerning the peripheral vasculature.
The duration of dual treatment and the issue whether clopi-
dogrel loading doses are effective or necessary in the
periphery both remain unclear.
The use of more recent platelet aggregation inhibitors
(especially ticagrelor in combination with ASA 100 mg/d)
in this indication had a comparable effect to the combina-
tion of ASA and clopidogrel [205]. However, their use fol-
lowing cardiology interventions demonstrated benefits
regarding efficacy leading to the recommendation of
preferring ticagrelor over clopidogrel in patients with acute
coronary syndromes [12]. In patients with clopidogrel resis-
tance, ticagrelor and prasugrel may be used replacing
clopidogrel.
Using batroxobin, a fibrinogen reducing serine protease,
a small pilot study detected a significant reduction in the
rates of restenosis and re-occlusion, with a consistent rate
of amputation, among patients with diabetes following cru-
ral interventions [385]. Adding batroxobin to ASA 100mg/
d in this indication, a subsequent larger-scale randomized
study in 129 subjects observed reduced restenosis and
increased leg salvage rates together with significantly
reduced major amputation rates in the group treated with
combination ASA-batroxobin after 12 months [386].
8.1.2 Heparins
Unfractionated and low-molecular-weight heparins show
both antithrombotic and antiproliferative effects [387].
The standard treatment with unfractionated heparins
(UFHs) is usually started immediately before and during
the course of intervention. The objective is to prolong the
activated clotting time (ACT) to 200 to 250 seconds [7].
In a monocentric open study, Strecker et al. administered
reviparin (3,500 IU 2x/d for 24 days) and ASA (100 mg/
d) to 42 patients who had received femoropopliteal stent
implants following PTA failure [388]. Compared with a his-
toric control group treated with UFH, the 1- and 2-year
rates of primary patency were higher with reviparin (88
% and 74 %) than with UFH (81 % and 50 %).
In a comparative study, 172 patients were treated with
body-weight-adapted doses of nadroparin for 7 days or
UFH i.v. after peripheral intervention of the femoropopli-
teal arteries. At 3weeks, 3months and 6months post-inter-
vention, the group given low-molecular-weight heparin
showed a significantly lower number of re-occlusions than
the group given UFH [389].
In another study, 275 subjects were treated with dal-
teparin (2,500 IU 1x/d for 3 months) and ASA (100 mg/
d) or ASA alone [390]. After the 12-month study period,
the restenosis and re-occlusion rates were identical in both
groups (44 % in the ASA-dalteparin group vs. 50 % under
ASAmonotherapy). Only the subgroup of patients with crit-
ical limb ischemia (CLI) and long occlusions under addi-
tional treatment with low-molecular-weight heparin
showed significantly higher patency rates after 12 months.
The underlying cause is remaining thrombotic material
which is often seen following endovascular revasculariza-
tion of complex, long lesions, particularly long chronic
Recommendation Class of
recommendation
Level of
evidence
There is little evidence to support
general dual antiplatelet therapy
in all PAD patients, however,
extrapolation from coronary data
may be considered in patients at
high risk of restenosis or re-
occlusion, accepting the higher
risk of side effects.
IIb B
Combination treatment with ASA
and cilostazol may be considered
in order to improve patency and
reduce amputation rates
following infrainguinal
endovascular treatment.
IIb B
Following infrainguinal treatment
with stent implantations,
temporary combinations of ASA
and clopidogrel should be
considered to improve patency.
IIa B
The same strategy is
recommended before catheter
thrombectomy (avoidance of early
thrombus formation at the vessel
wall by thrombin-activated
thrombocytes).
I
C
C
Recommendation Class of
recommendation
Level of
evidence
Ticagrelor is recommended
instead of clopidogrel in
combination with ASA where
there is proven clopidogrel
resistance or clopidogrel
intolerance.
I C
For the duration of DAPT,
especially in older patients and
patients at risk, prescribing
gastrointestinal ulcer prevention
by proton pump inhibitors may be
considered [382].
II C
Recommendation Class of
recommendation
Level of
evidence
Batroxobin may be considered in
combination with ASA100 mg/d
following below-the-knee artery
interventions.
IIb C
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occlusions. Remaining thrombus is also seen in most cases
following selective thrombolysis and following rotational
thrombectomy. Although not studied systematically, gen-
eral experience demonstrates fewer early re-occlusions
using intravenous heparins over several days post-interven-
tion. No randomized studies have addressed this indication
(and have probably lost their legitimacy due to long-term
experience).
8.1.3 Oral anticoagulants (OAC)
Three randomized controlled studies investigated the
extent to which OACs would constitute an alternative to
antiaggregant treatment (ASA and dipyridamole) following
peripheral angioplasty of the femoropopliteal and tibial
vasculatures. A total of 438 patients were randomized. In
all trials the groups treated with OAC (Vitamin K Antago-
nists) showed lower rates of arterial patency yet signifi-
cantly higher bleeding rates (HR 1.79; 95 % CI 1.3–4.6)
[199, 201, 391, 392]. Antiplatelet drugs should thus be
first-line in interventional treatments, as long as there are
no other imperative indications for OAC which are mostly
deriving from cardiology co-morbities such as atrial
fibrillation.
8.1.4 Direct oral anticoagulants (DOACs) in PAD
Provisional results presented from the pivotal randomized
Edoxaban in Peripheral arterial disease (ePAD) trial [391]
compared the effect of dual antiplatelet therapy (ASA and
clopidogrel for 3 months after PTA, followed by ASA 100
mg/d for another 3 months) with a combination of ASA
100 mg/d and edoxaban 60 mg o.d. for 3 months after
PTA followed by 3 additional months of ASA 100 mg/d.
In all categories, the ASA/edoxaban combination tended
to show lower bleeding rates and better outcome after 6
months (lower rate of major adverse cardiac events). This
proof of concept is currently being evaluated in larger trials
with edoxaban.
Additional analysis of the PAD subgroup (stable PAD,
CAD with asymptomatic PAD and stable carotid stenosis
patients) in the COMPASS trial population (X 46) revealed,
besides the 28% general survival benefit, an additional sig-
nificant 48 % reduction in major adverse limb events
including reduction in major amputation (HR 0.54 95 %
CI 0.35–0.82) for ASA 100mg/d combined with Rivaroxa-
ban 2 2.5mg /d compared to ASS 100mg/d and placebo.
The current VOYAGER trial investigates rivaroxaban in
combination with aspirin following PTA [215] (Table 8.1.4).
8.2 Surgical interventions: Peri- and
post-operative medical follow-up
Manymethods are available in terms of surgical revascular-
ization, including thromboendarterectomy, ring stripping,
thrombectomy, femoral bifurcation plasty, profundaplasty,
and bypass procedures applying both venous and synthetic
grafts. In particular, in the presence of multilevel disorders,
complex hybrid procedures can be employed, involving a
combination of balloon dilatation and, if required, stent
implantation for proximal lesions and simultaneous
bypasses for distal lesions [7].
The patency rates of all bypass procedures in the lower
limbs require adjuvant platelet inhibition treatment,
regardless of the type of bypass used [199]. Early occlu-
sions following venous and synthetic bypasses are mostly
caused by technical problems associated with blood flow
disorders. Medium-term and late occlusions may be caused
by neointimal hyperplasia in the graft itself or anastomosis.
Alternatively, arteriosclerosis may progress in the native
vascular bed [394]. The high thrombogenicity of the inner
surface of synthetic bypasses makes the principle differ-
ence between the thrombotic occlusions of venous and syn-
thetic bypasses. While venous bypasses are coated with
endothelium and thus less thrombogenic, synthetic
bypasses rarely show completely developed endothelium
layers [199].
Recommendation Class of
recommendation
Level of
evidence
Immediately before and during
interventions, UFH is
recommended in order to prevent
acute arterial thrombosis.
I B
Long(er)-term application of
heparin following peripheral
interventions has not been
evidenced as a general treatment
strategy following PTA but may be
considered, but limited to
endovascular treatment of
complex lesions, and the
situation after fibrinolysis and/or
rotational thrombectomy with
persistently impaired outflow.
IIb C
Recommendation Class of
recommendation
Level of
evidence
OAC (VKA) are not recommended
following PTA of the
femoropopliteal or tibial arteries
(with the exception of specific
indications) to prevent restenosis
or re-occlusions.
III A
Recommendation Class of
recommendation
Level of
evidence
Based on the results of the
COMPASS trial, the combined
therapy of ASA 100 mg/d and
rivaroxaban 2  2.5 mg/d
should be considered in PAD
patients without a high risk
of bleeding.
IIa B
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The ongoing Voyager PAD trial [215] will show, whether
there will be in the surgical group an advantage of postop-
erative dual treatment of low dose DOAC (rivaroxaban 2 
2.5 mg/d) and ASA 100 mg/d over ASA 100 mg/d alone.
8.2.1 Antiplatelet agents following surgery
Whether antiplatelet treatment is to be initiated preopera-
tively is a matter of ongoing controversy. In two out of three
studies, preoperative onset showed improved postoperative
rates of patency [395, 396]. Although, the third study failed
to substantiate improved bypass patency following postop-
erative initiation [397], the evidence is slightly in favor of a
preoperative onset of treatment with antiplatelet agents
[199].
Antiplatelet treatment is recommended to improve
patency rates following lower-leg bypass surgery, whereas
it is more effective in synthetic grafts than in autologous
conduits [7, 398–400]. A meta-analysis covering 11 ran-
domized clinical studies carried out before 1990 showed
administration of antiplatelet agents to significantly lower
the risk of bypass occlusion by 32 % [42]. Published in
1999, a meta-analysis of five trials explored ASA (alone
or in combination with other antiplatelet drugs) vs. placebo
in patients with infrainguinal bypasses. Bypass occlusions
were seen in 28.4%of 423 subjects given antiplatelet treat-
ment and in 36.6% of 393 subjects given placebo. The rel-
ative risk of infrainguinal graft occlusion was significantly
lowered (RR: 0.78) in patients under ASA [401].
In patients already receiving dual antiplatelet treatment,
the intra- and perioperative risks of arterial thrombosis are
to be balanced against individual bleeding risks. Clinical
experience has shown that clopidogrel is to be discontinued
ideally approx. 8 to 10 days before vascular surgery on
account of increased bleeding risks and that ASA treatment
is to be continued. However, cardiovascular risks, e.g.,
recent implantations of drug-eluting coronary stents,
should be considered.
A randomized prospective investigation of dual platelet
inhibition vs. ASA monotherapy in 108 patients with CLI
and vascular interventions (bypass surgery, major amputa-
tion) investigated the course of cardiovascular biomarkers
as indicators of coronary events. No significant difference
was identified between the patient groups, while the rate
of major bleeding was not significantly increased in the
group under dual treatment [402].
Recommendation Class of
recommendation
Level of
evidence
In patients already receiving dual
antiplatelet treatment, the intra-
and perioperative risks of arterial
(especially coronary) thrombosis
are recommended to be balanced
against individual bleeding risks.
I B
Table 8.1.4. Recommendations on antithrombotic therapy in patients
with symtomatic peripheral arterial disease.
Recommendation Class of
recommendation
Level of
evidence
Lower extremity artery disease
Long term SAPT is recommended I A
Long term SAPT is recommended in
patients after revascularisation
I C
Long term SAPT is recommended
after infra-inguinal bypass surgery
I A
In diabetic patients requiring SAPT
clopidogrel may be preferred over
aspirin [16, 179]
IIb B
VKA may be considered after
autologous infrainguinal bypass
IIb B
DAPT at least 1 month after
infrainguinal stent implantation
IIa C
DAPT may be considered in below
the knee prosthetic bypass graft
IIb B
SAPT in asymptomatic patients III A
DAPT at least 1 month after drug
coated balloon angioplasty
I C
DAPT at least 3 months after drug
eluting stent implantation
I C
DAPT at least 3 months after covered
stent implantation
I C
Combination of aspirin (100 mg/d)
and rivaroxaban (2  2.5 mg/d)
IIa B
Antithrombotic therapy for PAD Patients
requiring oral anticoagulation (OAC)
In patients with an indication for
OAC, oral anticoagulation alone
should be considered
IIa B
After endovascular revascularisation
aspirin or clopidogrel should be
considered in addition to OAC for at
least 1 month
IIa B
After endovascular revascularisation
OAC alone should be considered if
bleeding risks are high
IIa C
OAC and SAPT may be considered if
ischemic risk is high or there is
another firm indication for long term
SAPT
IIb C
AF = atrial fibrillation; CAS = cartoid artery stenosis; CHA2DS2-VASc =
Congestive heart failure, Hypertension, AGE  75 (2 points), Diabetes
Mellitus, Stroke or TIA (2 points), Vascular disease, Age 65–74 years,
Sex category; DAPT = dual antiplatelet therapy; LEAD = lower extremity
artery disease; OAC = oral anticoagulation; PADs = peripheral arterial
diseases; SAPT = single antiplatelet therapy.
Recommendation Class of
recommendation
Level of
evidence
Anti-platelet treatment in
peripheral bypass surgery should
be considered to be initiated
preoperatively. It should be
continued following surgery or
hybrid procedures and – in the
absence of contraindications –
subsequently on a long-term
basis.
IIa B
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Following venous bypass setting or synthetic bypass plac-
ing below the knee, the Clopidogrel and Acetylsalicylic
Acid in Bypass Surgery for Peripheral arterial disease (CAS-
PAR) study randomized 851 subjects to receive ASA (75 to
100mg) or combined clopidogrel (75mg) and ASA. No sig-
nificant difference was seen in patency rates. A subgroup
analysis, however, yielded a significant benefit of combina-
tion treatment in synthetic over venous bypasses [400].
Based on the results of the CASPAR trial, dual platelet
inhibition with ASA and clopidogrel can be considered fol-
lowing infragenual prosthetic bypass surgery.
8.2.2 Heparins
UFH is traditionally given intravenously before applying vas-
cular clamps and discontinuing blood flow in an attempt to
prevent thrombosis caused by stasis in the proximal and distal
vascular segments, as well as in the anastomotic segment. No
randomized studies have addressed this indication and have
probably lost their legitimacy due to long-term experience.
General recommendations for intraoperative monitoring
of anticoagulation, e.g., based on activated coagulation
time (ACT), are not possible because of little available data.
As a rule, 100 to 150 U/kg is given intravenously before
clamping. Due to the short half-life of UFH (50 to 80 min-
utes), 50 U/kg is subsequently to be given every 45 to 50
minutes until the vascular clamps are removed and circula-
tion is reestablished [199].
One single study compared three months of postopera-
tive low-molecular-weight heparin (dalteparin 1  2,500
U s.c.) with combined ASA and dipyridamole in 200
patients with synthetic bypasses or venous bypasses
[385]. The rate of bypass patency was better in the dal-
teparin group (79 %) than in the group given antiplatelet
treatment (64.1 %). A subgroup analysis resulted in signif-
icant benefits arising from low-molecular-weight heparin
among subjects presenting with CLI as against those with
intermittent claudication. This outcome still requires sub-
stantiation in a larger patient trial before evidence-based
recommendations can be made as to long-term postopera-
tive low-molecular-weight heparin in patients with CLI. In
this situation, the additional pleiotropic effects of low-
molecular-weight heparins are possibly beneficial.
8.2.3 Postoperative use of VKA
In 1979, a randomized study was carried out in 91 patients
with venous femoropopliteal bypass grafts and in 122
patients following thromboendarterectomy. The subjects
received ASA (1,000 mg), an ASA-dipyridamole combina-
tion, or monotherapy with OACs [403]. There were no sig-
nificant differences in 2-year patency rates. However, a
subgroup analysis revealed improved rates of patency fol-
lowing venous bypass application in the group under OACs.
In turn, patients given thrombendarterectomy did better
with antiplatelet treatment.
Following placement of venous or synthetic bypasses,
2,690 participants were randomized within the Dutch
Bypass Oral Anticoagulants or Aspirin (BOA) study to
receive OACs (international normalized ratio [INR] 3 to
4.5) or ASA 80mg/d [404]. Overall, no benefit was identi-
fied in either antithrombotic treatment group as to femor-
opopliteal vs. femorocrural bypass patency (RR 0.95; 95
% CI 0.82–1.11). Expenditure gains in years with quality
of life, and event-free survival were identical with ASA
and OAC (INR 3 to 4.5). However, a post-hoc subgroup
analysis of bypass material showed a significantly lowered
occlusion risk among patients with venous bypasses under
OACs, whereas the risks of synthetic bypass occlusions
under ASA were significantly lower. Patients under OAC
treatment showed significantly more frequent larger-scale
bleeding episodes compared with patients under ASA
treatment (HR 1.96; 95 % CI 1.42–2.71). Even in the pres-
ence of appropriate INR values, study participants above
the age of 72 presenting with diabetes and/or arterial
hypertension experienced increased bleeding risks.
The results of the BOA trial post-hoc analysis of the
patient subgroup with venous grafts is often used as an
argument in favor of OAC following venous bypass.
According to the evidence criteria, however, post-hoc anal-
yses do not yield sufficient validity to facilitate general rec-
ommendations. Moreover, an INR target range of 3 to 4.5
was established for the patient group treated with OACs.
Overall, 2,119 femoropopliteal and 531 femorocrural
interventions were performed. The proportionately low
number of crural interventions in the study and the high
INR target range, which is only recommended for patients
at a high risk for thromboembolism [1, 403], together make
it difficult to translate these results to the clinical setting.
There is insufficient evidence for the currently frequent
recommendation of OAC with an INR target range of 2 to
3 following infrapopliteal vascular surgery. Trials address-
ing this issue are lacking, notwithstanding the small study
published by Sarac with 56 patients [406]. With a mid-level
Recommendation Class of
recommendation
Level of
evidence
Administration of short-term low-
molecular-weight heparin should
be considered
postoperatively/post-
interventionally, especially in
patients with CLI. Both for DVT
prophylaxis and to enhance flow.
IIa B
Protamine is not recommended
to be used peri-operatively unless
significant bleeding or
dangerously high clotting times
are detected.
III B
Recommendation Class of
recommendation
Level of
evidence
DAPT (clopidogrel+ ASA) may be
considered after infragenual
synthetic material bypass
grafting.
IIb B
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OAC dosage (INR 2 to 3) in combination with ASA (325mg/
d), this study documented better bypass patency rates in 56
patients at risk of occlusions (CLI, relapse intervention,
poor run-off, poor vein material) as against ASA monother-
apy. This applied over a course of 3 years [406].
Additional analysis of the PAD subgroup (stable PAD,
CAD with asymptomatic PAD and stable carotid stenosis
patients) in the COMPASS trial population [212], as men-
tioned earlier (see Chapter 6), revealed, besides the 28 %
general survival benefit, an additional significant 48 %
reduction in major adverse limb events including 70 %
major amputation (HR 0.54 95 % CI 0.35–0.82) for ASA
100mg/d combined with Rivaroxaban 2  2.5mg /d com-
pared to ASS 100mg/d and placebo. The net benefit was 28
% risk reduction for the PAD subgroup of COMPASS com-
pared to the 24 % MACE reduction in the CAPRIE sub-
group [203].
A systematic review concerning the issue of antiplatelet
treatment vs. anticoagulation following peripheral vascular
bypass identified no advantage of either medical method
[401]. The Veterans Affairs trial randomized 831 patients
with venous and synthetic bypasses to either low-dose
OAC (INR 1.4 to 2.8) and ASA (325 mg) or ASA alone
[407]. At a 3-year follow-up, the groups showed no signifi-
cant differences. This result corresponds to the outcomes
of the Warfarin Antiplatelet Vascular Evaluation (WAVE)
trial in non-operated high-risk patients with PAD who
failed to show benefit under combined ASA and warfarin
or ASA alone [408]. Bleeding complications were signifi-
cantly more frequent, and the risk of bleeding doubled
under combined treatment. The subgroup of patients with
synthetic bypasses showed a 38 % reduction of risks for
bypass occlusions under the combination compared to
ASA monotherapy, but accepting significantly increased
bleeding rates under combined treatment.
The most recent investigation into this issue compared
combined VKA (INR 2.0 to 2.5) plus clopidogrel 75mg with
dual platelet inhibition (clopidogrel 75 mg plus ASA 100
mg) following femoropopliteal bypass surgery up to 9 years
of follow-up. Median follow-up was 6.6 years. The partici-
pants were either patients with synthetic prostheses above
the knee or patients with venous bypasses below the knee.
The rate of primary prosthesis patency and number of
severe peripheral ischemic events was shown to be higher
in the VKA group than in the ASA plus clopidogrel group
(p = 0.026 and p = 0.044, respectively). After three years,
97 % and 92 % of the subjects given VKA plus clopidogrel
vs. those given ASA plus clopidogrel were amputation-free.
The figures were 78 % vs. 64 % of patients after 8 years.
The incidence of severe anticoagulation-related complica-
tions and overall number of bleeds was seen to be compa-
rable in both groups (p = 0.06 and p = 0.7, respectively), yet
the rate of minor bleeding complications was significantly
higher in the VKA group (2.85 % per patient-year vs. 1.37
% per patient-year, p = 0.03) [409].
This recommendation is based on the overall analysis of
BOA trial data [404] and on the results published by Mon-
aco et al [409].
This recommendation is based on the post-hoc analysis
of the BOA trial which demonstrated significantly better
patency rates with venous bypasses under VKA (HR:
0.69). In infrainguinal venous bypasses, the benefits were
seen regardless of the localization of the distal anastomosis
(popliteal, crural, pedal). The ongoing trials with ASA and
novel OACs after PTA or vascular surgery [215] will answer
the question whether these new drugs offer a safer alterna-
tive in this indication.
Low-dose VKA (INR 1.4 to 2.7) combined with ASA (325
mg/d) offers no benefit compared with ASA alone [407]. In
this connection, as well, significantly increased rates of
bleeding complications were identified. The target range
of anticoagulation is to be determined individually follow-
ing a careful assessment of the risk-benefit ratio, the more
so as the target ranges applied to the participants in the
Dutch BOA trial were clearly higher than those usually
applied in many EU countries.
Recommendation Class of
recommendation
Level of
evidence
Routine general administration of
vitamin K antagonists following
peripheral bypass is not
recommended.
III B
Recommendation Class of
recommendation
Level of
evidence
After weighing possible
contraindications and bleeding
risks, VKA use may be considered
on an interdisciplinary basis in
the presence of infrapopliteally
applied venous bypasses, poor
outflow tracts, and high
amputation risks along with
potential bypass occlusion.
IIb B
Recommendation Class of
recommendation
Level of
evidence
There is no indication for the
frequent recommendation of VKA
therapy with an INR target range
of 2 to 3 following infrapopliteal
vascular bypass-surgery.
III B
The combined therapy of ASA
100 mg/d and rivaroxaban
2  2.5 mg/d should be
considered in stable PAD patients
without a high risk of bleeding,
particularly if associated with
CAD.
IIa B
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The extent to which low-molecular-weight heparins may
constitute an effective alternative to prevent bypass occlu-
sions in the presence of contraindications against VKA has
not been investigated in this patient group.
Patients under anticoagulation and under combination
treatment with ASA and VKA are to be closely monitored
on account of their clearly increased bleeding risks. This
applies particularly to patients under temporary ‘triple’
treatment for cardiac indications, necessitating laboratory
tests and clinical control.
The ongoing trials with ASA and NOACs after PTA or
vascular surgery [215]. will answer the question whether
these new drugs offer a safer alternative in this indication.
8.2.4 Statins
Statins are established secondary prophylactic measures in
cardiovascular risk patients, including those with PAD. A
multivariate regression analysis of a prospective registry
of patients after endovascular interventions showed the
combined endpoint of cardiac death, MI, major amputation
and re-PTA after statin administration to be significantly
reduced over at least 6 to 12 months. Short administration
over 30 to 90 days was shown to have no effect [410].
Another large-scale investigation in patients undergoing
vascular surgery demonstrated that statin administration
may improve the patency rates of vascular bypasses and
clinical outcome [411]. A population-based analysis of
Medicare data confirmed the positive effect of statin treat-
ment following peripheral vascular interventions [412].
8.3 Follow-up care after vascular
interventions
Data are very sparse with regard to the issue of controlled
follow-up care after interventional or surgical treatment of
peripheral vessels, however across the spectrum of PAD
reducing vascular risk is key and should be employed.
A Dutch observational trial in 711 patients consecutively
followed over three years following peripheral bypass sur-
gery found 50 % of patients to be given guideline-directed
medical treatment with ASA, statins and beta blockers (in
patients with ischemic heart disease). After adjusting for
clinical characteristics, such treatment was associated with
reducedmortality and a hazard ratio of 0.65 (95%CI 0.45–
0.94) [413]. However, based on prescriptions issued 6 to 10
months following primary vascular surgery, a Danish inves-
tigation identified low to moderate levels of guideline
adherence in terms of lipid-lowering treatments (50 %),
ACE inhibition / angiotensin II type 1A (AT1-A) (43 %),
and antihypertensive treatment (45%), as well as a further
decrease between 6months and 3 years post-surgery [414].
In terms of follow-up for patency there are no large-scale
controlled randomized trials or systematic overviews that
would address the frequency, duration of follow-up, or
the method of technical diagnosis following vascular and
especially endovascular interventions. However, the
restenosis and re-occlusion rates shown in studies in
patients with preceding vascular surgery [415, 416] clearly
underscore the importance of regular follow-up care and
postoperative / post-interventional control. Regular fol-
low-up care is useful, as suggested by results in patency
rates following interventional treatment or vascular sur-
gery. According to TASC II, patients with lower-limb bypass
surgery due to claudication or CLI are to be admitted to
clinical monitoring programs [7]. The postoperative moni-
toring recommendations contained in the follow-up pro-
gram of the TASC II guidelines include medical histories,
symptom inquiries, clinical examinations and pulse assess-
ment, and ABI/TBI measurements at rest and after exer-
cise for at least two years in the immediate postoperative
phase (mostly every 6 months) [7].
Current international guidelines recommend all vascular
patients should undergo regular clinical follow-up follow-
ing peripheral vascular interventions [28, 417]. In one trial,
regular follow-up based on duplex sonography was initially
recommended for one year following infrainguinal bypass
application [415]. The objective of ultrasound examination
is to detect possible bypass stenosis (i.a. anastomotic steno-
sis) early enough to perform (surgical or interventional)
reconstructions and avoid bypass occlusion. However,
another randomized multicenter study failed to substanti-
ate the benefits and cost effectiveness of such routine ultra-
sound examinations [418]. Over 18months, regular duplex
sonography applied to control venous bypasses yielded nei-
ther an increase in secondary patency rates nor improve-
ments in patients’ quality of life.
Recommendation Class of
recommendation
Level of
evidence
It is recommended that
administration of VKA or
combined VKA plus ASA 75–
100 mg/d must be strictly
monitored to prevent bleeding
adverse events.
I B
Recommendation Class of
recommendation
Level of
evidence
Long-term intensive statin
treatment should be considered
following endovascular
interventions and vascular
surgery, regardless of LDL
cholesterol concentrations, if
tolerated.
IIa B
Recommendation Class of
recommendation
Level of
evidence
Cardiovascular risk factor
management is recommended for
all PAD patients including those
post-procedure.
I A
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Despite these divergent study results and evidence lack,
many vascular medicine centers have well established post-
operative and post-interventional monitoring of vascular
reconstruction. For the reasons stated above, however, no
generally valid standards have yet been formulated, though
many experts agree an annual review. Analogous to the
results of the BASIL trial and many other clinical studies
following revascularization, secondary patency rates are
the consequence of regularly performed examinations. This
applies equally to surgical and interventional treatments.
It remains unclear whether duplex monitoring or clinical
examinations are better and more cost-effective. In general,
measurement of peripheral occlusive pressure following
successful arterial revascularization, ABI/TBI assessment,
and clinical physical examinations including pedal pulse pal-
pation are recommended. In patients with diabetes, these
measures are recommended to be on a yearly basis in the
framework of disease management programs.
To account for the significance of cardiovascular risk fac-
tors and comorbidity (particularly CAD and cerebral circu-
lation disorders), all patients with detected PAD should,
where possible, be integrated in a registry program. This
program should include vascular risk factors, and their
management, in addition to the symptoms and diagnosis
of PAD.
8.3.1 Follow-up vascular training/exercise
Following endovascular treatment in the aortoiliac seg-
ment, and albeit based on small patient numbers, the
results of several trials showed significant improvements
in maximum walking distances with subsequent structured
vascular training compared to no subsequent vascular exer-
cise [233]. Only one investigation has evidenced improve-
ments in walking distances due to additive walking
exercise following surgical vascular reconstruction. This
randomized controlled trial showed that, even after 6
months, additional walking training after peripheral bypass
surgery resulted in significantly longer walking distances
and improved quality of life in the interventional group
compared to the control group [419]. No effect was seen
in a less recent and smaller randomized trial. Overall, how-
ever, the available results indicate lack of exercise to be a
risk factor for vascular occlusions following surgical vascu-
lar reconstruction.
For this reason, regular physical exercise appears useful.
It also seems possible, although not yet investigated, that
this observation may lead to reduced rates of restenosis
and re-occlusion after PTA for patients having undergone
interventional treatment. Autonomous and daily interval
training over 60 minutes with 5- to 15-minute effort inter-
vals is recommended, where intensity is to reach maximal
pain [227, 228]. Nordic walking may be recommended as a
variation (the positive metabolic effect is higher but the
workload for the legs is lower than without walking sticks).
8.4 Rehabilitation in PAD
Treating physicians are responsible for giving patients
information about the options of post-intervention rehabil-
itation. Clinicians may initiate inpatient or outpatient care
in the form of follow-up rehabilitation. Follow-up rehabili-
tation should begin within 14 days after discharge from
acute treatment.
As rehabilitation measures are indicated, physicians
should consider the following issues:
 Is the given rehabilitation measure indicated, i.e. is
participation impaired and is there a (participation)
objective to be reached with rehabilitation?
 Is the given patient capable of being rehabilitated, i.e.
can he/she participate in rehabilitative treatment?
 What is the prognosis of rehabilitation outcome, i.e. is
there a realistic chance that the patient will meet the
intended rehabilitation objective?
These measures aim at the (partial) recovery of organ
function. In many cases, the main task of rehabilitation is
Recommendation Class of
recommendation
Level of
evidence
Due to the chronic nature of the
disease and the potential
consequence of major
amputations and non-retreatable
vascular lesions, regular clinical
and technical follow-up care and
timely re-intervention in the case
of complications are
recommended following surgical
and endovascular treatment.
I B
Recommendation Class of
recommendation
Level of
evidence
Despite lack of evidence – but
due to its general availability and
adequate validity – color-coded
duplex sonography is
recommended as the method of
choice to detect recurrent
stenosis / occlusions and further
pathological changes in operated
segments following clinical
examinations and Doppler
measurement of peripheral
occlusive pressures.
I C
Recommendation Class of
recommendation
Level of
evidence
It is recommended that patients
be rapidly integrated into
structured exercise program.
Furthermore, regular physical
activity (arm or leg muscle
training) is recommended to be
encouraged.
I B
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to exploit the possibilities of compensation in an attempt to
replace damaged organ functions. The less completely a
medical rehabilitation is achieved, the more the patient’s
personal and family behavior and environment must
adjust.
Rehabilitation consists of the following steps
The individual objectives of rehabilitation are dependent
upon the patients’ extent of occupational and social
participation.
 The rehabilitation process covers medical treatment,
physical therapy and ergotherapy, exercise treatment
adapted to the given patient’s level of performance,
disorder-specific courses of instruction and on nutri-
tion, which are altogether coordinated within an
interdisciplinary rehabilitation team under a physi-
cian’s guidance. As necessary, this treatment plan also
includes stage-adapted wound management.
 Final assessments serve to determine whether the
objectives of rehabilitation have been met, to formu-
late recommendations for further treatment, and to
issue sociomedical assessments of the patients’ per-
formance levels.
Rehabilitation can be carried out on an outpatient or
inpatient basis. Inpatient rehabilitation is to be offered as
needed. Patients with PAD are not to be refused rehabilita-
tion merely because adequate and accessible outpatient
institutions are not present. The lack of outpatient institu-
tions providing angiology rehabilitation and vascular sports
groups is striking. It remains a joint challenge for funding
agencies, societies of vascular medicine and patients’ sup-
port groups to find a remedy in this connection.
8.5 Post-amputation follow-up care
Patients’ occupational and social rehabilitation are to be
initiated along with their medical rehabilitation. Adequate
and individually fitted footgear is recommended following
minor amputations. Procedures following amputations
consist of wound and stump management, contracture
prophylaxis, remedial gymnastics, and muscle-building
training.
Major amputations entail secondary wound manage-
ment and treatment for possible phantom limb pain. Stump
pain is to be distinguished from phantom pain which is
reduced with timely epidural regional anaesthesia [420]
as long as there are no contraindications. Interdisciplinary
treatment is often successful in persistent pain conditions.
Psychological support with an aim to overcome amputa-
tion, is a critical constituent. Temporary prostheses are to
be indicated for all amputees, especially if the objective is
mobilisation via prosthesis from bed into a wheelchair. If
suitable, patients are to be offered prostheses training with
standing and walking exercises, as well as gait and walking
training.
In terms of stabilized mobilization and the secondary
prevention of further cardiovascular events, one of the tar-
gets is participation in para-sports and rehabilitation near
outpatient centers connected to vascular offices and clinics.
The aim of treatment, following high-level amputations, is
participation in a self-determined and fulfilled life, as well
as social reintegration. This comprises of consultation
and support: home care, disability-friendly living, support
in prosthesis care, disabled persons’ passes, nursing care
insurances, retraining, shuttle services, motor-vehicle
conversions, and as much as networking with medical spe-
cialists in specialty hospitals, physical therapists and podia-
trists as is required.
Recommendation Class of
recommendation
Level of
evidence
Rehabilitation programmes are
recommended in patients with
intermittent claudication post
intervention, such as:
I C
 instruction in structured
walking exercise
 optimisation of secondary
prevention and reduction of
cardiovascular risk
 promotion of compliance
 improvement and promotion
of participation in social life
Recommendation Class of
recommendation
Level of
evidence
Rehabilitation strategies are
recommended for all patients
post-intervention/surgical
procedures.
I B
Recommendation Class of
recommendation
Level of
evidence
It is recommended that following
major amputation, patients are to
be given adequate training and
information in rehabilitation and
prosthesis care.
I C
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9 The elderly patient with PAD
Multi-morbidity of old age comprises the following charac-
teristics: Immobility, a tendency to fall with/without vertigo,
cognitive deficits including dementia, incontinence, decubi-
tus ulcers, malnutrition and nutritional deficiency, fluid-bal-
ance disorders and electrolyte imbalance, depression and
anxiety disorders, chronic pain syndrome, sensory distur-
bances, visual and hearing impairment, and medication
problems. The concept of “frailty syndrome” and “reduced
resilience” can also be used to describe this constellation of
symptoms. Furthermore, multiple and often simultaneous
organ-specific disorders tend to present atypically.
Reduced ability to compensate for different stressors,
including diseases, social changes and bereavement, is typ-
ical of the very elderly with multi-morbidity problems. It
manifests as increased risk of disease complications and
treatment adverse events, prolonged convalescence,
together with a high risk associated with experiencing a loss
of independence. Therefore, both the prevention of avoid-
able morbidity and targeted rehabilitative follow-up in such
a group play a critical role in patient management and
should be considered in formulating treatment guidelines.
The prevalence of PAD increases with age and reaches
over 15–20 % among subjects beyond the age of 70 [9, 10];
and the proportion in diabetic patients then in people with-
out diabetes [56]. Qualitatively comparable epidemiologi-
cal studies in the frail elderly patient are lacking.
However, the frequency of PAD is assumed to be even
higher in this patient group. For example, the prevalence
of symptomatic PAD was seen to total 32 % (men) and
26 % (women) among 3,500 care home occupants aged
81 on average [421].
Among fit elderly patients, the clinical presentation of
PAD is marked by a more frequent presentation of CLI ver-
sus claudication, especially among patients with diabetes
[422]. There are indications also that advanced, yet clini-
cally silent PAD is even higher among frail elderly patients
[423]. Elderly subjects (both men and women) presenting
with subclinical PAD have already been shown to suffer
frommobility impairment [424]. Walking sticks or rollators
become frequently required in elderly PAD patients due to
ischemic muscle atrophy, inability to control their legs and
sensory impairments, often leading to a higher risk of fall-
ing with resulting injuries including fractures. Detection of
PAD in frail elderly patients is thus significant in terms of
prevention: Early revascularization may prevent such walk-
ing impairment. Furthermore, the risk of pressure lesions e.
g. on the heel are particularly increased in the bed-bound
patient. Conversely, undetected PAD following foot or
lower-leg interventions may contribute to wound healing
problems [425].
Once PAD has become symptomatic in elderly patients,
it often manifests in pedal/crural trophic lesions or in pain
at rest. Moreover, frail elderly subjects often experience
simultaneous coronary artery disease (68 %) or stroke
(42%) [426]. Generally, increased treatment risks are asso-
ciated with such multi-morbid patients. A small number of
retrospective studies have explicitly addressed PAD treat-
ment in elderly patients. The trait of frailty is consistently
described as detrimental in terms of maintaining self-suffi-
ciency following vascular surgery or catheter-based inter-
ventions for critical limb ischemia [427]. The risks of
confusion, falls, decubitus ulcers and loss of autonomy
are significantly higher with emergency surgery than elec-
tive interventions, particularly in the presence of pre-exist-
ing functional limitations (activities of daily living, ADL)
[428]. Despite this, actual vascular results are good with
the rate of leg salvage following successful vascular inter-
ventions being reported as high as approximately 90 %
[429].
The incidence of postoperative confusion in patients with
arterial vascular reconstructions is approximately 40 %
which is a further argument for the PTA-first strategy in
old and very old PAD patients. Pre-existing dementia, crit-
ical leg ischemia and age above 72 years are independent
risk factors for the development of postoperative confusion
in patients with CLI [430].
The basic principles in the diagnosis and treatment of
PAD apply also to frail elderly patients. The recommenda-
tions given in various parts of the present guidelines are
thus to be considered in this patient group, especially those
referring to the risk-benefit assessments of diagnostic and
therapeutic measures. It is crucial to understand the extent
to which symptoms of PAD influence frail elderly patients’
reduced overall quality of life, and balance them in relation
to the invasiveness of PAD treatments.
Frail elderly patients frequently experience lengthy peri-
ods of convalescence with initial reduced rehabilitative
abilities due to acute medical complications and problems
in recovering accustomed degrees of independence (e.g.,
Recommendation Class of
recommendation
Level of
evidence
It is recommended that foot pulse
palpation is part of a physical
examination in elderly patients,
even in the absence of PAD
symptoms, to identify the risk of
potential pedal (pressure)
lesions. Adequate vascular
evaluations are imperative in
patients with non-palpable
pulses, even in the absence of
trophic changes to avoid
ulceration and muscle atrophy
which contributes to falls.
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because of transient disorientation, incontinence, frailty
syndrome). This is the target patient group of early geriatric
rehabilitation which is performed either in specialty hospi-
tals or hospital divisions of geriatrics/medicine for the
elderly with high rehabilitative-geriatric quality standards.
Alternatively, it can be provided by geriatric rehabilitation
institutions meeting the staff and technical requirements
that are necessary to carry out such early geriatric rehabil-
itation to high acute medical standards. Initiation of com-
prehensive geriatric rehabilitation should be considered if
circulatory stability and overall health allow active partici-
pation in rehabilitative programs several times a day.
Geriatric rehabilitation has been proven to lower mortality,
improve functional outcomes, and reduce the number of
referrals to care homes [431].
Recommendation Class of
recommendation
Level of
evidence
It is recommended that the
requirements for (early)
comprehensive geriatric
rehabilitation are to be assessed
in elderly patients both prior to
and following intervention.
I C
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